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Deficiency of insulin results in a net loss of lean body mass and wasting of 
muscle. The defect of protein turnover underlying the loss of skeletal muscle could be 
a reduction in the rate of protein synthesis, an increase in the rate of protein 
breakdown or a combination of both. In the present work the abnormalities of protein 
metabolism occurring during insulin deficiency have been investigated in patients 
with type 1 diabetes, and the acute effects of insulin replacement, during different 
conditions of nutrient supply, have been investigated both in patients with type 1 
diabetes and in healthy subjects.
Incorporation of L -[ l -13C]leucine into biopsied skeletal muscle, arteriovenous 
leg exchange of L-[15N]phenylalanine and of L-[l-13C]leucine, and net release of 3- 
methylhistidine from leg tissues were used to assess muscle mixed protein synthesis, 
muscle mixed protein turnover and myofibrillar protein breakdown, respectively. 
Whole-body protein turnover was assessed by tracer dilution using L-[l-13C]leucine 
and L-[15N]phenylalanine.
Infusion of insulin reduced skeletal muscle mixed protein breakdown, both 
when plasma amino acids were allowed to fall and when their concentrations were 
elevated by exogenous amino acid infusion. In the diabetic patients muscle protein 
synthesis was not increased by insulin infusion alone; infusion of insulin combined 
with amino acids apparently increased synthesis as assessed by phenylalanine 
exchange but not when assessed by either leucine exchange or incorporation into 
muscle. In the healthy subjects there was a faster rate of muscle protein synthesis, 
assessed by phenylalanine exchange, during combined insulin with amino acid 
infusion in comparison with the diabetic patients. In healthy subjects infusion of 
mixed amino acids alone exerted an anabolic effect on muscle protein synthesis with
Summary
little, if any, alteration in the extent of either mixed or myofibrillar muscle protein 
breakdown. In comparisons with postabsorptive healthy subjects, abnormalities of 
muscle protein synthesis and breakdown and of amino acid oxidation in were not 
identified in type 1 diabetic patients during insulin withdrawal.
In the diabetic patients infusion of insulin alone reduced whole-body protein 
breakdown but also reduced protein synthesis to an equivalent extent; there was no 
net benefit on protein balance. However, infusion of insulin combined with amino 
acids reduced protein breakdown and improved net balance with no change in 
synthesis. In contrast, in the healthy subjects the same doses of insulin combined with 
amino acids stimulated protein synthesis in addition to reducing protein breakdown. 
The effects of amino acids alone in healthy subjects was both to stimulate whole-body 
protein synthesis and to reduce protein breakdown.
These investigations suggest that insulin exerts an anabolic action by reducing 
protein breakdown; insulin is only able to increase protein synthesis during conditions 
of increased amino acid availability. Muscle protein synthesis was resistant to 
stimulation by insulin in type 1 diabetic patients.
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APE atoms percent excess
ATP adenosine triphosphate
BCAA branched-chain amino acid
BCAT branched-chain amino transferase
BCKA branched-chain keto acid
BCKAD branched-chain keto acid dehydrogenase
DNA deoxyribonucleic acid
elF eucaryotic initiation factor
GTP guanosine triphosphate
IGF-I insulin-like growth factor I
IMW intramuscular water
Met-tRNAj“ 61 initiator methionyl-tRNA¡met
mRNA messenger ribonucleic acid
tRNA transfer ribonucleic acid
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The aim of the work described in this thesis was to define the effects of insulin 
on protein turnover both in muscle and in the whole-body. A specific aim was to 
identify under what conditions of substrate availability (i.e. amino acids and glucose) 
insuhn was anabolic. An additional aim was to identify differences that existed in 
protein turnover in type 1 diabetic patients compared to healthy nondiabetic subjects. 
Chapter 1 covers concepts of protein turnover and amino acid metabolism. The focus 
on the literature is of the effects of insulin on protein metabolism, both in vivo and in 
vitro. Because a wide range of metabolic effects result from insulin deficiency and from 
hyperinsulinaemia the possible effects of these alterations of substrate and hormone 
concentrations on protein metabolism are considered in detail. In particular, the effect 
of alteration in amino acid concentrations on protein metabolism is considered in 
detail in this introduction and is a major focus in the present studies. A number of 
additional effects, eg immobilisation, which may play a role in the protein and amino 
acid economy of diseased subjects are considered in this chapter.
1.2 The Dynamic Nature o f Protein
Protein is continuously renewed but different proteins are replaced at different 
rates. The term protein turnover should ideally be strictly confined to protein synthesis 
and protein breakdown although occasionally is used to include leucine oxidation. The 
whole-body protein turnover rate is a collective measure of the rates of turnover of all 
body proteins and it predominantly represents pools of proteins which turnover 
rapidly. The term flux is the rate of flow of an amino acid through the free amino acid
16
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pool, not only in the pathways of protein synthesis and breakdown, but also in the 
pathways of intermediary metabolism of the amino acid, in uptake from diet and in 
de novo synthesis. In the models employed to calculate amino acid flux, oxidation and 
rates of protein synthesis and breakdown, excretion of small amounts of amino acid 
in faeces and urine and metabolism of amino acids in pathways such as formation of 
nucleotides and porphyrins are usually considered to be of little quantitative 
importance and thus are not taken into account.
1.2.1 Mechanism of Protein Synthesis
Information of the amino acid sequence required to produce proteins is 
contained in the genetic material as double-stranded DNA (Figure 1.1) (Waterlow et 
al, 1978a; Kimball and Jefferson, 1988). Proteins are coded for by sequences of base 
pairs, termed exons, joined by segments which do not code, introns. In the production 
of protein a mRNA copy of the DNA is produced by transcription. The mRNA 
transports the amino acid sequence codes from the nucleus to the site of protein 
synthesis. Amino acids are located correctly in sequence in relation to the mRNA by 
tRNA, to which they are acyl-bound and by polyribosomes as the process of 
translation. Translation of the information in mRNA into protein comprises the three 
steps of initiation (which appears to possess an important rate limiting function) 
(Figure 1.2) (Pain 1986), elongation and termination. After synthesis the protein may 
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Figure 1.1. Transcription o f the genetic material to pre-mRNA, processing to mRNA 
and translation to the protein product
1.2.2 Mechanisms o f Protein Breakdown
There are a number of distinct mechanisms whereby proteins are hydrolysed 
to their constituent amino acids (Finley and Varshavsky, 1985; Mayer and Docherty, 
1986; Kettelhut et al, 1988). The most extensively studied system is the lysosome. The 
membrane bound lysosome contains acidic proteases (cathepsins) and acid hydrolases. 
The lysosome predominantly degrades membrane proteins and glycoproteins but may 
be involved in the hydrolysis of cytoplasmic proteins during conditions of insulin 
deficiency and poor nutritional conditions. For muscles in vitro maintained under 
optimal conditions of nutrition, tension, amino acid availability and with insulin the
18
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lysosome contributes little to proteolysis (Furuno and Goldberg, 1986; Lowell et al, 
1986).
Calcium dependent proteases are responsible for marked proteolytic activity at 
neutral pH (Furuno and Goldberg, 1986). The extent that this system is important in 
proteolysis in healthy resting muscle is not clear but it appears to play an important 
role in damaged muscle (Kettelhut et al, 1988).
A system of energy dependent proteases has been identified which reduces in 
activity when oxidative phosphorylation and gluconeogenesis are inhibited. This ATP 
dependent system is shown to breakdown myofibrillar components. Part of the system 
may be a heat stable polypeptide, ubiquitin (Fagan et al, 1987). This becomes 
conjugated at its carboxyl terminal to the protein substrate at e-amino groups on 
lysine residues of the protein, thus marking the protein for hydrolysis by a large 
enzyme complex, Ubiquitin-Conjugate-Degrading-Enzyme. This may be the most 
important system for protein breakdown in normal cells (Lowell et al, 1986). It is not 
clear at the present time if the ATP dependent system is largely dependent on 
ubiquitin tagging or if it predominantly functions separately.
1.3 Basic Concepts about Proteins and Amino Acids
Body protein in a normal man of 70 kg amounts to 10-11 kg, of which 50 to 
65% is muscle (Cahill, 1970). Skeletal muscle represents approximately 40% of total 
body mass, or 70% of lean body mass, and is composed of approximately 18% protein. 










Figure 1.2. Schematic diagram of initiation o f protein synthesis (Kimball and 
Jefferson, 1988). First a ternary complex is formed from eukaryotic initiation factor-2 
(eIF-2),guanosine triphosphate (GTP) and initiator methionyl-tRNA™1 (Met-tRNA ™l). 
The ternary complex binds to a 40S ribosomal subunit complexed to other initiation 
factors. With the hydrolysis o f ATP and binding o f additional initiation factors and 
mRNA, a 48S preinitiation complex is formed which enables the 60S ribosomal subunit 
to bind, forming an initiation complex. By altering the phosphorylation state o f the 
initiation factors, and hence their ability to bind and form these complexes, insulin and 
other factors may modulate initiation.
Amino acids may be present free or bound as protein. Free amino acids are 
incorporated into proteins by protein synthesis and are released from it by protein 





release from protein, from the diet 
and, for the dispensable (or non- 
essential) amino adds by de novo synthesis.
Skeletal muscle has both 
mechanical and metabolic functions.
Most of the total protein bound 
amino acids are present in muscle 
and about 50% of the free amino 
acids in addition (Munro, 1970).
Skeletal muscle can therefore be Figure 1.3. Two pool model o f protein turnover;
D, diet; S, Synthesis; B, Breakdown; 0, 
considered a reservoir of amino acids Oxidation
which are available for a variety of
metabolic processes. They may thus be used as substrates for the synthesis of protein, 
either locally or essentially in every other tissue in the body (Waterlow et al, 1978b). 
The amino acids may act as precursors for gluconeogenesis to enable glucose 
homeostasis during starvation (Cahill, 1970; Daniel et al, 1977). The gluconeogenic 
amino acids, alanine and glutamine, efficiently transport fuel from muscle to the liver 
and enter glucose synthesis by means of the glucose-alanine cycle (Figure 1.4) (Felig, 
1975). Intermediary metabolites of branched-chain amino acids may act as substrates 
for fatty acid synthesis (Bender, 1985). Amino acids may act as substrate for further 




Figure 1.4. Glucose - alanine cycle
a source of nitrogen used in the synthesis of alanine (Matsutaka et al, 1973), in the 
kidney for ammonia synthesis (Cahill, 1970) and as a fuel in white cells, etc. AN 
futher function is as buffer during acid-base alterations, eg occurring in starvation 
when no cation accompanies ketone, bicarbonate, sulphate and phosphate excretion, 
glutamine is metabolised by the kidney to glutamate and the ammonium ion is 
excreted in the urine (Pitts et al, 1965; Golden et al, 1982).
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1.4 Free Amino Acid Pools
The following facts concerning free amino acids have been pointed out by 
Munro (Munro, 1970): Free amino acids account for only 0.5 to 1% of the total amino 
acids in the body. Free amino nitrogen is predominantly in the form of only four of the 
eight dispensable amino acids, namely alanine, glutamate, glutamine and glycine. 
Half of the body free pool of amino acids is present in skeletal muscle which 
accordingly accounts for the largest proportion of the total body free amino acids of all 
tissues. For the dispensable amino acids in particular, the concentrations of the free 
amino acids within cells are much higher than their respective concentrations in 
plasma indicating the existence of either a concentration mechanism by transport 
processes which must ultimately be energy dependent (eg glutamine which uses the 
sodium gradient) or due to binding (eg taurine). The proportions of the individual 
amino acids within the free pool does not relate to their proportions within the protein 
bound amino acid pool. Specifically, the branched-chain amino acids compose 20% of 
protein but only 1% of the free amino acid pool.
1.4.1 Factors Influencing the Size o f the Free Pool
Dietary intake is the major factor causing frequent and substantial alterations 
in the size of the free amino acid pool. Protein turnover is a factor which only has a 
net contribution to the free protein pool when synthesis and breakdown are not equal 
in magnitude. For the non-essential amino acids de novo synthesis occurs. 
Transamination of pyruvate to alanine and the amidation of glutamate to glutamine, 
are both important in the transport of amino-nitrogen from muscle to the liver (Felig
23
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et al, 1969; Felig and Wahren, 1974). Changes in the concentrations of amino acids 
may, therefore, reflect changes in the extent of amino acid oxidation and of 
gluconeogenesis. The transport kinetics of the amino acid at the cell membrane may 
play a part in regulating the free amino acid pool. However, for most amino acids this 
transport process is rapid with a high rate of exchange between the plasma and the 
intracellular free pools. This results in an intracellular free pool with a short half-life. 
Amino acid oxidation regulates the size of the free pool.
1.4.2 Amino Acid Patterns
The plasma and free intramuscular concentrations and the ratio of 
intramuscular to plasma concentrations, in man, are shown in Table 1.1. Data for rat 
muscle are shown in Table 1.2.
There is no fixed relationship between the concentrations of amino acids in the 
bound and free amino acid pools (Munro, 1970), the ratios varying over 20 fold. 
Therefore, the patterns of amino acids in the free pool and their alterations may not 
necessarily reflect changes in the protein bound pool. During protein synthesis the 
relative amounts of the amino acids used may vary markedly from their relative 
distribution in the free pool. The differences in the patterns between the free and the 
bound pool are maintained by a number of mechanisms. Dietary protein generally has 
an amino acid composition similar to that of human proteins and, accordingly, to the 
mix of amino acids used in protein synthesis and released by protein breakdown. 
Changes in the extent of oxidation and the transmembrane transport of each amino 
acid may also play roles. The k^ for most trasaminases are above the range of normal
24
Introduction
Table 1.1. Plasma and 
Concentrations in Man*




Histidine 80 370 4.6
Isoleucine 60 110 1.8
Leucine 120 150 1.2
Lysine 180 1150 6.4
Methionine 20 110 5.6
Phenylalanine 50 70 1.4
Threonine 150 1030 6.8
Valine 220 260 1.2
Dispensable
Alanine 330 2340 7.3
Arginine 80 510 6.5
Asparagine 50 470 9.5
Citrulline 30 40 1.6
Cysteine 110 180 1.6
Glutamate 60 4380 74
Glutamine 570 19450 34
Glycine 210 1330 6.5
Ornithine 60 300 5.1
Proline 170 830 4.9
Serine 120 980 6.9
Taurine 70 15440 220
Tyrosine 50 100 2.0
*Bergström et al, 1974.
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amino acid concentrations so that catabolism is to some extent driven by supply of 
substrate (Krebs, 1972). It follows, therefore, that if a substrate has a high steady 
state concentration (e.g. lysine and threonine) its oxidative system is likely to possess 
a low activity (Krebs, 1972). Conversely, the relatively low concentration of branched- 
chain amino acids in the free pool indicates that their oxidative enzymes have a high 
capacity and normal activity.
1.4.3 Influence o f Diet on Free Amino Acid Pool
Protein deficient diets produce a reduction of up to 50% in the concentration 
of indispensable amino acids in plasma, with increases of the same order in the 
dispensable amino acids (Lunn, 1976). It may seem paradoxical, therefore, that 
starvation results in increases in the plasma indispensable amino acids with 
reductions in the dispensable amino acids (Munro, 1970). Starvation also increases the 
concentrations of indispensable amino acids in muscle, presumably because of reduced 
incorporation into proteins and increased protein breakdown (Millward et al, 1974), 
the branched-chain amino acids being particularly sensitive to such dietary 
modulation. In protein deficiency in man the branched-chain amino acids are 
specifically reduced by the greatest extent (Holt et al, 1963). Conversely, during 
fasting the branched-chain amino acids are increased to the greatest extent in muscle 
(Millward et al, 1976). Amino acids with a high ratio of bound/free are most sensitive 
to changes induced by dietary influences and alterations in amino acid turnover eg 
branched-chain amino acids which together constitute 20% of muscle protein.
26
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Table 1.2. Bound and Free Amino Acid Concentration in Rat Muscle*
Protein Free Ratio
(pmol/g net weight) (Protein/Free)
Indispensable
Histidine 26 0.39 67
Isoleucine 50 0.16 306
Leucine 109 0.20 556
Lysine 58 1.86 31
Methionine 36 0.16 225
Phenylalanine 45 0.07 646
Threonine 60 1.94 31
Valine 83 0.31 272
Dispensable
Alanine 111 2.77 40
Arginine 67 0.25 269
Aspartate (+amide) 110 1.13 97
Glutamate (+amide) 148 9.91 15
Glycine 117 1.94 60
Serine 74 1.96 38




1.4.4 Dynamic Nature o f the Free Amino Acid Pool
The free amino acid pool of the rat can be calculated to turn over about every 
hour (Munro, 1970). In man the indispensable amino acid pool is smaller but because 
of the greatly reduced rate of protein turnover and thus a reduced flux the overall 
result is that it turns over more slowly than that of the rat (Bergstrom et al, 1974). 
Different amino acid pools turn over at different rates: that of leucine, which has a 
relatively high ratio of bound/free (Table 1.2), turns over about once every 60 min but 
in contrast lysine, with a lower ratio, takes ten hours. In some tissues free amino acid 
turnover is relatively rapid, eg in jejunum which has a turnover rate of 25 %/day, in 
contrast to muscle with a turnover rate ten-fold slower.
1.4.5 Transport Kinetics o f Free Amino Acids
The rate of uptake of most free amino acids to human muscle is directly 
proportional to their plasma concentrations (Banos et al, 1973; Lundholm et al, 1987). 
It is conceivable that amino acid delivery might limit rates of protein synthesis in man 
with the amino acid having the smallest ratio of rates of delivery to incorporation into 
protein possibly constraining protein synthesis under conditions of high amino acid 
demand, such as during growth spurts or periods of tissue repair after injury, if 
dietary amino acid intake was concurrently reduced. For leucine, the blood 
concentration of which is about 0.12 mmol/1, if blood flow to total body muscle is 
approximately 1 1/min and protein synthetic rate is about 1.5 %/day (Halliday et 
al, 1988) then the daily total blood leucine delivery (170 mmol) is about 3.4 times the 
total amount of leucine incorporated into protein daily. Although this calculation 
suggests that it might be possible for the rate of muscle protein synthesis to exceed 
the rate of leucine delivery under certain conditions with greatly accelerated protein
28
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accretion, this must be considered unlikely if account is made of leucine released from 
muscle by protein breakdown. However, if  hyperinsulinaemia concurrently reduces 
amino acid release via protein breakdown thus reducing plasma (Fukagawa et al, 
1985; Fukagawa et al, 1986; Tessari et al, 1986b) and muscle amino acid 
concentrations (Alvestrand et al, 1988), it is possible that amino acid delivery might 
restrict protein synthesis (Castellino et al, 1987). The foregoing analysis is fair but it 
should be emphasized that it only takes account of the broadest scheme of 
requirements. It may be that if transport, synthesis or breakdown occur in distinct 
compartments then the analysis may be to simplistic. Similarly it does not take into 
account the possible signalling roles of specific amino acids.
1.5 Assessment o f Protein Turnover
Changes in muscle bulk and lean body mass may be measured by computed 
axial tomography (Haggmark et al, 1978; Bulcke et al, 1979; Termonte et al, 1980; 
Maughan et al, 1984; Buckley et al, 1987), magnetic resonance imaging (Andrew, 
1980), whole-body potassium (40K) counting (Preston et al, 1985), water (3HHO or 
2HHO) dilution (Jensen et al, 1988a), total body electrical conductivity (Segal et al,
1985), densitometry (Dumin and Womersley, 1974) and anthropometry (Durnin and 
Womersley, 1974) but with these techniques changes in lean body mass and muscle 
size may only be determined over periods of weeks. Measurement of urinary excretion 
of creatinine or 3-methylhistidine may also be used as a measure of muscle mass. The 
principal techniques available for assessing protein turnover are:
a) Nitrogen balance techniques where the dietary nitrogen intake and urinary 
output of nitrogen are measured (and the faecal and sweat outputs of nitrogen either
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measured or estimated) allowing an estimate of the net protein balance but neither 
protein synthesis nor breakdown (turnover in the true sense).
b) Urinary release of 3-methylhistidine, generally expressed as the ratio of 
3-methylhistidine/creatinine, is an index of total myofibrillar protein breakdown in 
the whole-body (Ballard and Tomas, 1983).
c) 3-Methylhistidine release from leg tissues, measured as the product of 
arteriovenous concentration differences and blood flow, which may be a more specific 
assessment of skeletal muscle myofibrillar protein breakdown (Rennie and Millward,
1983).
d) Use of single dose of an isotope labelled amino acid to assess turnover or flux 
of the amino acid in the free amino acid pool from the rate of dilution of the tracer 
(Figure 1.5) (Henriques et al, 1955; Reilly and Green, 1975; Umpleby et al, 1986; 
Cobelli et al, 1987; Bier, 1989).
e) Estimation of protein turnover from dilution of [15N] in metabolism end 
products (urea or ammonia) from labelled dispensable amino acids, usually 
[15N]glycine (Sprinson and Rittenberg, 1949; Olesen et al, 1954; Fern et al, 1981; 
Waterlow, 1981).
f) Continuous infusion of a labelled amino acid to assess the turnover or flux of 
the amino acid in the free amino acid pool (Figure 1.6) (O’Keefe et al, 1974; Matthews 
et al, 1980; Clarke and Bier, 1982).
g) Incorporation of labelled free amino acid into the bound amino acid pool within 
tissue or plasma proteins (Figure 1.6), either in vitro or in vivo, (Schoenheimer et al, 
1942; Halliday and McKeran, 1975; Rennie et al; 1982).
h) Use of a single dose of tracer combined with a large dose of non-labelled amino 
acid to flood the free amino acid pool and thereby label the intracellular amino acid
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compartments with tracer to a similar extent as the accessible amino acid in plasma 
(Garlick et al, 1989a).
i) Simultaneous employment of arteriovenous phenylalanine tracer exchange and 
amino acid balance techniques to assess skeletal muscle protein breakdown and 
synthesis (Gelfand and Barrett, 1987; Thompson et al, 1989).
j) Measurement of tissue ribosome content to assess the capacity for protein 
synthesis (Millward et al, 1973) or measurement of polyribosomal profile in tissue 
biopsy samples to assess translational activity (Hammarqvist et al, 1988; Kimball and 
Jefferson, 1988; Wernerman et al, 1989).
Details of the techniques employed in the present investigations are covered 
in the next chapter.
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Figure 1.5. Schematic representation o f the exponential decay in plasma 
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Figure 1.6. Upper panel: Schematic representation o f a continuous infusion o f stable 
isotope labelled tracer. Lower panel: Incorporation of the tracer into muscle
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1.6 Maintenance, Growth and Wasting o f Lean Body Mass
Lean body mass is maintained when protein synthesis and breakdown are in 
balance. Growth occurs when protein synthesis exceeds protein breakdown; protein 
breakdown may be reduced or increased in magnitude (Figure 1.7). Conversely, 
wasting occurs when breakdown exceeds protein synthesis; protein breakdown is not 











Figure 1.7. Hypothetical mechanisms of growth and tissue wasting
33
Introduction
1.6.1 Mechanisms o f Growth o f Lean Tissues
Growth can be occur when rates of protein breakdown are increased; under 
these conditions protein synthesis must be markedly elevated if growth is to occur. 
This situation is encountered in the growth periods of immature animals where rates 
of protein synthesis (Garlick et al, 1989b) and breakdown are higher than in adults 
of the species on a fractional basis (Millward, 1980a; Millward, 1980b). The increased 
protein breakdown may allow remodelling of muscle rather than enabling growth to 
take place (Millward et al, 1975; Maruyama et al, 1978). During refeeding in 
malnourished rats both protein synthesis and protein breakdown increase (Young et 
al, 1971). Cardiac hypertrophy, which develops in such conditions as systemic 
hypertension and aortic stenosis, is associated with both increased protein synthesis 
and breakdown, resulting in a net protein synthesis (Gudbjamason et al, 1964; Zak 
and Fischman, 1971; Morkin et al, 1972). It follows that a finding of increased protein 
breakdown does not necessarily indicate impairment of growth.
In contrast to the changes of mass of cardiac muscle, increases in liver tissue, 
which may occur after liver resection are associated with both increased protein 
synthesis and reduced protein breakdown (Scomik, 1974; Swick and Ip, 1974).
Reduced protein breakdown is demonstrated in a rapidly growing strain of rat 
(Bates and Millward, 1978). Alteration of thyroid status by administration of 
triiodothyronine at low levels to rats after thyroidectomy is shown to stimulate normal 
growth despite reduced protein synthesis; the balance between synthesis and 




1.6.2 Mechanisms o f Wasting o f Lean Tissues
In contrast to growth, for wasting to occur protein breakdown must exceed 
protein synthesis. Analogous to the circumstances for growth, there are a number of 
possible mechanisms whereby wasting might occur (Figure 1.7).
Mill ward and colleagues have put forward the idea that alteration in protein 
synthesis by muscle tissues is the dominant pathophysiological mechanism which 
facilitates muscle wasting in a number of distinct conditions (Millward et al, 1976; 
Rennie et al, 1983). However, during increased protein synthesis there may be a 
paradoxical adaptive increase in protein breakdown which tends to oppose the effect 
of the changes in protein synthesis. Such changes occur during muscle hypertrophy 
induced by exercise (Laurent et al, 1978) and the opposite changes occur during 
starvation where both rates of protein synthesis and breakdown decrease (Millward 
and Waterlow, 1978). It is not yet established that synthesis is of principal importance 
in regulating tissue mass and certainly this does not appear to be the case for all 
other tissues. In liver protein breakdown appears to be of greater importance in 
regulating liver size than does protein breakdown (Garlick et al, 1973; Emery et al, 
1986).
A full pattern has not been described for the abnormalities of protein synthesis 
and breakdown occurring in different pathophysiological situations in man where 
muscle wasting occurs. However, there is information about the pattern of muscle 
protein turnover found in a number of specific conditions. In patients with cardiac 
cachexia muscle protein breakdown is increased (Morrison et al, 1988c). In contrast 
in a number of other conditions where muscle wasting occurs protein breakdown is not
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increased but muscle protein synthesis is reduced. These conditions include patients 
on their first day after operation, when undergoing abdominal surgery (Rennie et al, 
1984); patients with Duchenne muscular dystrophy (Rennie et al, 1982a) and myotonic 
muscular dystrophy (Halliday et al, 1985); patients with untreated thyrotoxicosis 
(Morrison et al, 1988a) and patients with emphysema (Morrison et al, 1988b). In 
cancer patients with muscle wasting, not only is muscle protein synthesis reduced but 
in addition muscle protein breakdown is reduced (Lundholm et al, 1982).
1.6.3 Contribution by Muscle to Whole-body Protein Turnover
Information about the extent to which different tissues contribute to whole- 
body protein synthesis in man is limited. Muscle probably contributes from 25-50% 
of whole-body protein turnover in man (Munro, 1970; Rennie et al, 1982b; Nair et al, 
1988a; Chapter 4); The revised data published by Rennie and colleagues (Halliday et 
al, 1988) suggests that the figure of 25%, calculated with amended methodology, may 
be a better estimate than the original value of 50%. It follows that changes in muscle 
protein metabolism may not be evident by alterations of whole-body protein turnover 
if opposing changes occurred in other tissues in the body. As protein turnover in many 
other tissues is more rapid than that in muscle, changes in protein turnover in liver 
and the splanchnic region might overshadow any changes occurring in muscle 
(Sakamoto et al, 1983; Emery et al, 1984).
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1.6.4 Factors Which Induce Acute, Severe Muscle Wasting
In attempting to develop a complete picture of the control of muscle protein 
metabolism it must be noted that there are a number of factors which have acute and 
severe effects on muscle protein metabolism but which play little if any part in the 
physiological regulation of muscle mass in man. Such factors include absence of neural 
influences (Afting et al, 1981); severe infection or components of infection including 
lipopolysaccharide endotoxins (Wannemacher et al, 1971; Powanda, 1977; Fish and 
Spitzer, 1984; Filkins, 1985; Jepson et al, 1986) and damage occurring during raised 
intracellular calcium concentrations (Jackson et al, 1984).
1.7 Physiological and Pathophysiological Regulation o f Protein Turnover by Feeding, 
Fasting and Substrate Supply
There is an extensive body of knowledge about the factors which modulate 
protein turnover in animals but for man such information is limited. There may be 
species differences with regard to the effects of any stimulus in animals or man and, 
in addition, many, if not most, experiments of the regulation of amino acid metabolism 
in animals have been undertaken in young growing animals which may behave 
differently from adult man. It, therefore, cannot be determined to what extent the 
information available from animal studies pertains to man. Many studies have 
employed in vitro experiments and even in these where human tissue has been used 
there may be major differences between the response of the isolated (often dying) 
tissue and of the intact animal.
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I plan in this account to concentrate on information available from in vivo 
human studies but will also include information from animal studies, both in vivo and 
in vitro, whenever pertinent information from human studies is either unavailable or 
is limited by the methodology that can be employed in man. An additional rationale 
for considering the results from in vitro and in vivo animal studies is that where 
accord exists with the results from studies in man the information may be considered 
secure. In contrast where the results are discrepant there may be methodological or 
theoretical deficiencies which would render any results invalid.
1.7.1 The Effect o f Feeding and Fasting
A net uptake of amino acids by muscle must occur during feeding (although it 
is difficult to document in man in vivo) and a net release occurs during fasting (Elia 
and Lavesey, 1983). Studies of the incorporation of [ l-13C]leucine into quadriceps in 
healthy man show that protein synthesis is greater during feeding than during fasting 
(Rennie et al, 1982b; Halliday et al, 1988). These results have been confirmed by the 
in vivo application of a technique based on the exchange of [l-13C,15N]leucine by 
human forearm tissues (Cheng et al, 1985; Cheng et al, 1987). In addition these 
authors showed that feeding resulted in increased leucine deamination, reamination 
and oxidation and improved the net balance between synthesis and breakdown, but 
their results suggested that feeding had no effect on the rate of mixed muscle protein 
breakdown. The lack of any effect of feeding on muscle protein breakdown is also 
shown by Tracey and colleagues who assessed myofibrillar protein breakdown by limb 
release of 3-methylhistidine during parenteral feeding (Tracey et al, 1988). Feeding
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of steak in man was shown to induce net amino acid uptake by the leg but this effect 
is partly offset by an increased net keto acid output (Elia and Livesey, 1983).
Both the muscle biopsy based and the arteriovenous exchange-based techniques 
have as a theoretical disadvantage the possibility that changes in the plasma 
concentration of the amino acid tracee, leucine, which occur during feeding might alter 
the tracer equilibrium between the accessible plasma pool and that at the site of 
incorporation of precursors for protein synthesis within cells. Increases in amino acid 
transport occurring at increased amino acid concentration (Lundholm et al, 1987) 
result in increased tracer and tracee exchange between plasma and the intracellular 
pool (Layman and Wolfe, 1987) and a closer approximation by the plasma enrichment 
to the intracellular enrichment. Estimates of intracellular amino acid metabolism 
during postabsorptive conditions, therefore, tend to be underestimated when the 
plasma amino acid enrichment or specific activity is used as a basis for calculations 
but underestimated to a lesser extent during feeding. It is follows that the tracer 
dilution technique employed in most studies tends to overestimate the increases in 
protein synthesis during feeding. Where the keto acid of leucine, a measure of the 
intracellular leucine labelling (Matthews et al, 1982; Schwenk et al, 1985a; Layman 
and Wolfe, 1987; Horber et al, 1989), was used to define precursor pool enrichment in 
the biopsy-based studies (Rennie et al, 1982b; Halliday et al, 1988) overestimation of 
the effects of feeding on protein synthesis would occur to a much lesser extent, if at 
all.
Gar lick and collaborators, employing a flooding dose technique to minimise the 
differences in tracer enrichment between the plasma compartment and the precursor
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pool for protein synthesis within the cell and, thereby, reduce the uncertainty about 
precursor labelling, have reported higher fractional protein synthesis rates in skeletal 
muscle in man (Garlick et al, 1989) than Halliday and colleagues (Halliday et al,
1988). Garlick found no effect of feeding on muscle protein synthesis in man using the 
flooding dose technique but did when the constant infusion technique was used (P. J. 
Garlick, personal communication). It remains to be determined if the addition of large 
quantities of leucine during these studies may have had some independent effect and 
masked any effects of feeding and fasting.
In fasted growing rats an effect of refeeding on muscle protein synthesis occurs 
after only 1 h (Garlick et al, 1983), results concordant with the results of the studies 
in man by Rennie and by Halliday. In vitro studies with muscle suggest that 
deficiency of nutrient supply both depresses protein synthesis and increases protein 
breakdown (Li and Goldberg, 1976; Li et al, 1979).
In contrast to the situation in muscle, loss of protein from liver during fasting 
does not occur as a result of a decrease in protein synthesis (Garlick et al, 1973, 
Garlick et al, 1975) in animals. Feeding causes a marked depression in the rate of 
liver protein breakdown (Conde and Scomik, 1976). The effect of feeding to increase 
protein synthesis in muscle and to reduce protein breakdown in liver (and possibly in 
muscle), might not be reflected in the results of in measures of whole-body protein 
breakdown. Liver protein turnover is much faster than muscle protein turnover and 
changes in liver protein turnover might overshadow any changes in muscle.
Mixed feeding is shown to increase whole-body protein synthesis in man 
(Garlick et al, 1980; Motil et al, 1981a; Motil et al, 1981b; Clugston and Garlick, 1982; 
Rennie et al, 1982b; Clague et al, 1983; Hoffer et al, 1985; McNurlan et al, 1987),
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although not in all reports (Young et al, 1987; Beaufrere et al, 1989). Feeding, in most 
of these reports, reduced whole-body protein breakdown (Motil et al, 1981a; Motil et 
al, 1981b; Clugston and Garlick, 1982; Hoffer et al, 1985; Young et al, 1987; Tracey 
et al, 1988; Beaufrere et al, 1989) but no effect was reported by some authors (Garhck 
et al, 1980; Rennie et al, 1982b; Clague et al, 1983; Young et al, 1987). These measures 
of the effect of feeding are also subject to the uncertainties of precursor labelling 
detailed above although use of an a-ketoisocaproate-based model in a number of the 
studies may minimise this problem. In some studies substantial errors due to 
recycling of trace may have occurred: this problem, identified by Schwenk and 
colleagues (Schwenk et al, 1985b), leads to underestimation of protein synthesis where 
synthesis was measured sequentially following a period of fasting during prolonged 
tracer infusion. Failure to take account of metabolism of ingested leucine or protein 
by gut and by liver generally results in overestimates of the reduction in protein 
breakdown occurring during feeding. However, in studies where simultaneous 
intragastric and intravenous tracers were infused (Nissen and Haymond, 1986; 
Tessari et al, 1988; Beaufrere et al, 1989) reductions in whole-body protein breakdown 
are reported to occur with feeding. An additional source of error with most of the 
studies referenced above is failure to measure or account for the decreased proportion 
of bicarbonate which is fixed during feeding (Hoerr et al, 1989). Where this was 
accounted for feeding is reported to reduce whole-body protein breakdown but to have 
no effect on whole-body protein synthesis (Beaufrere et al, 1989).
Prolonged fasting, for four days, is shown to increase whole-body leucine flux 
or proteolysis (Jensen et al, 1988b), and to reduce skeletal muscle protein synthesis 
in man (Ess6n et al, 1989). The effect of fasting in the longer term is to reduce protein
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utilization as a source of substrate for gluconeogenesis but such changes take about 
a week to be apparent (Kettelhut et al, 1988).
1.7.2 The Effect o f Amino Acids
During infusion of mixed amino acids in man, increased net amino acid uptake 
occurred both in leg tissues and in the splanchnic bed (Gelfand et al, 1986). In that 
report muscle was estimated to remove about 25-30% of the total amino acid load 
infused and the splanchnic viscera (gut and liver) removed 65-70%. No account was 
taken of release of keto acids and amino acid metabolites in this study (Gelfand et al,
1986). In a subsequent study, where [l-14C]leucine was infused to assess protein 
synthesis and breakdown during mixed amino acid infusion, amino acid infusion 
apparently increased skeletal muscle and visceral tissue protein synthesis and reduced 
skeletal muscle and visceral tissue protein breakdown (Gelfand et al, 1988); again the 
model employed in this study did not account for the intermediary metabolism of 
leucine.
Infusion of a solution of mixed amino acids is reported to increase whole-body 
protein synthesis (Castellino et al, 1987; Tessari et al, 1987; Pacy et al, 1988a). A 
uniform effect of the mixed amino acid infusion on whole-body protein breakdown was 
not reported: a decrease was found in two studies (Castellino et al, 1987; Pacy et al, 
1988a) but no change was reported in one of the studies in which a different kinetic 
model was employed (Tessari et al, 1987) ie a double-primary pool model as opposed 
to a reciprocal-pool model.
Infusion of branched chain amino acids had no effect on either net leg protein 
balance or myofibrillar protein breakdown in either healthy subjects or in patients
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with cardiac cachexia (Morrison et al, 1988c), and leucine had no effect on limb protein 
balance in man (Hagenfeldt et al, 1980; Eriksson et al; 1983). Abumrad and colleagues 
reported a transient and unsustained effect of leucine on forearm amino acid balance 
(Abumrad et al, 1982). Branched chain amino acids had no effect on protein synthesis 
assessed by ribosomal profile in man (Hammarqvist et al, 1988), but paradoxically 
leucine injection is reported to increase the proportion of muscle ribosomes as 
polyribosomes of fasted rats (Buse et al, 1979). Infusion of substantial amounts of 
leucine alone is reported to increase whole-body protein synthesis slightly in man 
(Schwenk and Haymond, 1987). In this study the investigators infused [4,5-3H]leucine 
and a-keto[l-14C]isocaproate rather than an amino acid tracer different from the 
substrate under test (Schwenk and Haymond, 1987). It is possible that alterations 
occured in the equilibrium between the tracer in plasma and in intracellular 
compartments due to increases in leucine concentration, and hence transmembrane 
transport; this must weaken any conclusions from the study.
In samples of human muscle studied in vitro a ten-fold increase in amino acid 
concentrations alone increased protein synthesis (Lundholm and Schersten, 1977). In 
addition complete mixtures of amino acids are reported to enhance protein synthesis 
in cell free systems (Tyobeka and Manchester, 1985). Leucine is reported to stimulate 
rat muscle protein synthesis in vitro (Buse and Reid, 1975) but this effect was not 
found in a study in rats in vivo (McNurlan et al, 1982). In a subsequent investigation 
both leucine and isoleucine were shown to have such an effect in vitro; in contrast 
neither other amino acids nor a-ketoisocaproate had such an effect (Hedden and Buse,
1982). It appears that the branched-chain amino acids (in particular leucine) are 
responsible for the effect of amino acid mixtures on stimulation of muscle protein
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synthesis and of reductions in muscle protein breakdown (Buse and Reid, 1975; Fulks 
et al, 1975, Li and Jefferson, 1978; Adibi, 1980; Walser, 1984; May and Buse, 1989). 
The mechanisms whereby such effects are mediated are not known as the km for the 
charging of tRNA is likely to be much lower than the intracellular concentration of 
amino acids so that the TRNA is always fully charged (Shenoy and Roger, 1978; Flaim 
et al, 1982; Tyobeka and Manchester, 1985). The observation of a reduction in 
ribosomal subunits during provision of branched-chain amino acids (Li and Jefferson, 
1978; Buse et al, 1979) indicates an effect of amino acids on initiation of protein 
synthesis.
In addition to an increase in muscle protein synthesis, mixtures of amino acids 
seem to reduce muscle protein breakdown in rodent muscles in vitro (Fulks et al, 
1975; Frayn and Maycock, 1979). The effects of amino acids on liver protein turnover 
are both to reduce breakdown (Woodside and Mortimore, 1972; Mortimore et al, 1987) 
and to increase synthesis (Flaim et al, 1982).
There is a possible role of glutamine in controlling protein synthesis 
(MacLennan et al, 1987); this amino acid may play a key role in mediating the effects 
of corticosteroids (Muhlbacher et al, 1984) and of the injury process in general (Rennie 
et al, 1986) on protein turnover.
Garlick has suggested that the effect of amino acids is to increase the 
sensitivity of muscle protein to insulin (Garlick and Grant, 1988; McNurlan and 
Garlick, 1989). This may be an important mechanism whereby amino acids exert their 
anabolic effect but such a theory does not fully explain the effects of amino acids in 
vitro where insulin does not change.
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1.7.3 The Effect o f Substrates
There is little information available about the effects of different substrates on 
protein turnover in man.
fi-hydroxybutyrate: The ketone body (3-hydroxybutyrate has been suggested to 
increase muscle and whole-body protein synthesis and to reduce wbole-body leucine 
oxidation in man (Nair et al, 1988b). It remains possible that this effect resulted from 
alterations in acid base homeostasis, a factor shown to have effects on protein 
turnover and amino acid oxidation in dogs (Rodriguez et al, 1989). There is no 
apparent effect of P-hydroxybutyrate on whole-body protein breakdown (Miles et al, 
1983, Nair et al, 1988b).
Glucose: Infusion of glucose at 4 mg kg'1 min'1 is reported to reduce whole-body 
leucine oxidation and to decrease whole-body protein breakdown in healthy man with 
no effect on protein synthesis (Robert et al, 1984). In addition to an increase in plasma 
glucose concentration, plasma insulin increased (from 10 to 27 Mu/1) and there was 
a trend of reduced glucagon concentrations. It is possible that the effects of glucose 
provision were mediated by such alterations in hormones and were not a direct effect 
of glucose. In type 1 diabetic subjects during euglycaemic (5.9 mmol/1) and 
hyperglycaemic (15.9 mmol/1) insulin clamps, whole-body protein breakdown and 
leucine oxidation were greater during the latter study conditions (Robert et al, 1985). 
In these studies insulin was infused at 1.65 U/h during euglycemic studies and at 0.24 
U/h during hyperglycemic studies which may have directly induced the differences in 
protein metabolism. Feeding excessive energy nutrients of either carbohydrate, fat or 
a mixture of both improved nitrogen balance and decreased leucine oxidation; these 
induced a reduction in protein breakdown but no alteration in protein synthesis (Motil
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et al, 1981b). Experiments with rat muscle in vitro show that low concentrations of 
glucose in the perfusing media results in increased leucine oxidation than occurs 
during glucose replacement (Buse et al, 1972), and glucose alone has been reported to 
increase muscle protein synthesis (Hedden and Buse, 1982). In these studies lactate 
and pyruvate had similar effects to glucose, and protein synthesis was dependent on 
the cytoplasmic redox potential (i.e. ratio of NADH/NAD+) (Hedden and Buse, 1982).
Triglycerides: Infusion of medium-chain triglycerides and long-chain 
triglycerides in man improves the net amino acid balance across forearm suggesting 
either increased protein synthesis or reduced proteolysis of skeletal muscle 
(Wicklmayr et al, 1987). Increases in plasma fatty acid concentrations in dogs reduced 
whole-body leucine flux and leucine oxidation and tended to reduce whole-body protein 
synthesis (Tessari et al, 1986c). Conversely, decreased plasma free fatty acid 
concentrations increased whole-body leucine flux and oxidation and decreased whole- 
body protein synthesis (Tessari et al, 1986c). The medium-chain fatty acid, octanoate, 
is reported to either increase (Buse et al, 1S72; Paul and Adibi, 1986; Spydevold and 
Hokland, 1981; Wagenmakers and Veerkamp, 1982) or to decrease (Buffington et al, 
1979; Buxton et al, 1984) leucine oxidation by rat muscle but to inhibit leucine 
oxidation in rat liver (May et al, 1980; Spydevold and Hokland, 1981). Octanoate is 
reported to reduce muscle protein synthesis in vitro (Wagenmakers and Veerkamp,
1984) and whole-body protein synthesis in dogs in vivo (Rodriguez et al, 1986).
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1.8 The Effect o f Hormones
Our understanding of the effects of hormones comes principally from studies 
in animals, often with in vitro preparations. While these enable information to be 
gained about apparently individual effects of hormones, the approach ignores the 
complicated interactions which exist between hormones, in both the regulation of their 
own secretion and that of other hormones and in interactions between them at end 
organs.
1.8.1 Insulin
Insulin acts on a membrane receptor which possesses intrinsic tyrosine kinase 
activity (Kahn and White, 1988). The events within the cell which occur after insulin 
binds are not clearly elucidated but appear to result from phosphorylation of 
intermediates.
In postabsorptive healthy man, regional infusion of insulin appears to reduce 
skeletal muscle protein breakdown, assessed by dilution of phenylalanine tracer, but 
has no obvious effect on skeletal muscle protein synthesis (Gelfand and Barrett, 1987). 
In addition no effect of systemic infusion of insulin was found on the rate of leucine 
incorporation into quadriceps muscle in type 1 diabetic subjects studied dining insulin 
withdrawal and hyperglycaemia and during insulin replacement and euglycaemia 
(Pacy et al, 1989).
In contrast to these results from studies in man, insulin has been shown 
repeatedly to increase skeletal muscle protein synthesis in animals, both in vitro 
(FIaim et al, 1980; Jefferson, 1980; Airhart et al, 1982; Stirewalt et al, 1985; Kimball
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and Jefferson, 1988) and in vivo (Hay and Waterlow, 1967; Pain and Garlick, 1974; 
MiUward ei al, 1976; Pain et al, 1983; Ashford and Pain, 1986a; Ashford and Pain, 
1986b). The effect of insulin is to promote the initiation of translation (Fulks et al, 
1975, Li and Jefferson, 1978; Kimball and Jefferson , 1988) and to maintain ribosomal 
levels predominantly by reducing degradation of ribosomes but also with an effect on 
synthesis particularly in heart muscle (Ashford and Pain, 1986a; Ashford and Pain, 
1986b). Stimulation of gene expression for specific proteins (e.g. albumin) has been 
demonstrated in vitro (Lloyd et al, 1987; Dillmann, 1988). Despite reports of increased 
uptake of a-aminoisobutyrate (AIB), a non-metabolizable synthetic amino acid, into 
cells by insulin at supraphysiological concentrations (Kipnis and Noall, 1958) there 
appears to be no physiological effect of insulin per se on transport of all amino acid 
into cells (Hundal et al, 1989). In addition, there appears to be no effect of insulin on 
TRNA charging (Airhart et al, 1982; Stirewart et al, 1985).
The positive effect of insulin on protein synthesis has not always been 
confirmed, particularly in the fed state (Pain and Garlick, 1974; Oddy et al, 1987; 
McNurlan and Garlick, 1989). The reason for these differences in response to insulin 
in the different preparations are not apparent but may have occurred as a result of 
reduced viability of the in vitro preparations, or from differing substrate utilization 
of tissues studied in vitro or possibly from the alteration by streptozotocin of thyroid 
status in addition to induction of diabetes (Barrett and Gelfand, 1989). The net 
catabolic state of tissues studied in the in vitro situation may maintain a generous 
source of amino acids to supply protein synthesis, whereas the much reduced rates of 
protein breakdown which occur in vivo may limit amino acid availability and prevent
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any increase in protein synthesis by insulin. In the rat protein synthesis by the liver 
is less sensitive to alterations of insulin than muscle (Hay and Waterlow, 1967; Pain 
and Garlick, 1974).
In type 1 diabetic subjects, withdrawal of insulin results in elevation of whole- 
body protein breakdown, an increase in plasma amino acid concentrations and an 
increase in rates of whole-body leucine oxidation (Nair et al, 1983; Robert et al, 1985; 
Tessari et al, 1986a; Umpleby et al, 1986; Nair et al, 1987a; Pacy et al, 1989). In 
contrast, in these subjects whole-body protein synthesis is neither reduced during 
insulin withdrawal, compared to healthy subjects, nor is it increased by insulin 
replacement. On the basis of these results it has been assumed that the effects of 
insulin in adult man are primarily on whole-body protein breakdown with no direct 
effect on whole body-protein synthesis.
Insulin is known to stabilize lysosomes and thereby limit muscle protein 
breakdown (Kettelhut et al, 1988). For muscle myofibrillar proteins lysosomes are not 
generally considered to be involved in protein breakdown (Lowell et al, 1986). 
Lysosomes are a site for proteolysis of non-contractile proteins of muscle and are 
important as a site of protein breakdown in liver. Insulin may reduce mixed skeletal 
muscle protein breakdown but have no effect on myofibrillar protein breakdown in 
vitro (Smith and Sugden, 1986), although other workers show a restraining effect of 
insulin on myofibrillar protein breakdown in diabetic rats (Smith et al, 1989). Whole- 
body protein synthesis may be reduced by about 30% by insulin infusion (Castellino 
et al, 1987; Tessari et al, 1987) suggesting that protein breakdown by lysosomes may 
account for about 30% of total protein breakdown in the body.
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During studies in healthy man in which amino acids were infused with insulin 
to prevent insulin-induced hypoaminoacidaemia, insulin appeared to have no effect 
on whole-body protein synthesis; in contrast alteration of amino acid concentrations 
did alter whole-body protein synthesis (Castellino et al, 1987; Tessari et al, 1987; 
Flakoll et al, 1989). The concentration of amino acids within cells may not have been 
represented by the plasma concentrations and amino acid availability at a tissue level 
may not have been comparable during hyperaminoacidaemia in the absence and in the 
presence of insulin in these studies. In these studies insulin reduced whole-body 
protein breakdown (Castellino et al, 1987; Tessari et al, 1987; Flakoll et al, 1989).
1.8.2 Growth Hormone
Growth hormone causes children to grow (Tanner et al, 1977) and improves 
nitrogen balance in man (Manson and Wilmore, 1986; Clemmons et al, 1987; Ponting 
et al, 1988, Ziegler et al, 1988). In pharmacological doses in healthy man, growth 
hormone decreases whole-body leucine oxidation and increases whole-body protein 
synthesis but appears to have no effect on whole-body protein breakdown (Horber and 
Haymond, 1989). In growth hormone deficient children whole-body protein synthesis 
is depressed and growth hormone treatment rapidly increases whole-body protein 
synthesis (Richter et al, 1987). There is no published information about the effect of 
growth hormone on muscle protein turnover in man but in animals it appears to have 
a direct anabolic action by increasing muscle protein synthesis (Cameron et al; 1988). 
Most of the effects of growth hormone are mediated by insulin-growth factor I (Isgaard 
et al, 1989), but in addition insulin secretion is increased by growth hormone and this
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may play an independent part in the mediation of growth hormone action on protein 
metabolism.
1.8.3 Insulin-like Growth Factor I
The effects of growth hormone are predominantly mediated by the two insulin- 
like growth factors I and II (IGF-I and IGF-II), factors postulated to exist on the basis 
of pioneering experiments by Salmon and Daughaday (Salmon and Daughaday, 1957). 
About half of IGF-I is produced by the liver (Daughaday and Rotwein, 1989). Almost, 
all tissues have the capacity to express the growth factors (Han et al, 1988) and, 
therefore, they may function predominantly as paracrine rather than as endocrine 
agents. IGF-I acts on receptors with close structural homology to the insulin receptor 
(Rechler and Nissley, 1989). Only the relatively recent development of specific 
antibodies against IGF-I and its receptor have enabled a clear separation of IGF-I 
effects from these of insulin. The growth factor, IGF-I, possesses potent stimulatory 
activity on protein synthesis in vitro (Froesch et al, 1985). In contrast, when infused 
intravenously in rodents IGF-I apparently decreased whole-body protein synthesis and 
breakdown and reduced the rates of protein synthesis in a number of specific tissues 
(Jacob et al, 1989). These results may have resulted from use of supraphysiological 
doses, where the IGF-I was not associated with its specific binding protein, and a 
direct effect mediated via the insulin receptor may have resulted. An additional 
uncertainty with this piece of work is that the magnitude of the protein turnover rates 
are a few fold lower than would be expected in the rat. It has been shown that growth 
hormone has greater growth promoting effects than IGF-I suggesting that additional
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factors other than IGF-I are important in mediating the effects of growth hormone 
(Skottner et al, 1987). Results of the effect of IGF-I and IGF-II on protein turnover in 
man are not available at present but the recent introduction of synthetic IGF-I by 
recombinant gene technology should stimulate research in this area.
1.8.4 Cortisol
The glucocorticoids, and cortisol in particular, have a negative effect on protein 
balance. In man short courses of cortisol increase whole-body protein breakdown 
(Beauffere et al, 1989) and stimulate transfer of nitrogen from leucine to alanine and 
to glutamine with a resultant increased synthesis of these gluconeogenic amino acids 
(Simmons et al, 1984; Daurmaun et al, 1988). In subjects with longer-duration hyper- 
glucocorticoidaemia from untreated Cushing’s syndrome increased whole-body protein 
breakdown was not observed (Tessari et al, 1989). This overtly anomalous result may 
have arisen either as a result of expression of the leucine kinetic results after 
normalization for total body weight as opposed to lean body mass (due to decreased 
muscle and protein mass in patients compared to controls), or may relate to use of a 
leucine kinetic model where flux is derived from the sum of leucine and a- 
ketoisocaproate primary pool estimations. It is also likely that these different effects 
of cortisol in the longer term are the result of adaptive mechanisms such as increased 
insulin concentration and to a predominant action of glucocorticoids to impair protein 
synthesis. Wolfe has suggested that amino acid homeostasis may escape control by 




From the results of animal-based studies corticosteroids may both increase 
protein myofibrillar protein breakdown and decrease muscle protein synthesis 
(Rannels and Jefferson, 1980; Odedra et al, 1983; Kayali et al, 1987), but no effect on 
myofibrillar protein breakdown was shown by Beaufrere and colleagues in man 
(Beauffere et al, 1989). Glucocorticoids decrease glutamine concentrations in plasma 
and muscle (Muhlbacher et al, 1984): this may be a possible mechanism whereby they 
action on protein turnover as glutamine appears to regulate protein turnover during 
injury (Rennie et al, 1986). Glucocorticoids are also known to reduce RNA 
concentration and to inhibit translation (Rannels and Jefferson, 1980) in animals and 
to decrease muscle ribosome concentration in man (Wemerman et al, 1989).
1.8.5 Adrenaline and Noradrenaline
Infusion of adrenahne in healthy man decreases muscle ribosome concentration 
(Wemerman et al, 1989) and decreases whole-body protein breakdown, leucine 
oxidation and stimulates de novo alanine synthesis (Miles et al, 1984; Kraenzlin et al, 
1989). This may be a direct effect or possibly an indirect effect mediated by alterations 
in insuhn concentration. Muscle protein breakdown appears to be reduced by 
adrenahne (Kraenzlin et al, 1989). There is less direct information about the effect of 
noradrenaline (Gelfand et al, 1984) and its possible effects have not been elucidated. 
An interesting possibility is that alteration of catecholamine concentrations by insulin 
infusion (Rowe et al, 1981; Liang et al, 1982) may mediate some of the metabolic 




1.8.6 Thyroxine and Triiodothyronine
In man thyroxine excess results in a depression of skeletal muscle protein 
synthesis but unaltered myofibrillar protein breakdown, as assessed by the increased 
arteriovenous net efflux of tyrosine and unaltered 3-methylhistidine balance across 
the leg (Morrison et al, 1988a). Morrison and colleagues did not demonstrate any 
significant effect of hypothyroidism on leg protein balance but in animal studies 
hypothyroidism results in reduced protein synthesis by muscle (Brown et al, 1981), 
corrected by replacement treatment with triiodothyronine (Brown and Millward,
1983). Excess replacement results in increased muscle protein synthesis in rats 
(Brown and Millward, 1983) and in increased muscle protein breakdown (Brown and 
Millward, 1983; Barrett and Gelfand, 1989). The mechanism of this effect is not clear 
(Millward and Rivers, 1989) but may involve control of ribosome levels. In their study, 
Morrison and colleagues found impaired whole-body protein synthesis both in the 
thyrotoxic patients and in the hypothyroid patients. The differences between animal 
and man may relate to different durations of thyroid abnormality but a clear 
explanation is not available.
1.8.7 Glucagon
In man glucagon increases whole-body protein breakdown and leucine oxidation 
when insulin is deficient (Nair et al, 1987b) but not with insulin replacement 
(Fukagawa et al, 1990). Similar effects are reported in studies in pigs (Ostaszewski 
and Nissen, 1988). Although it has been suggested that glucagon inhibits muscle 
protein synthesis in vivo such an effect is only seen at pharmacological doses (Preedy
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and Garlick, 1988) and probably has no physiological significance: there is no effect 
of glucagon on muscle ribosome concentration or on the proportion of muscle 
ribosomes as polyribosomes in man (Wemerman et al, 1989). In rats in vivo a 
deleterious effect of glucagon on muscle and whole-body nitrogen balance is seen, even 
in the presence of insulin (Almdal and Vilstrup, 1988).
1.8.8 Testosterone
Testosterone, administered in pharmacological doses, increases skeletal muscle 
protein synthesis in man, with no apparent effect on whole-body protein synthesis 
(Griggs et al, 1989).
1.8.9 Tumour Necrosis Factor-a and Interleukin-1
This polypeptide hormone, produced by lymphocytes or macrophages, appears 
to increase skeletal muscle protein breakdown (assessed by net amino acid efflux from 
the limb) in cancer patients but conversely to increase whole-body protein synthesis 
(possibly in liver) (Warren et al, 1987; Starnes et al, 1988). Studies undertaken with 
in vitro conditions have generally, but not universally, failed to confirm such an effect 
of increased muscle protein breakdown (Evans et al, 1989), suggesting that the effects 
of tumour necrosis factor-a (TNF) may be mediated indirectly, e.g. by increases in 
cortisol or glucagon. There is generally thought to be little or no effect of interleukin-1 
(IL-1) on protein turnover but a related factor, interleukin-6 may have a stimulatory 
effect on muscle protein breakdown (Evans et al, 1989). However, IL-1 has been
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suggested to increase muscle protein breakdown in some situations and the effect may­
be mediated by prostaglandin E2 (Baracos et al, 1983) but this IL-1 was not pure.
1.8.10 Prostaglandins
Prostaglandin E2 and F2a increase protein breakdown in rat muscle in vitro 
(Rodemann and Goldberg, 1982). The inhibitor of prostaglandin synthesis, ibuprofen, 
inhibits the increased whole-body proteolysis seen in man during infusion of E. Coli 
endotoxin (lipopolysaccharide), but the effects may be indirect by alteration of the 
concentrations of the major stress hormones (U. Keller, personal communication).
1.9 The Influence o f Exercise and Immobility on Protein Turnover
Strength training in young men increases skeletal muscle protein synthesis (K. 
Yarasheski and D.M. Bier, personal communication) and both improves net amino acid 
balance and reduces myofibrillar protein breakdown of the human limb (Albert et al,
1989). Functional electrical stimulation increases muscle protein synthesis in 
paraplegic patients (Pacy et al, 1988b). Immobilisation in a plaster cast decreased 
human muscle protein synthesis by a quarter and the authors estimated that muscle 
protein breakdown decreased in addition (Gibson et al, 1987; Gibson et al, 1988). The 
reduced muscle protein synthesis during immobilisation was abolished by functional 
electrical stimulation so that muscle wasting was abolished (Gibson et al, 1988; 
Gibson et al, 1989).
In the whole-body, exercise increases protein breakdown and leucine oxidation 
(Rennie et al, 1981; Albert et al, 1989).
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1.10 Pathophysiological Regulation o f Amino Acid Metabolism
There are clear details of the mechanisms of muscle and protein wasting in 
very few conditions in man. There is depression of skeletal muscle protein synthesis 
in muscular dystrophy (Rennie et al, 1982a; Halliday et al, 1985; Halliday et al, 1988): 
in these studies patients with end-stage muscle disease were studied (when muscle 
may be extensively replaced by connective tissue and when immobility may play a role 
in depressing muscle protein turnover) and these results may not be applicable to 
patients with the early stages of these diseases. In patients with cardiac cachexia 
myofibrillar protein breakdown is increased but whole-body protein turnover is 
depressed (Morrison et al, 1988c). In patients with hepatic cirrhosis there does not 
appear to be any detectable abnormality in the whole-body protein turnover rate 
(Millikan et al, 1985; Mullen et al, 1S86) or in children with cystic fibrosis (Thompson 
and Tomas, 1987). Increased whole-body protein breakdown occurs in homozygous 
sickle cell disease (Badaloo et al, 1989).
1.9 The Effect o f Trauma and Sepsis on Protein Metabolism
Surgical trauma decreases the breakdown rate of muscle myofibrillar proteins 
(Rennie et al, 1984) and reduces net amino acid release from the leg (Stjemstrom et 
al, 1986). In addition reductions in muscle protein synthesis occur (Wolfe et al, 1989). 
Leucine oxidation increases following injury, as does energy expenditure, but severe 
injury results in greater leucine oxidation than other energy-equivalent conditions 
suggesting a degree of breakdown of protein homeostatic mechanisms. This appears 
to be the result of liberation of amino acid stores in muscle perhaps with the beneficial
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effect of making substrate available for synthesis of reactive proteins. The increase in 
leucine oxidation may be an inevitable consequence of the increased leucine 
concentration. The report of an effect of branched chain amino acids to reduce nitrogen 
loss (Cerra et al, 1983) appears unlikely as they would most likely undergo catabolism.
The counterregulatory hormones may be important in modulating the increased 
proteolysis of injury but the paracrine hormones and cytokines may be equally, if not 
more important (Wolfe et al, 1989). In sepsis, studied using a model with 
lipopolysaccharide from E. Coli, there is an increase in muscle protein breakdown and 
a reduction in muscle protein synthesis (Jepson et al, 1986) and when 
lipopolysaccharide is infused in man whole-body protein breakdown increases (U. 
Keller, personal communication).
1.11 The Present Studies
The aim of the studies detailed in this work was clarification of the role of 
insulin deficiency and its replacement in the modulation of protein synthesis. There 
has been intense interest by a number of workers in this area of research during the 
last few years and many of the references in the bibliography were not available when 
I started my work. Our initial hypothesis was that insulin exerted an anabolic effect 
on muscle by increasing muscle protein synthesis in man. In view of the profound 
reductions in amino acid concentrations which occur during hyperinsulinaemic 
conditions we expected no increase of either muscle or whole body protein synthesis 
when insulin was given alone but we anticipated an effect when insulin was 
administered with adequate quantities of amino acids and energy substrates.
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Accordingly, we designed protocols to study the action of insulin and the effect of 
amino acid availability on muscle protein synthesis. We realized that there is a 
substantial body of evidence suggesting that the insulin-like growth factors may be 
more important than insulin and in addition non-hormonal influences, eg exercise may 
predominate in regulating protein turnover. A further aim was to further develop and 
refine a number of techniques for estimating muscle protein turnover. Specifically 
these included: a technique with anterior tibial muscle biopsy for measuring skeletal 
muscle fractional protein synthesis; assessment of leg protein turnover with using 
labelled-phenylalanine; and use of [l-13C]leucine for assessing leg protein turnover and 
leucine metabolism.
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The measurement of protein turnover in vivo was shown to be possible in a 
series of pioneering experiments with 15N and 2H labelled amino acids initiated in the 
1930’s (Schoenheimer and Rittenberg, 1938; Schoenheimer et al, 1939a; Schoenheimer 
et al, 1939b; Schoenheimer et al, 1942). In the last decade, there has been an 
increased impetus to investigation of amino acid metabolism in vivo in man due to the 
ready availability of a large range of commercially-produced stable isotope-labelled 
amino acids and the development of reliable and relatively inexpensive mass 
spectrometers.
The stable isotopes most commonly used to investigate human protein 
metabolism are 2H (i.e. Deuterium or D), 13C, 15N and 180. There are substantial 
advantages to be gained in employing stable rather than radioactive isotopes for the 
investigation of human metabolism. There are no useful radioactive equivalents of 
either 15N or 180. Stable isotopes do not decay and release no ionizing radiation, a 
particularly important point for studies in children, women in the reproductive years 
and young healthy people in general. Precautions are not required to protect the 
investigators handling these compounds from radioactive hazard. When analyzing 
stable isotope samples to determine the tracee molar enrichment only one 
measurement is required, whereas, the analysis of samples to determine radioactive 
tracee specific radioactivity requires separate measurements of radioactive and 
chemical concentrations, with the result that the coefficient of variation of the latter 
analysis is likely to be greater. A minor disadvantage is that these isotopes are 
ubiquitous and basal or background values must be measured and taken into account.
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2.1.1 Tracer : Tracee Differential Metabolism
It is generally assumed that stable isotope labelled amino acids are metabolised 
in an identical way to their tracee. Proof supporting this assumption is deficient 
although indirect evidence is available. Where similar tracers are concurrently infused 
in the same subjects either minimal or no differences are found in metabolism of the 
tracers. For example we have found systematic differences of only 4% in the whole- 
body leucine flux rate in dogs when measured simultaneously with [ l - 14C]leucine and 
[4,5-3H]leucine (W. M. Bennet and M. W. Haymond, unpublished). It is not clear if 
such differences are due to in vivo differential tracer metabolism or alternatively to 
analytical imprecision. We have observed earlier retention times for [2H10]leucine 
compared with [12C] or [ l - 13C]leucine and also for [2H5-p/ieny/]phenylalanine 
compared with [14N] or [ 15N]phenylalanine during gas chromatography mass 
spectrometry of ieri-butyldimethylsilyl derivatives on a capillary column (C. M. 
Scrimgeour and W. M. Bennet, unpublished). Similar effects are seen during high- 
pressure liquid chromatographic separation of labelled a-ketoisocaproate: 
a-keto[4,5-sH]isocaproate elutes slightly before and a -k eto [l-14C]caproate slightly 
after unlabelled a-ketoisocaproate (B. A. Krom and F. F. Horber, personal 
communication). These differential isotope effects in vitro suggest that similar effects 
may occur in vitro.
Bacteria die when grown in 2H20  enriched higher than 50%, and systematic 
tracer:tracee differences must be accounted for when energy expenditure is measured 
with the doubly labelled water technique (i.e. when 2HH180  is administered) (Nagy, 
1980). For example, vapour lost from the body contains 5% less deuterium and 1% less
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180  than body water. Foods may have different natural abundance of 13C; this is most 
marked for sugars from different sources. Plants with C3 photosynthesis (e.g. potato 
or sugar beet derived glucose) have less 13C than plants with C4 photosynthesis (e.g. 
com derived glucose) (Schoeller et al, 1980). These observations collectively suggest 
that isotope fractionation may occur for labelled amino acids, but such an effect is 
likely to be of the order of a few percent at maximum.
2.2.1 Overview o f Techniques Employed in the Whole-body
In the studies described here two stable isotope labelled amino acids (i.e. 
L - [ l - 13C]leucine and L -[16N]phenylalanine) were used with conceptually different 
modelling approaches to assess protein turnover in the whole-body and in skeletal 
muscle. These techniques provide different and complimentary measures of protein 
turnover in the whole-body, in anterior tibialis muscle, and in leg tissues 
(predominantly skeletal muscle). Since the metabolically active pools accessible to 
these distinct trace techniques were different and the model-dependent assumptions 
underlying them were variable, the results obtained may not always be in agreement 
or even comparable between techniques. Three important features of both amino acids 
are a) they are indispensable, b) the free pool of these amino acids is small compared 
to their respective bound pools (Table 1.2) and c) transport into cells, by the L-system 
transporter, is not dependent on endocrine regulation (Yudelevitch and Boyd, 1987; 
Hundal et al, 1989).
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The following techniques were used to measure amino acid metabolism in the 
whole-body:
a) The stable isotope labelled amino acid L - [ l - 13C]leucine was used with a 
plasma a-ketoisocaproate based open four-pool model to determine rates of 
whole-body leucine kinetics (Rennie et al, 1982b; Schwenk et al, 1985a; Bier 1989).
b) The stable isotope labelled amino acid L -[15N]phenylalanine was used with a 
two-pool model to determine the rates of whole-body phenylalanine kinetics (Clarke 
and Bier, 1982).
2.2.2 Overview o f Techniques Employed to Assess Skeletal Muscle Metabolism
Use of these stable isotope labelled amino acids also enabled measurements to 
be made of skeletal muscle protein turnover in leg tissues. These tracer techniques 
and, also, a non-tracer technique used to measure skeletal muscle protein turnover 
were as follows:
c) Anterior tibialis protein synthetic rate was determined from the incorporation 
of L - [ l - 13C]leucine into protein obtained from muscle biopsy samples, during a 
continuous infusion of the tracer (Rennie et al, 1982b; Halliday et al, 1988).
d) Arteriovenous exchange of phenylalanine by the leg was determined using 
L -[15N]phenylalanine. This technique provided measures of protein balance, protein 
synthesis and protein breakdown of skeletal muscle (Gelfand and Barrett, 1987; 
Thompson et al, 1989).
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e) Arteriovenous exchange and oxidation of leucine by the leg was determined 
using L - [ l - 13C]leucine. This provided measures of synthesis and breakdown of 
skeletal muscle (Cheng et al, 1985; Cheng et al, 1987).
f) Arteriovenous release of 3-methylhistidine from leg tissues was determined. 
This provided a semi-quantitative index of myofibrillar protein breakdown of skeletal 
muscle (Lundholm et al, 1982; Rennie and Millward, 1983; Rennie et al, 1983).
2.2.3 Application o f Techniques
In all the studies undertaken whole-body leucine turnover was measured 
(technique No. a). Incorporation of leucine into skeletal muscle (No. c) was measured 
in on group of healthy subjects to test the effect of infusion of mixed amino acids and 
in one group of type 1 diabetic subjects to assess the effect of insulin during increased 
amino acid availability. In the remainder of the subjects whole-body phenylalanine 
kinetics were measured using L -[1£N]phenylalanine (No. b) and leg arteriovenous 
exchange of phenylalanine and leucine were measured (Nos. d & e respectively): these 
groups comprised two groups of healthy subjects where the effects of amino acid 
availability and the effect of insulin were investigated and one group of type 1 diabetic 
subjects where the effect of insulin and the effect of amino acids was investigated. Leg 
release of 3-methylhistidine (No. f) was also determined in one subgroup of healthy 
subjects to ascertain the effect of alteration of amino acid concentrations.
65
Modelling Protein Turnover
2.3.1 Whole-body Protein Turnover Determined with [ l - I3C]Leucine: Equations for 
Steady State Conditions
When tracer-labelled amino acid is infused intravenously it is metabolised by 
the body in the same way as endogenous amino acids. Where the essential amino acid 
leucine (which is not synthesized de novo) is infused as the tracer, it mixes throughout 
the plasma space and disappears into cells. Within cells it may enter into protein 
synthesis, and become incorporated into protein, or it may undergo catabolism. 
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Figure 2.1. Leucine intermediary metabolism
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a-ketoisocaproate (2-keto-4-methyl-pentanoate, 2-ketoleucine), by branched-chain 
amino transferase (BCAT) which is widely distributed in human tissues (Goto et al,
1977). Accordingly, the removal of nitrogen label from leucine in man is rapid, both 
in the whole-body (Matthews et al, 1981) and by muscle (Cheng et al, 1985; Cheng et 
al, 1987). Where a carbon or hydrogen label is used to label leucine, the label is not 
lost during transamination (Matthews et al, 1982) but the label may be diluted by 
unlabelled leucine and a-ketoisocaproate (Figure 2.1). The keto acid, 
a-ketoisocaproate, may undergo irreversible oxidative decarboxylation by branched- 
chain keto acid dehydrogenase (BCKAD) present on the inner mitochondrial 
membrane (May and Buse, 1989) and also widely distributed in man with about 60% 
in muscle (Khatra et al, 1977) (Figure 2.1). The 13C label is lost dining decarboxylation 
and 1SC02 is produced. In the rat plasma concentrations of a-ketoisocaproate are 
about 15-35 pmol/1 and the relative tissue to plasma concentration ratios are about 
0.4 for muscle, 0.2 in heart and 0.3 in liver (Hutson and Harper, 1981).
The free tracer, both in plasma and in intracellular fluid, is diluted by non­
labelled amino acids either released by protein breakdown or from the diet. The rates 
of these metabolic processes can be determined by measurement of the 13C enrichment 
of plasma a-ketoisocaproate and of its oxidation product, carbon dioxide, excreted in 
breath and by comparison with the rate of infusion of tracer. The immediate 
metabolite of leucine, a-ketoisocaproate, is measured in preference to leucine on the 
assumption that this provides a closer measure of the tracer enrichment of leucine in 
the intracellular milieu (Matthews et al, 1982; Rennie et al, 1982b; Schwenk et al, 
1985a; Layman and Wolfe, 1987; Horber et al, 1989). Based on an open four pool
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a-ketoisocaproate-based model or reciprocal pool model (Figure 2.2) (Schwenk et al, 
1985a; Bier 1989) the components of whole-body amino acid turnover can be calculated 
(Rennie et al, 1982b; Matthews et al, 1982); a leucine tracer is infused into the plasma 
leucine pool and plasma a-ketoisocaproate is sampled or alternatively a tracer of 
a-ketoisocaproate is infused and plasma leucine sampled, hence the term "reciprocal".
Figure 2.2. Open four pool or reciprocal pool leucine model (see text)
Leucine kinetics are calculated from the 13C enrichment of a-ketoisocaproate 
in plasma and of C02 in breath after plateau conditions of labelling have developed 
during a primed continuous infusion of L - [ l - 13C]leucine (Figure 1.6) (Matthews et al, 
1980; Rennie et al, 1982b): the prime doses of both [13C]leucine and sodium 
[13C]bicarbonate are given to achieve plateau conditions more rapidly than by a
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continuous infusion alone (Allsop et al, 1978; Matthews et al, 1980). The individual 
components of leucine turnover may be calculated from the following equation 
(O’Keefe et al, 1974) (Figure 1.3):
Q = S + 0 = B + D
Where:
Q = the rate of leucine turnover or flux,
S = non-oxidative leucine disposal or protein synthesis,
0  = oxidation of leucine,
B = endogenous leucine appearance or protein breakdown, and 
D = dietary intake of leucine.
The units ofwhole-body leucine kinetics are micromoles of leucine per kilogram 
total-body weight per hom* (pmol*kg'1#h_1). This equation assumes that leucine 
disposal by routes other than protein synthesis and leucine oxidation is negligible. The 
equation is only valid for steady-state conditions where a true plateau exists for the 
13C enrichment of a-ketoisocaproate and the plasma concentrations of plasma leucine 
and a-ketoisocaproate are constant.
The flux or turnover of leucine is calculated from the following equation 
(Matthews et al, 1980; Rennie et al, 1982b):
Where:
i = infusion rate of L - [ l - 13C]leucine in pmol^kg'^h"1,
Ei = 13C enrichment of the infused L - [ l - 13C]leucine in atoms % excess (APE), and
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Ep = 13C enrichment of a-ketoisocaproate in plasma (APE) after tracer equilibration.
Well mixed samples reflecting metabolism in all tissues in the whole-body are
required and, therefore, arterialized venous samples are taken with the "hot-box"
technique (Section 3.5).
The constant 1 is subtracted to correct for the rate of tracer infusion where a
stable tracer is employed (Matthews et al, 19S0; Tessari et al, 1985). This correction
assumes that the absolute flux increases in proportion to the rate of tracer infusion
and that the endogenous flux is unaltered. Where the rate of i is less than 10% of Q
there appears to be no measurable effect of infusing the tracer either on the flux or
oxidation of leucine (Tessari et al, 1985).
The rate of release of carbon dioxide (pmol of 13C02*kg“1,h '1) from oxidation
of the [ l - 13C]leucine tracer is (Matthews et al, 1980):
Vco2 • Eco2 60 • 4.16 • 104
F13co2 =   •-- -------------------------------
W 100 • 0.81
Where:
Vco2 = Expiration rate of carbon dioxide (1/min at Standard Temperature and 
Pressure, STP),
ECO, = 13C enrichment in expired carbon dioxide (APE) after isotope equilibration, and 
W = body weight of the subject (kg).
The factors:
60 converts min to h,
4.16 • 104 converts 1 of carbon dioxide (at STP) to pmol of carbon dioxide,
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100 converts enrichment in atoms % excess to a fraction, and
0.81 takes account of the reduced quantity of carbon dioxide released in expired breath 
following tracer oxidation after passage through the bicarbonate pool, on account of 
fixation of carbon dioxide in tissues (Issekutz et al, 1968; James et al, 1976, Hoerr et 
al, 1989).
The rate of whole-body leucine oxidation (pmol*kg ^ h -1) is:
1 1
0  = F 13c o 9 *  100
\ Ep Ei
From leucine flux (Q) and leucine oxidation (O) the whole-body non-oxidised 
leucine disposal (S) or leucine incorporation into protein (i.e. protein synthesis) is:
S = Q - O
Leucine release by protein breakdown (B) is calculated from flux (Q) and 
dietary intake (D):
B = Q - D
Where the studies are conducted in the fasted or postabsorptive state dietary 
intake is zero (D = 0) and:
B = Q
A number of assumptions are integral requirements to the use of the these 
equations based on the labelling of a-ketoisocaproate; these are:
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a) There is no difference in the metabolism of 13C-labelled leucine and 
a-ketoisocaproate compared with unlabelled endogenous leucine and 
a-ketoisocaproate.
b) There is negligible release of tracer-labelled leucine from protein after it has 
been incorporated by protein synthesis, i.e. there is negligible recycling of tracer. 
Schwenk and colleagues (Schwenk et al, 1985b) have reported that tracer recycling of 
up to 30% occurs in studies where tracer is infused for 24 h. However, recycling 
probably occurs to a minor extent, perhaps less than about 5% in studies of less than 
10 h. It has been shown that the leucine flux rate in healthy postabsorptive subjects 
is not different at the end of 4 h in comparison to 8 h of study during continuous 
[ l - 13C]leucine infusion (Nair et al, 1988b), suggesting that recycling is minimal during 
studies of this duration.
c) There are four pools of free leucine (Figure 2.2): a) free as leucine in the 
intravascular space and extracellular matrix, b) free as leucine within cells where 
rapid exchange occurs with intracellular a-ketoisocaproate (Pool c), which in turn 
rapidly exchanges with a-ketoisocaproate in the intravascular compartment (Pool d).
d) Transamination and reamination of leucine to a-ketoisocaproate is a very 
rapid process, such that intracellular free leucine and a-ketoisocaproate have the 
same tracer enrichment. Matthews and colleagues (Matthews et al, 1981) have 
demonstrated that in man the rates of transamination and reamination of leucine are 
fast in comparison with the oxidation of a-ketoisocaproate. Cheng and colleagues 




e) The degree of dilution of the tracer or the enrichment of a-ketoisocaproate in 
plasma is representative of that of both a-ketoisocaproate and leucine at an 
intracellular level, in the precursor pools for a-ketoisocaproate oxidation and for 
leucine incorporation into protein, respectively, in all tissues throughout the body. At 
the present time information that this assumption actually holds true is not available 
for man. Animal studies, both in vitro and in vivo, of leucine incorporation into muscle 
suggest that the charging of leucyl-tRNA (i.e. the leucine precursor pool for protein 
synthesis) is predominantly from plasma or extracellular fluid (Davey and 
Manchester, 1969; Martin et al, 1977; Clark and Zak, 1981; Everett et al, 1981; 
Martin, 1981; Airhart et al, 1982). However, Schneible and colleagues (Schneible et 
al, 1981) reported conflicting observations from a study of chicken muscle in vitro: i.e. 
that leucine entering into protein synthesis was predominantly derived from leucine 
released by protein breakdown within the cell. They also reported that leucine 
entering oxidation derived predominantly from the extracellular milieu.
f) In subjects, in whom leucine was infused parenterally, it entered into cells, and 
mixed in the intracellular free leucine and a-ketoisocaproate pools before undergoing 
metabolism.
g) Estimates of C02 fixation obtained from studies of infusion of sodium 
[13C]bicarbonate or sodium [14C]bicarbonate are appropriate to estimate fixation of C02 
released from leucine oxidation within mitochondria. In addition, these estimates are 
appropriate under all conditions of study. It practice it appears that a greater 
proportion of C02 is fixed from leucine oxidation (within mitochondria) than from 
bicarbonate infused into the plasma space, as assessed by greater isotope labelling of
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glucose by incorporation of the C02 during gluconeogenesis (F. F. Horber, P. C. Butler 
and M. W. Haymond, personal communication); leucine oxidation, therefore, may be 
systematically underestimated by the general adoption of a 19% bicarbonate fixation 
value. In addition, bicarbonate fixation (on a proportional basis) is reduced during 
feeding (Hoerr et al, 1989) and may be altered by acid-base disturbances such as 
diabetic decompensation and by insulin replacement.
2.3.2 Whole-body Protein Turnover Determined with [ l - 13C]Leucine: Kinetic Equations 
for Non-steady State Conditions
The equations described above are only suitable for calculation of whole-body 
leucine kinetics in the steady-state, i.e. when the plasma concentrations and 13C 
enrichments of leucine and a-ketoisocaproate are constant. Under most conditions of 
study these conditions are met by giving appropriate priming doses of leucine and by 
allowing a period of about one hour or more after commencement of the tracer 
infusion before sampling. This period is adequate to allow a plateau to develop even 
after major perturbations have occurred in protein metabolism such as with 
intravenous infusion of mixed amino acid solutions. In postabsorptive healthy subjects 
plasma leucine concentrations tend to slowly increase because of breakdown from 
protein but the increase is negligible in comparison to whole-body leucine flux rates. 
It has been shown that the whole-body leucine flux rate is the same when measured 
after 4 h in comparison to 8 h of continuous infusion of [ l - 13C]leucine in healthy 
postabsorptive subjects (Nair et al, 1987b).
74
Modelling Protein Turnover
In contrast to the steady state, in healthy subjects where insulin secretion is 
suppressed by somatostatin infusion, progressive increases occur for at least three 
hours in the plasma leucine concentration and in the whole-body leucine flux, such 
that plateau conditions are not attained (Nair et al, 1987b). When insulin is replaced, 
the reductions which occur in plasma leucine concentration and in whole-body leucine 
flux both in healthy subjects (Fukagawa et al, 1985; Fukagawa et al, 1986; Tessari et 
al, 1986b; Castellino et al, 1987) and in diabetic subjects (Tessari et al, 1986a; Nair 
et al, 1987) are such that the criteria for applying steady-state models may not be 
fulfilled within 3 to 4 hour study periods.
Alternative equations may be used to calculate whole-body leucine kinetics 
during non-steady state situations. These equations take account of the changes which 
occur in plasma leucine and a-ketoisocaproate concentration and the changes in 13C 
enrichment of plasma leucine and a-ketoisocaproate. The equations were developed 
by Steele (Steele, 1959) for use in studies of glucose metabolism with radio-active 
tracers. The equations were adapted for use in stable-isotope studies by Miles and 
colleagues (Miles et al, 1983). The equations detailed here have been further modified 
by incorporation of a whole-body leucine volume of distribution of 0.6 1/kg (i.e. total 
body water). This is based on the assumption that leucine is distributed at an 
equivalent concentration throughout total-body water and that changes which occur 
in the concentration of plasma leucine reflect these occurring in leucine within all cells 
of the body. The original equations, which used the volume of distribution for 
extracellular water (0.15 1/kg), may be more appropriate for glucose metabolism 
studies. In contrast, the value of 0.6 1/kg should render the equations more
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appropriate for calculating whole-body leucine metabolism as, in man, intramuscular 
leucine concentrations are shown to increase when plasma amino acid concentrations 
are increased by exogenous infusion (Lundholm et al, 1987), and to decrease when 
plasma leucine concentration is decreased by infusion of insulin (Alvestrand et al, 
1988). The total leucine volume of distribution may be calculated from the sum of 
leucine and a-ketoisocaproate concentrations, as leucine rapidly and reversibly 
transaminates to its keto-acid (Matthews et al, 1981; Cheng et al, 1985; Cheng et al,
1987).
During a primed constant infusion of [ l - 13C]leucine, samples are obtained to 
determine the 13C enrichment and concentration of plasma a-ketoisocaproate and, in 
addition, the plasma leucine concentration.
The whole-body leucine rate of appearance is calculated with the following 
equation (Miles et al, 1983):
1 Pi + P2 \ / Ep2 Epl ^
2 / \ t2 tl /




Ra = whole-body leucine rate of appearance (pmol#kg‘ 1#h '1), 
i = infusion rate of the [ l - 13C]leucine tracer (pmol»kg“1,h"1),
Ei = molar enrichment of the [1—13C]leucine tracer (atoms excess),
Pi and P2 = whole-body leucine pool sizes at two consecutive tune points, and
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Epi and Ep2 = fractional molar 13C enrichments of plasma a-ketoisocaproate (atoms 
excess) at these time points.
The whole-body leucine pool size (Pi and P2) is calculated using the following 
equation:
P = (Cleu + Ciac) • 0.6
Where:
Cleu = plasma leucine concentration (pmol/1), and 
CKIC = plasma a-ketoisocaproate concentration (pmol/1).
Units are pmol/kg and the constant 0.6 is derived from the value for total-body water 
distribution.
The whole-body leucine rate of appearance (Rd) is calculated with the following 
equation:
(P2 - Pi)
Rd = R a  ---------------
(t2 - tl)
The endogenous component of leucine appearance (protein breakdown) is 
calculated with the following equation:
End-Ra = Ra - D
Where:
End-Ra = endogenous component of whole-body leucine appearance (pmol^kg-1 •h'1), 
and
D = rate of administration of exogenous leucine or dietary leucine (pmol, kg-1»h-1).
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The non-oxidised component of leucine disappearance (protein synthesis) is 
calculated as follows:
NOLD = Rd - O
Where:
NOLD = non-oxidised component of whole-body leucine disappearance (pmol'kg"1» h"1), 
and
0  = whole-body leucine oxidation (pmol*kg-1*h-1) calculated as in section 2.3.1.
A number of assumptions underlie the use of these equations. These are the 
same as the assumptions for leucine modelling under steady state conditions with the 
following additional assumptions:
a) The plasma concentrations of leucine and a-ketoisocaproate reflect the 
intracellular concentrations in all cells of the body.
b) The volume of distribution of whole-body free leucine and of a-ketoisocaproate 
is 0.6 pmol/1.
2.4 Whole-body Protein Turnover Determined with [1BN]Phenylalanine: Equations for 
Steady State Conditions
The 15N enrichment of plasma phenylalanine, during a primed continuous 
infusion of L -[1BN]phenylalanine under plateau conditions, is used to calculate the 
components of whole-body phenylalanine kinetics. A two pool model is employed with
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a) the free pool of phenylalanine in plasma and in cells and b) the protein-bound pool 
of phenylalanine (Figure 2.3). The equations are (Clarke and Bier, 1982):
Q = B + D
Where:
Q = the rate of phenylalanine turnover or flux,
B = endogenous phenylalanine appearance or protein breakdown, and 
D = dietary intake of phenylalanine.
The units of whole-boay phenylalanine kinetics are micromoles of phenylalanine per 
kilogram total body weight per hour (pmol*kg-1,h-1).
The plasma phenylalanine flux is calculated with the equation:
Ei 
—  -1  
Ep
Where:
i -  infusion rate of L -[15N]phenylalanine (pmol*kg_1*h_1),
Ei = 15N enrichment of the infused L -[ 15N]phenylalanine (APE), and 
Ep = 15N enrichment of plasma phenylalanine (APE) after tracer equilibrium. In the 
studies reported here the femoral vein was used as sampling site. Ideally with 
phenylalanine the tracer would have been infused into the left heart and well mixed 
samples obtained from the right heart (Layman and Wolfe, 1987), a clearly impractical 
approach for studies in man. By infusing into a vein left heart infusion is 
approximated and sampling from a vein draining a large vascular bed may have
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enabled samples to be obtained which would have been little different from right heart 
samples.
The first steps in the 
catabolism of phenylalanine 
involve hydroxylation of the 
arom atic ring, producing 
t y r o s i n e .  To c a l c u l a t e  
phenylalanine entry into protein 
an estimate of the rate of
conversion of phenylalanine to Figure 2.3. Two pool model o f protein turnover
with phenylalanine; D, diet; S, synthesis; B, 
tyrosine is required: this is breakdown; C, catabolism to tyrosine
calculated from simultaneous
measurements of phenylalanine flux, tyrosine flux (with an additional tyrosine tracer), 
and appearance of the infused phenylalanine tracer in plasma tyrosine. In the studies 
reported here tyrosine flux and phenylalanine catabolism to tyrosine were not 
measured and, therefore, no estimate of non-catabolized phenylalanine disappearance 
(i.e. protein synthesis) can be made. Only whole-body total phenylalanine appearance 
and protein breakdown can be measured with the technique used. The equations of 
whole-body phenylalanine turnover are only valid where plateaux exist for both the 
15N enrichment and the concentration of plasma phenylalanine.
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There are a number of assumptions underlying the use of these equations; 
these are:
a) The metabolism of 15N-labelled phenylalanine is the same as that of unlabelled 
endogenous phenylalanine.
b) There is negligible recycling of tracer after it is incorporated into protein.
c) There are two pools of phenylalanine: a) free, both in the intravascular and 
intracellular compartments, and b) bound into protein.
d) The degree of dilution of the label (the enrichment of phenylalanine in plasma) 
is representative of that of intracellular phenylalanine in the precursor pool for 
protein synthesis. Although this has not been confirmed in man it is shown in animal 
tissue in vitro and in vivo, for leucine at least, that leucyl-tRNA is charged with 
leucine coming predominantly from extracellular fluid or plasma (see section 2.3.1). 
It is also known that phenylalanine readily enters into cells by the L-system 
transporter (used by leucine) and, in addition, in liver by the T-system transporter. 
Neither of these transporters are dependent on hormonal changes (Yudilevich and 
Boyd, 1987). It, therefore, appears likely that the phenylalanyl-tRNA in man may 
charge predominantly from plasma, and that tracer studies in man in which plasma 
phenylalanine enrichment is measured provide some measure of metabolism at an 
intracellular level. This approach awaits validation.
e) In subjects where phenylalanine was infused parenterally it entered into cells 
and mixed fully throughout the free phenylalanine pool.
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2.5 Anterior tibialis muscle protein synthesis measured from incorporation of 
[l - 13 C]leucine
This is an invasive technique in which mixed protein synthetic rate may be 
determined from samples of muscle obtained by percutaneous muscle biopsy. During 
a primed continuous infusion of L - [ l - 13C]leucine a short period of time is allowed to 
elapse in which equilibration of the tracer occurs throughout plasma and muscle free 
leucine pools; a plateau of leucine tracer enrichment can then be attained. At this 
point the tracer labelling of leucyl-tRNA in the protein synthetic precursor pool 
should also be at plateau; if protein synthesis occurs at a steady rate, [ l - 13C]ieucine 
incorporation into protein will be constant with respect to time (Figure 1.6). The 13C 
enrichment of plasma a-ketoisocaproate provides a measure of that of leucyl-tRNA. 
When biopsies are taken at two time points, during steady-state 13C enrichment of 
leucine, skeletal muscle protein fractional synthetic rate can be calculated with the 
following equation (Rennie et al, 1982b):
AEmuscle 1
ks = -------------- • ---------• 100
EKIC At
Where:
Ks = muscle protein fractional synthetic rate (%/ h),
AEmuscle = increase in 13C enrichment of muscle-bound leucine during the time 
between the two biopsies (APE),
EKIC = mean 13C enrichment in plasma a-ketoisocaproate during the period between 
the two biopsies (APE), and
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At = time interval between the two biopsies (h).
This technique has fewer underlying assumptions than these for measuring 
whole-body protein turnover; the assumptions are:
a) There is no difference in the metabolism of tracer-labelled and endogenous 
leucine.
b) The 13C enrichment of plasma a-ketoisocaproate is representative of that of 
leucyl-tRNA in the precursor pool for protein synthesis (see section 2.3.1).
2.6 Arteriovenous Phenylalanine Exchange by Leg Tissues Determined with 
L -[15N]Phenylalanine
This technique may be used to measure arteriovenous uptake and release of 
phenylalanine across the leg (Gelfand and Barrett, 1987; Thompson et al, 1989), which 
predominantly contains skeletal muscle (Haggmark et al, 1978). In skeletal muscle the 
only metabolic fates of phenylalanine are incorporation into protein and release from 
protein; catabolism of phenylalanine to tyrosine occurs predominantly in liver and 
does not occur in muscle. Uptake and release of phenylalanine by the leg are, 
therefore, indices of protein synthesis and breakdown respectively.
The 15N enrichment of arterial and venous plasma phenylalanine, during a 
primed continuous infusion of [1BN]phenylalanine, and plasma concentrations may be 
used to calculate phenylalanine exchange by leg tissues from the degree of dilution of
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the tracer in the venous outflow in comparison with the arterial inflow. T h e
following equations (simplified from these of Cheng et al, 1985) may be used (Gelfand
and Barrett, 1987; Thompson et al, 1989):
I EA-phe \
Bkdn = ------------ 1 J • CA-phe • BF
\ EV-phe I
Where:
Bkdn = release of phenylalanine (protein breakdown) across the leg in nmol of 
phenylalanine per 100 g of leg tissue per minute (nmol* 100 g'^m in“1),
EA-phe = 15N enrichment of arterial plasma phenylalanine (APE),
EV-phe = 15N enrichment of venous plasma phenylalanine (APE),
CA-phe = arterial plasma concentration of phenylalanine in nmol/ml or pmol/1, and 
BF = blood flow of the leg in ml per 100 g leg per minute (ml* 100 g '^m in '1).
The net arteriovenous balance or the efflux of phenylalanine, a measure of 
protein balance, may be calculated with the following equation:
Bal = (CA-phe - CV-phe) • BF
Where:
Bal = arteriovenous balance of phenylalanine across the leg (nmol* 100 g'^m in"1), and 
CA-phe and CV-phe = arterial and venous plasma phenylalanine concentrations (pmol/1). 
The term flux should be avoided and the term balance is preferred. The former term 
was coined before the application of tracer techniques to the investigation of leg amino 
acid metabolism. The results with tracer techniques show that the flux of "flow" of 
amino acids is much greater than their respective net balances.
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The arteriovenous uptake of phenylalanine or protein synthesis is calculated 
with the equation:
Syn = Bal = Bkdn
Where:
Syn = arteriovenous uptake of phenylalanine (nmol® 100
These equations are only applicable for a steady-state of concentration and 1BN 
enrichment of plasma phenylalanine.
There are a number of assumptions which are integral to use of these 
equations; these are:
a) There is no difference between the metabolism of 15N-labelled and endogenous 
phenylalanine.
b) There is negligible recycling of tracer after incorporation into protein.
c) Rapid exchange of phenylalanine occurs between plasma and muscle and,
therefore, the 15N enrichment of venous phenylalanine represents that entering 
protein synthesis -within muscle, i.e. that of muscle phenylalanyl-tRNA.
d) The concentration of phenylalanine in plasma is the same as that of free 
phenylalanine within muscle.
e) When steady-state conditions are changed by a therapeutic action, complete
exchange of phenylalanine occurs in the intramuscular free pool before further
measurements are made.
f) The blood cells exchange amino acids rapidly and are involved in the across- 
limb amino acid exchange. Pilot studies in our laboratory suggest that this is the case
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but exchange of tracer by the blood elements may be slower than that of plasma (R.
Smith, M. J. Rennie, personal communication).
g) The arterial blood flow is the same as the venous blood flow.
2.7 Arteriovenous Leucine Exchange by Leg Tissues Determined with [l - 13C]Leucine 
This technique may be used to measure uptake and release of leucine, that of 
its keto-acid a-ketoisocaproate, and release of carbon dioxide from oxidation of 
a-ketoisocaproate by leg tissues (Cheng et al, 1985). Leucine may undergo equivalent 
metabolism in leg tissues as in the whole-body: therefore, leucine may undergo 
reversible transamination to a-ketoisocaproate or may be incorporated into protein 
(Figure 2.1). The a-ketoisocaproate may be irreversibly decarboxylated to produce 
isovaleryl-CoA with loss of the 13C label as 13C02 (Figure 2.1). In arteriovenous 
exchange studies these metabolic fates of leucine must be accounted for if accurate 
measures are to be calculated for leucine incorporation into and release from protein.
13C enrichments and concentrations of arterial and venous plasma leucine, 
plasma a-ketoisocaproate and of blood carbon dioxide are measured in samples 
obtained during plateau conditions of a primed continuous infusion of 
L - [ l - 13C]leucine. Oxidation of a-ketoisocaproate by the leg may be calculated from 
the equation (Cheng et al, 1985):
(Cv-co2 • Ev-cOj) - (Ca -co2 • Ea -co2)





Oxid = oxidation of a-ketoisocaproate (nmol* 100 g '^m in '1),
Cv-C02 and CA-C02 = concentration of carbon dioxide in venous and arterial blood 
(mmol/1),
Ev-COa and Ea-C02 = 13C enrichment of carbon dioxide in venous and arterial blood 
(APE),
EV-KIC = 13C enrichment of venous plasma a-ketoisocaproate (APE), and 
BF = blood flow (ml* 100 g_1*min_1).
The constant 1000 changes pmol* 100 g '^ m in '1 to nmol* 100 g_1*min_1.
The sum of the plasma concentrations of leucine and a-ketoisocaproate is used 
in the calculations of leucine exchange by the leg. Termed the total leucine carbon 
(TLC), this (for the arterial value) may be calculated as follows:
CA-TLC = CA-leu + CA-KIC
Where:
CA-TLC = combined arterial plasma concentrations of leucine and a-ketoisocaproate, 
the total leucine carbon (pmol/1),
CA-leu = arterial plasma concentration of leucine (pmol/1), and 
Ca-K3C = arterial plasma concentration of a-ketoisocaproate.




The combined 13C enrichment of arterial plasma leucine and plasma 
a-ketoisocaproate (the arterial 13C enrichment of total leucine carbon) may be 
calculated with the equation:




EA-TLC = arterial 13C enrichment of plasma total leucine carbon (APE),
EA-leu = arterial I3C enrichment of plasma leucine (APE), and 
Ea-KIC = arterial 13C enrichment of plasma a-ketoisocaproate (APE).
The venous 13C enrichment of plasma total leucine carbon may be calculated with 
analogous equations.
The net balance of leucine incorporated into protein may be calculated with the 
equation:
Bal = [(C a-tlc - C v-tlc) • BF] - Oxid
Where:
Bal = net leucine balance between protein synthesis and protein breakdown, (i.e. net 
protein synthesis) in nmol of leucine* 100 g"1#min_1.
The rate of release of leucine from protein (i.e. protein breakdown) may be 




-1 • BF • C a -tlc  - Oxid
Ev -tlc
Bkdn = total leucine release from protein (nmol *100 g 1#min 1).
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The rate of total entry of leucine into protein (i.e. protein synthesis) may be 
calculated with the following equation:
Syn = Bal + Bkdn
Where:
Syn = protein synthesis (nmol* 100 g '^ m in '1).
There are a number of assumptions which underlie these equations; these are:
a) There are no difference between the metabolism of [ l - 13C]-labelled and 
endogenous leucine and a-ketoisocaproate.
b) There is negligible recycling of tracer after it is incorporated into protein.
c) Rapid exchange of leucine and a-ketoisocaproate occurs between plasma and 
muscle and the 13C enrichment of venous leucine and a-ketoisocaproate is 
representative of that entering protein synthesis within muscle, i.e. that of muscle 
leucyl-tRNA.
d) The concentration of leucine and a-ketoisocaproate in plasma is the same as 
that free in intramuscular water.
e) Where steady-state conditions are changed by a therapeutic action an complete 
exchange of leucine and a-ketoisocaproate occurs in the intramuscular free pools 
before further measurements are made.
f) Venous plasma a-ketoisocaproate 13C enrichment is representative of that of 
a-ketoisocaproate undergoing oxidation.
g) Blood cells exchange amino acids rapidly and are involved in the across-limb 
amino acid exchange.
h) The arterial blood flow is the same as the venous blood flow.
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2.8 Myofibrillar Protein Breakdown Determined by Release o f 3-Methylhistidine from 
the Leg
3-Methylhistidine (i.e. AT—methylhistidine) is an amino acid produced by post- 
translational methylation at the N1 position of histidine-73 of the actin chain 
(Vanderkerckhove and Webster, 1984). When released by the breakdown of 
myofibrillar proteins, 3-methylhistidine is not reincorporated into protein by protein 
synthesis and does not undergo intermediary metabolism (Young et al, 1973). 
3-Methylhistidine, or its hepatically acylated derivative, is excreted and provides a 
quantitative marker of myofibrillar protein breakdown.
3-Methylhistidine is a constituent of actin (Asatoor and Armstrong, 1967) and 
the heavy chain of myosin in white muscle (Johnson et al, 1967), proteins which 
together constitute some 50% of muscle protein. Release of 3-methylhistidine, 
therefore, provides a specific index of breakdown of these myofibrillar proteins. It 
follows that factors modulating the breakdown of actin and myosin will induce 
changes in 3-methylhistidine release. In contrast, factors modulating changes in the 
rate of breakdown of mixed non-myofibrillar proteins may not cause any change in 
3-methylhistidine release. Therefore, apparently conflicting results may be obtained 
from studies comparing changes in protein breakdown measured using 
3-methylhistidine and phenylalanine release (Smith and Sugden, 1986).
The release of 3-methylhistidine in urine has been widely advocated and used 
as an index of skeletal muscle protein breakdown in vivo (Ballard and Tomas, 1983). 
Objections to such use (Rennie and Millward, 1983) are based on the existence of 
3-methylhistidine in non-muscle protein pools which turnover rapidly and contribute
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substantially to the total urine release of 3-methylhistidine (Clark and Spudich, 1977; 
Young and Munro, 1978; Emery et al, 1986). For the rat, estimates of the source of 
total 3-methylhistidine release from skeletal muscle, skin and gastrointestinal muscle 
are 25%, 7% and 10% respectively; the source of more than half of the total urine 
excretion of 3-methylhistidine was not identified (Millward et al, 1980c). For healthy 
man such information is not available. However, in man during sepsis about 80% of 
excreted 3-methylhistidine derives from skeletal muscle with approximately 20% from 
non-muscle sources (Sjolin et al, 1989). In studies of human protein metabolism 
seemingly directly conflicting results are reported with regard to the changes which 
may occur in urine excretion and leg efflux of 3-methylhistidine (Rennie et al, 1983). 
It is, therefore, likely that urine excretion of 3-methylhistidine is not adequately 
specific for monitoring human skeletal muscle protein breakdown in vivo and only 
3-methylhistidine efflux from the leg has been employed as an index of skeletal 
muscle breakdown in the studies reported here. The major difficulty with the leg 
arteriovenous exchange technique is that the plasma concentration of 
3-methylhistidine is very low (2-6 pmol/1) and can only be measured with 
sophisticated techniques. Therefore, in the present studies results are only available 
from the group of healthy subjects where amino acid analysis was by automated ion 
exchange chromatography with fluorometric detection.
The 3-methylhistidine efflux was calculated with the following equation:
Bal = (CA-3-mehis - CV-3-mehis) • BF
Where:
CA-3-mehis and Cv-3-mehis = plasma concentrations of 3-methylhistidine (pmol/1), and
91
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Units are nmol of 3-methylhistidine per 100 g per minute (nmol® 100 g-1*min_1).
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Healthy volunteers were recruited from the staff of the University of Dundee 
and Ninewells Hospital and Medical School, Dundee, from the students of the 
University of Dundee and from the general public. Type 1 diabetic subjects were 
recruited from the diabetic outpatient clinic at Ninewells Hospital and Medical 
School. The healthy subjects had no acute or chronic illness and were not taking 
any medication. The diabetic subjects were all established on insulin treatment, 
had stable insulin-dependent diabetes and were free from major diabetic 
complications: their only treatment was insulin. In all subjects biochemical tests 
of renal, hepatic and thyroid function were normal and the diabetic subjects did 
not have proteinuria on repeated testing. All subjects had stable body weights 
prior to study and were consuming weight-maintaining diets. The diabetic subjects 
were prescribed diets in which carbohydrate supplied over 50% and fat 35 to 40% 
of the energy contents. The carbohydrate component of the diet was not highly 
refined and had a high fibre content.
Each subject was given a full verbal and written explanation of the 
procedures to be undertaken and their risks. Each subject gave written consent 
before participation in the study. The research protocols were approved by the 




The stable isotope labelled amino acids L - [ l - 13C]leucine (99% 13C) and 
L -[16N]phenylalanine (99% 1BN), and sodium [13C]bicarbonate (99% 13C) were 
purchased from Tracer Technologies Incorporated, Newton, MA, U.S.A. 
L-lp/ienyZ-Tljjphenylalanine (98% 2H5) was obtained from Cambridge Isotope 
Laboratories, Woburn, MA, U.S.A.. Immediately prior to administration the tracers 
were mixed in sterile pyrogen-free sodium chloride solution (150 mmol/1), using an 
aseptic technique, and the tracers were sterilized by passage through 0.22 pm 
filters (Millipore SA, Molsheim, France). The tracer infusates were diluted to a 
total volume of 500 ml in glass bottles and were infused via a second 0.22 pm 
filter.
3.3 Materials
Neutral human insulin (Humulin S, Eli Lilly and Company Ltd, 
Basingstoke, U.K.) was infused during the euglycaemic insulin clamp studies. 
Commercial mixed amino acid solutions (Synthamin 9 and Synthamin 14) were 
obtained from Travenol Laboratories Ltd, Thetford, U.K.; their composition is 
shown in Table 3.1. During the euglycaemic insulin clamp studies potato-starch 
derived glucose was infused: this had a low natural abundance of 13C (-20.180 
Ŝ CPDB0/«,) as opposed to regular maize-derived glucose (-9.85 Ŝ CPDB0/«,) (Lacroix 
et al, 1973; Schoeller et al, 1980; Scrimgeour et al, 1988b). The potato-derived 
glucose (Tunnel Refineries Ltd., Greenwich, U.K) was dissolved (1 mol/1) in 
distilled water, passed through 0.22 pm filters, autoclaved and demonstrated to be
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sterile, low in particulate matter and pyrogen free, before infusion into the 
subjects.
Table 3.1. Composition o f Synthamin Amino Acid Solution




























All subjects were admitted to the Department of Medicine, Ninewells 
Hospital and Medical School at 08.30 h on the day of study. Their weight, height 
and body fat composition (from skinfold thickness at four sites, Dumin and 
Womersley, 1974), were determined and thereafter the subjects remained 
semirecumbent throughout the study. The study room was maintained at a 
thermoneutral temperature (25 to 27°C).
3.5 Blood Sampling
Arterialized venous blood samples were taken from a 1.7 mm outer-diameter 
cannula (Venflon, Viggo AB, Helsingborg, Sweden) placed retrogradely in a dorsal 
hand vein, and maintained patent by a slow infusion of sodium chloride solution 
(150 mmol/1). Before sampling the hand was warmed for a minimum of 15 min by 
insertion into a thermostatically controlled chamber with a circulating air 
temperature of 75 to 80°C (Abumrad et al, 1981). A requirement of the whole-body 
kinetic technique is the need to obtain mixed blood which is representative of that 
in all tissues, i.e. arterial blood, and the arteriovenous exchange technique also 
places a requirement for arterial samples. Arterial cannulation poses unacceptable 
risks to healthy subjects (Hall, 1971), and was not used in the present studies. The 
arterialized venous "hot-box" technique that was utilized has been validated for 
obtaining arterial samples for blood gases and lactate (Forster et al, 1972), glucose 




A second 1.7 mm outer-diameter cannula was placed in a vein of the 
contralateral forearm for infusion of amino acids, tracers, insulin and substrates. 
In the arteriovenous exchange studies a third 1.7 mm. outer-diameter cannula 
(5V6" Abbocath-T, Abbott Hospitals Incline, North Chicago, IL, U.S.A.) was placed 
in either common femoral vein for sampling the mixed venous outflow from the leg. 
To insert this longer sampling cannula, a shorter cannula (45 mm long by 1.7 mm 
outer-diameter, Argyle Medicut, Sherwood Medical, Tuliamore, Ireland) was first 
used to cannulate the vein, through which an 18 gauge flexible wire was 
introduced. The Abbocath-T cannula was then inserted over the guide-wire into 
the common femoral vein. Local anaesthetic (lignocaine 200 g/1) was infiltrated 
before all cannulations.
A sphygmomanometer cuff placed around the ankle was inflated to a 
pressure of 200 mmHg for 60 sec before femoral blood sampling to occlude the 
venous drainage of the foot. Blood was removed from the femoral vein canula at 
a rate of only 1 ml/sec to avoid disturbing the blood flow and tracer equilibrium 
of the leg. The femoral site allows sampling of mixed venous blood from the leg. 
In sedentary subjects the thigh is composed of about 82% muscle (Hfiggmark et al,
1978) and skin accounts for only a small proportion but does, at least in rats, have 
a relatively fast protein turnover rate in comparison to muscle. In rats, the muscle 
protein turnover rate is about 6 to 9% per day and in skin the rate (20 to 35% per 
day) is about 3 to 4 times faster (Chikenji et al, 1983). In addition in man bone 
accounts for about 10% of leg volume: this tissue has a very slow turnover rate 
and bone blood flow was not recorded by the technique used in these studies. The 
remaining proportion of leg, adipose tissue, has a low unit blood flow and
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contributes to phenylalanine metabolism to a negligible extent. This suggests that 
muscle protein turnover predominantly accounts for the protein turnover of the 
human leg.
■  I  -  ’  ■  ■  ■ ■ ■  -  ' - • ■  ■  I  ■  '  T I  • f «  L X i K W K I B E f
Table 3.2. Additives used in Blood Sample Tubes
Analysis Additive Quantity
Leucine Enrichment Li Hep
Phenylalanine Enrichment Li Hep
a-ketoisocaproate Enrichment Li Hep
a-ketoisocaproate Cone. Li Hep
Amino acid Cone. Li Hep
Glucose Fluoride Oxalate
D-(-)-3-hydroxybutyrate Cone. Perchloric acid 1:1 v/v




Glucagon EDTA-Aprotinin 500 KTU/ml
Insulin-like Growth Factor 1 EDTA
Packed Cell Volume Li Hep
Blood Gas Cone. Li Hep (syringe)
Blood C 02 Enrichment & Cone. Orthophosphoric acid
Abbreviations: La Hep, lithium heparin; EDTA, ethylenediaminetetra acetic 
acid; KIU, kallikrein inhibitor units.
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3.5.1 Blood Sample Handling
The blood samples were added to tubes which contained additives 
appropriate for subsequent biochemical assays (Table 3.2). All samples were stored 
on ice prior to separation of plasma in a refrigerated centrifuge (4°C) at 1700 times 
gravity for 20 min. Samples were stored at -20°C until analysis with the exception 
of the samples for glucagon and lactate which were stored at -80 or -196°C. To 
prepare plasma for amino acid concentration analysis, the plasma was 
deproteinised with sulphosalicylic acid (100 g/1, 1:4 v:v) containing norvaline 
internal standard (64 pmol/1), incubated for 30 min at 4°C to precipitate
p-lipoproteins, passed through 0.45 pm filters before storage at -20°C. The
perchloric acid extracts of blood for D-(-)-3-hydroxybutyrate analysis were 
neutralised by the addition of an alkaline solution containing 2 mol/1 KOH, 
0.4 mol/1 KC1 and 0.4 mol/1 imidazole before storage frozen. Free insulin 
concentration was determined in the insulin treated diabetic subjects after removal 
of antibody-bound insulin with the following method (Rudkowski and Antony, 
1986): blood was centrifuged immediately after sampling and the plasma was mixed 
with an equal volume of a solution of polyethylene glycol 6000 (250 g/1, 
biochemistry grade, in phosphate buffer 0.05 mol/1, pH 7.4), centrifuged again and 
the supernatant stored at -20°C before insulin radioimmunoassay. To treat and 
store blood for subsequent determination of whole blood carbon dioxide 
concentration and 13C enrichment, the blood (1 ml) was added to 20 ml glass tubes 
(Vacutainer, Becton Dickinson, Rutherford, NJ, U.S.A.) immediately on sampling:
before use these tubes were prepared by adding 1 ml of a mixture of
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orthophosphoric acid (6 mol/1) and silicone antifoam (10% by volume) and the tubes 
were degassed to a pressure of 0.4 mbar and sealed (Read et al, 1984).
3.6 Breath Sampling and Indirect Calorimetry
Before tracer administration and at intervals throughout the studies expired 
breath was collected into 2 1 latex bags and an aliquot was transferred into 20 ml 
evacuated glass tubes (Vacutainer) for storage and subsequent determination of 13C 
enrichment in carbon dioxide, as detailed below. Total carbon dioxide production 
and oxygen consumption was determined with a microcomputer-controlled, 
ventilated-hood, indirect calorimeter (Illingworth et al, 1986). This continually 
extracted air at a rate of 45 1/min from a plastic hood, fitted over the patients 
head, and passed this via a calcium chloride-packed drying column to an infrared 
carbon dioxide detector (SS-200, Analytical Development Company Ltd., Hoddesdon, 
U.K.) and a paramagnetic oxygen detector (Servomex 540A, Taylor Instrument Ltd., 
Crowborough, U.K.). The analogue detector outputs were connected through an 
analogue-to-digital signal converter to a microcomputer. Barometric pressure was 
monitored continuously with a digital meter and the microcomputer was 
programmed with the ambient air temperature. Carbon dioxide production and 
oxygen consumption were calculated each minute and results were expressed in 
1/min at standard temperature and pressure. Before and after each calorimetry 
session the gas detectors were calibrated with standard gas mixtures: for the 
oxygen meter these were nitrogen, for zero calibration, and room air for 20.94% 0 2; 
for the carbon dioxide meter nitrogen was used and a gas mixture containing 0.8%
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carbon dioxide. From the oxygen uptake and carbon dioxide output resting energy 
expenditure was calculated with Weir’s formula (Weir, 1949).
3.7 Muscle Biopsy Technique
Anterior tibial muscle was biopsied using 6.5 mm Tilley Henckel ethmoid 
punches (S. Murray and Co., Sheffield, U.K.) via a 10 mm long skin incision made 
after 5 ml of 20 g/1 lignocaine local anaesthetic was infiltrated superficially to the 
fascia (Dietrichson et al, 1987). At each time point one to three biopsies were 
obtained providing 100 to 300 mg wet weight of muscle. The biopsies were from 
the fullest part of the shin and were taken 10 mm deep to the fascia. After each 
biopsy firm pressure was applied for 10 to 15 min over the site, and the skin 
incision was held closed with surgical tape. A second biopsy was taken from either 
the same leg, at a distance of 40 mm to the first biopsy, or from the contralateral 
leg. A third biopsy was taken from the leg contralateral to that first biopsied. The 
muscle samples were immediately frozen in liquid nitrogen and stored at -196°C 
until analysis.
3.8 Leg Blood Flow
Leg blood flow was measured by mercury-silastic strain-gauge 
plethysmography (Whitney, 1953; Needham, 1972; Englund et al, 1972; Sumner, 
1985). The technique is shown to give reproducible results (Roberts et al, 1986) 
and to show appropriate blood flow changes resulting from exercise (Hughson,
1988). Occlusion of the venous return from the leg appears to result in 
underestimation of leg blood flow (Hiatt et al, 1989). With the subject
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semirecumbent their heel was raised 200 mm from the bed and the maximal 
circumference of their calf was measured. A strain-gauge of appropriate length was 
selected and a baseline signal obtained by adjusting the balance resistance of a 
Wheatstone Bridge when a 20 g weight was suspended on the gauge to tension it. 
The gauge output was displayed on a chart recorder with a range setting of 10 mV 
per 200 mm and paper speed of 2 mm/sec. The gauge was then placed round the 
calf and the gauge was tensioned, by adjustment of a lengthening screw, to produce 
the same electrical deflection as that produced by the 20 g weight. The system was 
then repeatedly calibrated by adjusting the calibration screw of the gauge four 
turns (a distance of 1.818 mm) which produced a deflection on the pen recorder. 
When the venous return from the leg was transiently occluded, by inflation of a 
large thigh cuff to a pressure of 60 mmHg, the arterial input remained unaltered 
and a linear increase occurred in both leg volume and diameter, from which blood 
flow could be measured by comparison with the calibration deflections.
A second cuff around the ankle was inflated above arterial blood pressure 
(200 mmHg) to exclude blood flow from the foot for 2 min prior to blood flow 
measurements. Then the thigh cuff was automatically inflated to a pressure of 
60 mmHg for 14 sec, during which time blood flow was recorded, and the cuff was 
then deflated for 6 sec to allow venous drainage from the leg. The procedure was 
repeated a minimum of three times at each time point.
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3.8.1 Equation for Calculating Leg Blood Flow:
S • 200
Blood Flow = ------------
C • d
Where:
S = Slope of trace • 120 (mm/min),
C = Calibration height on chart recorder equivalent to a 1 mm change in gauge 
circumference (mm), and
d = calf circumference at the level of the gauge (mm).
The constant 200 relates the rate of change in gauge length to blood flow 
per emit weight (100 g) of leg tissue. Units are ml per 100 g of leg tissue per min 
(ml* 100 g '^m in '1).
3.8.2 Strain-Gauge Construction
The mercury-silastic gauges were constructed from fine bore silastic tubing 
(0.5 mm inner-diameter, 0.5 mm wall thickness), filled with a column of mercury 
and plugged with copper at each end to complete the electrical circuit and to 
anchor the ends of the silastic tubing to the gauge mounts (Needham, 1972). A 
Wheatstone Bridge circuit was employed, with adjustable rheostats, and this was 






At the start of tracer infusion doses of L - [ l - 13C]leucine (0.9 mg/kg) and 
sodium [13C]bicarbonate (either 0.16 or 0.24 mg/kg) were administered to prime 
their respective body pools (Allsop et al, 1978; Matthews et al, 1980). A continuous 
infusion of L - [ l - 13C]leucine at a rate of 1 mg^kg'^h'1 was administered 
throughout the studies. This was diluted to a volume of 500 ml in sodium chloride 
(150 mmol/1), and was delivered at a rate of either 77 or 56 ml/h with IMED 928 
volumetric infusion pumps (IMED Ltd, Abington, U.K.). In the arteriovenous 
exchange studies priming doses of L -[15N]phenylalanine (0.45 mg/kg) were 
administered, followed by a continuous infusion (0.5 mg» kg'1 »h '1) throughout the 
studies.
3.9.2 Insulin Infusion
Insulin was diluted immediately prior to use (0.5 units/ml) in sodium 
chloride (150 mmol/1) containing 5% blood (by volume) to minimise adhesion of the 
insulin to the plastic infusion syringe and tubing. An exponentially-decreasing 
priming dose was administered over 10 min followed by a continuous infusion at 
0.29 nmol*m~2»min~1 (40 m-units• m"2• min'1) (DePronzo et al, 1979). The rate of 
the insulin infusion was controlled with a Treonic IP3 digital syringe pump 
(Vickers Medical, Basingstoke, U.K).
3.9.3 Glucose and Mixed Amino Acid Infusions
In the hyperinsulinaemia studies with diabetic subjects glucose was infused 
when the plasma glucose concentration fell to 5 mmol/1, at a sufficient rate to
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maintain a stable plasma glucose concentration of 5 mmol/1. In the healthy subjects 
studied with insulin infusions the plasma glucose was allowed to fall by 0.3- 
0.5 mmol/1 before glucose was infused: this plasma glucose concentration, 0.3- 
0.5 mmol/1 lower than the subjects fasting glucose concentration, was maintained 
during the euglycaemic clamp to minimise endogenous secretion of insulin by the 
subject. Priming doses of mixed amino acid solutions were infused over the first 
10 min of the mixed amino acid infusions: these priming dose provided the same 
dose of mixed amino acids as the amount infused during each hour of the 
subsequent continuous infusion. This protocol produced steady-state conditions for 
both the plasma leucine concentration and the 13C enrichments of leucine and 
a-ketoisocaproate about 30 min after commencement of a mixed amino acid 
infusion. The solutions of glucose and amino acids were infused and controlled with 
separate IMED 928 volumetric infusion pumps.
3.10 Protocols o f Study
In all of investigations described the subjects consumed a weight-maintaining 
diet during the week before study. They took their evening meal between 5-30 and 
7 pm, on the evening prior to the study. Thereafter they consumed no food by 
mouth until completion of the study on the following day; only water was given.
Two separate study protocols were used with the muscle biopsy technique 




This was used to assess the effects of mixed amino acid infusion alone on 
whole-body leucine turnover and anterior tibialis muscle protein synthesis in 
healthy postabsorptive men (Figure 3.1). Mean enrichment values during the 







Figure 3.1. Protocol a, The influence o f amino acids on leucine incorporation into 
anterior tibialis muscle
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3.10.2 Protocol b
This was used to assess the acute effects of insulin infusion on protein 
turnover in insulin withdrawn type 1 diabetic subjects. Mixed amino acids were 
continuously infused to maintain amino acid availability. Whole-body leucine 
metabolism and anterior tibialis muscle protein synthesis were assessed (Figure 
3.2).
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Figure 3.2. Protocol b, The effect o f insulin with amino acids on incorporation o f 
leucine into anterior tibialis muscle
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Two separate protocols were used to assess leg arteriovenous exchange of 
phenylalanine and leucine:
3.10.3 Protocol c
This protocol was used to assess the effects of mixed amino acid infusion 
alone on skeletal muscle protein turnover and whole-body leucine and 
phenylalanine kinetics in healthy postabsorptive subjects (Figure 3.3). Comparisons 
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This was used to assess the acute effects of insulin, with and without mixed 
amino acid infusion, on skeletal muscle protein turnover and whole-body leucine 
and phenylalanine kinetics in both healthy subjects and type 1 diabetic subjects 
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Figure 3.4. Protocol d, The effect o f insulin, with and without amino acid infusion, 
on leg exchange o f phenylalanine and leucine
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LABORATORY ANALYSIS
3.11 Gas Chromatography Mass Spectrometry
Gas chromatography-mass spectrometry was carried out on either a Finnigan 
1020 instrument (Finnigan MAT Ltd, Hemel Hempstead, U.K.) or on a Hewlett- 
Packard 5971A MSB instrument (Hewlett-Packard Ltd, CheadJe Heath, U.K.). 
These mass spectrometers were fitted with 20 m and 12 m by 0.2 mm inner 
diameter QV-1 WCOT chemically bonded fused silica columns (Pierce UK Ltd, 
Cambridge, U.K.) respectively. Gas chromatography oven temperature was 
programmed to increase from 140 to 270°C at 20°C/min after a 1 min lag. The 
injector temperature was 240°C and injection, in the splitless mode, using decane 
as solvent was complete in 30 s. The carrier gas was helium at 50 kPa. The 
instruments were operated in the electron-impact mode with an ionization energy 
of 70 eV.
3.11.1 13C Analysis o f Plasma Leucine
1-13C Enrichment of leucine in plasma was determined after extraction of 
amino acids and preparation of ¿eri-butyldimethylsilyl derivatives by reaction with 
N-methyl-N-(ieri-butyldimethylsilyl)trifluoroacetamide (Regis Chemical Company, 
Morton Grove, IL, U.S.A.) (Mawhinney et al, 1986) (Table 3.3). The [1 -13C] 
enrichment in leucine was determined by monitoring ion currents m/z 302 and 303. 
The retention time for this derivative of leucine was 3.7 to 3.8 min.
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3.11.2 IBN  Analysis of Plasma Phenylalanine
The preparation of plasma phenylalanine samples for 1BN enrichment 
analysis by gas chromatography-mass spectrometry was identical to that used for 
leucine (Table 3.3). The same ion currents were monitored. The retention times for 
the phenylalanine derivative were in the range of 5.6 to 5.8 min (longer than these 
for leucine). The analysis of leucine and phenylalanine was normally carried out 
on the same sample.
3.11.3 13C Analysis o f Intramuscular Free Leucine
The 13C enrichment of intramuscular leucine was determined in neutralized 
perchloric acid (0.5 mold) extracts of ground, freeze-dried muscle. The samples were 
purified using cationic ion exchange-chromatography (Table 3.4).
i-Butyldimethylsilyl derivatives were prepared and gas chromatography-mass 
spectrometry was carried out a minimum of two times on each sample. When 
calculating the 13C enrichment for the intramuscular leucine a correction was made 
to the measured value on the basis that 13% of the water content of the samples, 
by weight, was extracellular (Bergstrom et al, 1974).
3.11.4 13C Analysis o f Plasma a-Ketoisocaproate
To determine the 13C enrichment of plasma a-ketoisocaproate, 
o-trim ethylsilyl quinoxalinol derivatives were prepared using 
6is-(trimethylsilyl)trifluoroacetamide (Regis Chemical Company or Sigma Chemical 
Company Ltd, Poole. U.K.) (Table 3.5) (Rocchiccioli et al, 1981). Gas 
chromatography-mass spectrometry was by analogous methods to these used for
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plasma amino acid analysis with monitoring of ion-currents m/z 232 and 233. 
Ketovalerate was included as internal standard to quantify the a-ketoisocaproate.
3.12 Isotope Ratio Mass Spectrometry
The enrichment of 13C in carbon dioxide was measured with an automated 
Finnigan MAT breath gas analysis system attached to a Finnigan Delta D isotope 
ratio-mass spectrometer.
3.12.1 I3C analysis o f Carbon Dioxide in Breath and Blood
Carbon dioxide in breath was cryogenically purified on-line before 
measurement of enrichment (Scrimgeour and Rennie, 1988). Analysis of 13C 
enrichment of carbon dioxide in whole blood was performed with the same 
equipment after liberation of the carbon dioxide with orthophosphoric acid. The 
total blood concentration of carbon dioxide was measured at the same time by 
comparing the pressure of the carbon dioxide released from the blood into the 
evacuated sample tubes with that from a range of carbonate standards prepared 
in the same way (Scrimgeour and Rennie, 1988).
3.12.2 13C Analysis o f Protein-Bound Leucine
To prepare the muscle samples for the determination of [ l - 13C]leucine 
enrichment, the samples were freeze-dried, ground and free amino acids were 
extracted with ice-cold perchloric acid and the residue hydrolysed in 6 mol/1 
hydrochloric acid (Tables 3.6.1 and 3.6.2). Leucine was separated by preparative 
gas chromatography (Smith et al, 1988). The carboxyl carbon of the isolated leucine
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Table 3.3. Determination o f Isotope Ratio of Plasma Leucine and Phenylalanine
This analysis was based on the method of Mawhinney et al (1986) and
employed a ¿-butyldimethylsilyl derivative, separation by gas chromatography
and isotope quantification by mass spectrometry in the electron impact mode.
Method
1) To a microcentrifuge tube add 600 pi of plasma and 20 pi of urease 
solution (Urease from jack bean, Type IX, 500 units/ml in 0.01 mol/1 
phosphate buffer, pH 6.7 with sodium azide 1 pmol/1), vortex to mix and 
incubate at 37°C for 15 min. For samples where high leucine and 
phenylalanine concentrations are anticipated the initial volume should 
be appropriately reduced.
2) To precipitate the proteins, add 700 pi methanol/HCl (4:1 v/v), vortex to 
mix and centrifuge at high speed for 5 min.
3) Decant supernatant to a screw-top microcentrifuge tube and remove the 
solvent by overnight rotary-evaporation.
4) Add 200 pi pyridine and 50 pi Af-methyl-A-(i-butyldimethylsilyl)- 
trifluoroacetamide, cap tightly and vortex.
5) Incubate at 80°C for 60 min total; remove from the oven after 30 min, 
vortex to mix and return to the oven.
6) Add 400 pi decane, vortex and centrifuge for 3 min at high speed.
Transfer to autosampler vials.
was liberated as carbon dioxide by ninhydrin and its 13C enrichment was 
determined with the breath gas system, optimised for small quantities of carbon 
dioxide (Scrimgeour et al, 1988a).
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3.13 Amino Acid Concentrations in Plasma and Muscle
Amino acid concentrations were determined in sulphosalicylic acid extracts 
of plasma and perchloric acid (0.5 mol/1) extracts of muscle. Automated amino acid 
analyzers were used employing either a) ion-exchange chromatography with elution 
and separation of amino acids with strongly acidic lithium citrate buffers, norvaline 
as internal standard, post-column derivatization with o-pthalaldehyde/-
2-mercaptoethanol and fluorometric detection (LC5000, Biotronic GmbH, München, 
F.D.R.); b) ion-exchange chromatography, lithium citrate buffers, no internal 
standard, post-column derivatization with ninhydrin and photometric detection 
(LC5000); or c) reversed-phase high-pressure liquid chromatography (HPLC), 
norvaline as internal standard, pre-column on-line derivatization with 
o-pthalaldehyde/2-mercaptoethanol and fluorometric detection (LKB Bromma, 
Sweden) (Graser et al, 1985). The HPLC system column (Spherisorb ODS II, 3 pm, 
125 mm by 4.6 mm) was equipped with a guard column (10 mm by 4.6 mm) filled 
with the same material. Elution was performed with a sodium phosphate buffer 
(12.5 mmol/1, pH 7.2)- acetonitrile gradient. All the samples from every patient 
within a study series were analyzed with the same amino acid analyzer. 
Calculation of the values for the intramuscular concentration was done on the 
assumption that 13% of the water content, by weight, was intracellular.
3.14 Plasma Glucose Analysis
Concentration of plasma glucose was determined with a Glucose Analyzer 2 
(Beckman Instruments, Irvine, CA, U.S.A.), which employed a glucose oxidase 
reaction. With this instrument plasma glucose could be analyzed within 80 sec of
117
Genera! Methodology
blood sampling, allowing rapid adjustments to be made to the glucose infusion rate 
during the euglycaemic insulin clamp studies.
3.15 Plasma Hormone Concentrations
Plasma hormones were measured by radioimmunoassay. Insulin was 
determined with a double- antibody kit (Ire-Medgenix Sa, Brussels, Belgium); the 
primary incubation period was increased to 20 h to optimise the sensitivity of the 
assay. Plasma free insulin concentration, in extracts prepared at the bedside, was 
measured with the same radioimmunoassay procedure, but the kit standards were 
treated with polyethylene glycol- phosphate buffer solution in an identical manner 
to the samples from the insulin treated patients. Glucagon was measured with a 
double-antibody kit (ICN Biomedicals Inc, Carson, CA, U.S.A.), cortisol was 
measured with an antibody- coated-tube kit (Immunodiagnostics Systems Ltd, 
Washington, U.K) and insulin-like growth factor 1 with a double- antibody kit 
(Nicols Institute Diagnostics, San Juan Capistrano, CA, U.S.A.). C-peptide, 
measured at the start of the diabetic studies only, was with a double-antibody kit 
(Ire-Medgenix Sa).
3.16 D-(-)-3-Hydroxybutyrate and Lactate Analysis
The blood concentration of D-(-)-3-hydroxybutyrate was measured by an 
nicotinamide-adenine dinucleotide-linked 3-hydroxybutyrate dehydrogenase enzyme 
assay (Williamson and Mellanby, 1974) and lactate was by an analogous technique 
with lactate dehydrogenase (Gutmann and Wahlefeld, 1974).
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3.17 Blood Gas Analysis
The P 02, oxygen saturation, pH and total bicarbonate concentrations of 
arterial and venous blood was measured using a Coming 189 blood gas analyzer 
(Corning Medical, Medfield, Massechusits, U.S.A.).
3.18 Statistical Analysis
In the text, tables and figures mean values and standard errors are 
presented. In some studies for D-(-)-3-hydroxybutyrate and hormones the results 
were transformed to their natural logarithms before statistical analysis: The means 
presented are the log6 transformations of the logarithmic means; the ranges are the 
natural of values of the 95% confidence limits below and above the loge means. 
Results from the two phases within studies were compared with the two-tailed 
Student’s ¿-test for paired data. A ¿-test for means was used to compare different 
study groups. A stepwise regression analysis was performed to compare rates of 
protein synthesis with indices of insulin sensitivity and substrate supply. A 
microcomputer-based statistics package was used for the calculations (Microstat, 
Ecosoft Inc, Indianapolis, IN, U.S.A.).
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Table 3.4. Determination of Isotope Ratio of Intramuscular Free Leucine
This analysis was also based on the method of Mawhinney et al (1986) and
employed a ¿-butyldimethylsilyl derivative, separation by gas chromatography
and isotope quantification by mass spectrometry in the electron impact mode.
Method
1) A weighed sample of muscle (about 100-300 mg) is lyophilized overnight 
and then ground with a glass rod in a plastic test tube.
2) Extract free amino acids by adding 3 ml perchloric acid (0.5 mol/1, with 
norvaline 64 pmol/1 to quantify amino acids using the amino acid 
analyzer), vortex and stand in ice for 30 min.
3) Centrifuge for 20 min (3000 RPM, 4°C) and decant supernatant. The 
isotope ratio of protein-bound leucine is determined in the residue 
(Table 3-6).
4) To 500 pi of the supernatant add one drop of universal pH indicator and 
neutralise with potassium bicarbonate (2 mol/1). Vortex, let stand in ice 
for 20 min and vortex again.
5) Centrifuge (3000 RPM, 20 min, 4°C) and pipette off supernatant. Mix 
with an equal volume of glacial acetic acid. Apply to a 2.5 ml bed of ion- 
exchange resin (Dowex 50W-X8(H+), 100-200 mesh), prewashed in HC1 
(1 mol/1).
6) The column is washed with HC1 (2x1 ml) and then distilled deionized 
water (2x1 ml).
7) The amino acids are eluted with 3 ml of ammonia solution (4 mol/1) and 
are collected in a screw-top microcentrifuge test tube.
8) Remove the ammonia by overnight rotary-evaporation.
9) Add 50 pi pyridine and 50 pi Ar-methyl-A,'-(/-butyldimethylsilyl)- 
trifluoroacetamide, cap tightly and vortex.
10) Incubate at 80°C for 60 min total; remove from the oven after 30 min, 
vortex to mix and return to the oven.




Table 3.5. Determination o f Isotope Ratio o f Plasma a-Ketoisocaproate
This analysis used the method of Rocchiccioli et al (1981), further modified
by Ford et al (1985), employing a quinoxalinol derivative, separation by gas
chromatography and isotope quantification by mass spectrometry in the
electron impact mode.
Method
1) To a micro-centrifuge tube add 600 pi plasma, 30 pi ketovaleric acid 
solution (0.1 mg per ml) and 800 pi ethanol to precipitate the protein. 
Vortex to mix.
2) Centrifuge at high speed for 3 min, decant the supernatant to a test tube 
and dry under a stream of nitrogen at 50°C.
3) To the residue add 200 pi distilled water and 100 pi o-phenylenediamine 
solution (2% w/v in HC1 4 mol/1).
4) Heat in the oven for 60 min at 90°C, then cool.
5) Extract with 2 by 1 ml aliquots of ethylacetate and dry the combined
extracts over anhydrous sodium sulphate.
6) Decant the dried ethylacetate to a reaction vial, taking care not to
transfer any sodium sulphate. Dry under nitrogen at room temperature.
7) Dissolve the residue in 100 pi pyridine. Add 100 pi 6is-(trimethylsilyl)- 
trifluoroacetamide, cap tightly and heat at 120°C for 30 min.
8) Cool vials and evaporate to dryness under nitrogen at room temperature.
9) Dissolve the residue in 500 pi decane containing 5% ¿¿s-(trimethylsilyl)- 
trifluoroacetamide and transfer to an autosampler vial.
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Table 3.6.1. Determination o f Isotope Ratio of Muscular Bound Leucine
This analysis was based on the method of Smith et al (1988) where ground 
muscle protein is washed and acid-hydrolysed, leucine is separated by 
preparative gas chromatography of trifluoroacetyl isobutyl esters, and isotope 
quantification is by isotope ratio mass spectrometry of the carboxyl carbon 
after liberation as C 02 with ninhydrin.
Method
Protein Extraction
1) A weighed sample of muscle (about 100-300 mg) is lyophilized overnight 
and then ground with a glass rod in a plastic test tube.
2) Extract free amino acids by adding 3 ml perchloric acid (0.5 mol/1), vortex 
and stand in ice for 30 min. Centrifuge for 20 min (3000 RPM, 4°C) and 
decant supernatant.
3) To the residue add a further 3 ml perchloric acid (0.2 mol/1), vortex to 
mix and decant the supernatant. Repeat two times.
4) Add 3 ml NaOH (0.5 ml), mix and incubate at 37°C for 60 min in a 
water bath. Remove 100 pi, which can be used for a protein assay. Add 
2 perchloric acid (1 mol/1) and centrifuge (3000 RPM, 20 min).
5) Suspend in 2 ml of perchloric acid (0.2 mol/1), vortex, centrifuge and 
decant supernatant.
6) Add 5 ml perchloric acid (1 mol/1) resuspend the pellet and heat at 70°C 
for 30 min in a water bath. Centrifuge (3000 RPM, 20 min) and decant 
supernatant.
7) Suspend the protein pellet in 3 ml HC1 (6 mol/1) and transfer to a 
hydrolysis tube. Heat at 120°C overnight.
Ion-Exchange Chromatography
8) Transfer to a centrifuge tube and remove the solvent by rotary 
evaporation. Dissolve the residue in 50% glacial acetic acid.
9) Apply to a 2.5 ml column of ion-exchange resin (Dowex 50W-X8(H+), 100- 
200 mesh, prewashed with 1 mol/1 HC1). Rinse out the hydrolysis tube 
with 2x1 ml HC1 (1 mol/1). Rinse the column with deionized distilled 
water (2x1 ml).
10) Elute the amino acids with 3 ml ammonia solution (4 mol/1). Collect the 
eluent into reaction vials, and blow-off the ammonia under nitrogen for 
about 30 min at room temperature (until pH is 7-9). Freeze with liquid 
nitrogen and lyophilize overnight.
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Table 3.6.2. Determination o f Isotope Ratio o f Muscular Bound Leucine
Derivatization Procedure
11) Add an aliquot of dichloromethane (500 pi) and dry by evaporation under 
nitrogen at room temperature. Dissolve the residue in 400 pi 3 mol/1 HC1- 
isobutanol and heat at 110°C for 30 min. Allow to cool and evaporate 
under nitrogen at room temperature.
12) Dissolve the residue in ethyl acetate (250 pi) and trifluoroacetic anhydride 
(100 pi; and react at 120-130 min for 30 min, releasing the pressure after 
15 min. Allow to cool and evaporate off solvent under nitrogen at room 
temperature.
13) Dissolve in 100 pi of n-heptane and transfer to an autosampler vial. 
Reduce the volume to 100 pi under nitrogen at room temperature.
Preparative Gas Chromatography
14) An aliquot (50-100 pi) of sample is injected into the injection port of a 
Pye 304 chromatograph fitted with a wide-bore glass column 
(6 mm inside diameter x 4.6 m) packed with 2% EGA on 60-80 mesh 
Chromosorb W AW (Phase Sep, Queensferry, Clwyd, U.K.) and with a 
post column splitter (split ratio 99:1).
15) Argon was the carrier gas at a flow of 30 ml/min. The temperature of 
the injector was 200°C and the oven was programmed from 150 to 165°C 
at 2 °C/min, then held at 165°C for 6 min before being increase to 220°C 
to drive off later eluting amino acid derivatives.
16) The leucine derivative is condensed in a demountable U-trap, cooled with 
liquid nitrogen. The leucine fraction is identified by comparison of 
retention times with these of leucine standards (about 11.5 min).
17) The leucine derivative is hydrolysed by adding 100 pi KOH (1 mol/1) and 
heating at 90°C for 45 min or leaving at room temperature overnight. The 
sample is transferred 2 ml of buffer (pH 2) to a Vacutainer and is stored 
at 4°C overnight.
18) The vacutainer is cooled in ice before adding ninhydrin (25 mg) and a 
drop of antifoaming agent. After degassing and sealing the sample is 
heated in a water bath at 90°C for 30 min to liberate the carboxyl-C as 
COz for isotope ratio mass spectral analysis (Scrimgeour et al, 1988a).
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4.1 Summary
Anterior tibial muscle protein synthesis in seven healthy postabsorptive men 
was determined from increases in muscle protein bound leucine enrichment during 
a primed continuous infusion of L - [ l - 13C]'ieucine. Biopsies were taken 30 min after 
the beginning of leucine infusion (when plasma 13C enrichment was steady), 240 
min later during continued fasting and again after 240 min of infusion of a mixed 
amino acid solution which increased plasma total amino acid concentrations by 
37%. The mean enrichment of 13C in plasma a-ketoisocaproate was used as an 
index of the enrichment of the precursor pool for leucine metabolism. Anterior 
tibial muscle mixed protein synthetic rate during fasting was 0.055±0.003 
(Mean±SEM) %/h and this increased by an average of 35% during infusion of 
mixed amino acid to 0.074+0.008 %/h (P<0.05). Whole-body protein breakdown 
(expressed as the rate of endogenous leucine appearance in plasma) was 121±3 
jimol#kg-1,h"1 during fasting and decreased (P<0.01) by an average of 12% dining 
amino acid infusion. Leucine oxidation was 18±1 pmol^kg'^h*1 during fasting and 
increased (P<0.001) by 89% during amino acid infusion. Whole-body protein 
synthesis (non-oxidative leucine disappearance) was 104±2 pmol• kg"1 • h"1 during 
fasting and rose by 13% (P<0.001) during mixed amino acid infusion.
Enrichment of muscle free leucine was only 61+7% of that in plasma 
a-ketoisocaproate and this increased to 74±7% (P<0.02) during mixed amino acid 
infusion.
The results suggest that increased availability of amino acid reverses whole- 
body protein balance from negative to positive and a major component of this is 
the increase in muscle protein synthesis.
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4.2 Introduction
Studies of quadriceps muscle protein synthetic rates in man have shown 
increases during mixed oral feeding (Rennie et al, 1982b; Halliday et al, 1988). In 
studies of amino acid exchange across human limbs, an apparent increase in 
protein synthesis but no change in protein breakdown occurred during mixed oral 
feeding which should elevate insulin secretion (Cheng et al, 1985; Cheng et al, 
1987). In contrast, insulin infusion in fasting healthy subjects not only did not 
induce an increase in indirect indices of protein synthesis but reduced protein 
breakdown (Gelfand and Barrett, 1987). Infusion of insulin in diabetic patients did 
not increase quadriceps muscle protein synthesis but did markedly reduce plasma 
amino acid concentrations (Pacy et al, 1989). These observations suggest that amino 
acids per se may regulate muscle protein synthesis.
The individual contributions of amino acids, energy (i.e. equivalents of 
carbohydrate and lipids) and other paracrine and endocrine hormones in the control 
of skeletal muscle protein synthesis in man are not known. It is known that in 
man, infusion of substantial amounts of either leucine (Schwenk and Haymond,
1987) or mixed amino acids (Castellino et al, 1987; Tessari et al, 1987) increased 
whole-body protein synthesis but only a mixed amino acid infusion reduced whole- 
body breakdown, and although the branched chain amino acids and leucine in 
particular are said to have anabolic effects on animal muscle (May and Buse, 1989) 
there was no data for human muscle in vivo.
From the whole-body protein turnover results in man and the results from 
in vitro studies we formulated the hypothesis that amino acids would increase 
skeletal muscle protein synthesis in man. If this was the case it would in part
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explain, the apparent inability of insulin to increase skeletal muscle protein 
synthesis in man (Pacy et al, 1989) as decreased amino acid availability occurs 
during insulin infusion. The aim of the study reported here was to study the
effects of an intravenous infusion of mixed amino acids without additional fuel 
substrates or hormones on the skeletal muscle protein synthetic rate in 
postabsorptive healthy man. A subsidiary aim was to whole-body protein turnover 
and to examine the changes induced by provision of amino acids.
4.3 Methods
4.3.1 Subjects
Seven healthy men (age range 24.5-39.5, mean 29.5+1.9 years; weight 
73.1±1.2 kg; body mass index 23.8±0.3 kg/m2) were studied.
4.3.2 Protocol
A muscle biopsy based protocol was employed (Protocol a, Section 3.10.1, 
Figure 3.1). After an overnight (15 h) fast a dorsal hand vein was cannulated for 
blood sampling and a contralateral forearm vein was cannulated for all infusions. 
Basal blood and breath samples were obtained (time -15 min). A primed (7.17±0.19 
pmol/kg) continuous (7.39±0.09 pmol^kg'^h'1) infusion of L - [ l - 13C]leucine was 
established and NaH13C03 (1.86±0.03 pmol/kg) injected intravenously. Thirty min 
later (time 30 min) an anterior tibialis muscle biopsy was obtained (Section 3.7) 
and a second biopsy was obtained after a further 240 min (time 270 min). A third 
muscle biopsy was obtained after a further 240 min period (510 min). After the 
second muscle biopsy a priming dose of a commercial preparation of mixed amino
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Time (mln)
Figure 4.1. Plasma leucine concentration in the absence (-15 to 270 min) and in the 
presence (270 to 510 min) o f a mixed amino acid infusion
acids (Synthamin 9, Section 3.3, Table 3.1) was given (83.5 mg of amino acids/kg 
over 10 min), with a second bolus of NaH13COa (0.94±0.01 pmol/kg); amino acids 
were continuously infused until the end of the study at a rate of 1.52 ml*kg~1#h-1 
providing 83.5 mg of amino acids»kg'1 »h_1, 46.5 pmol of leucine • kg"1 »h"1 and 0.33 
g of nitrogen »kg'1 »day-1. Arterialized venous blood samples, with the hot-box 
technique (Section 3.5), and breath samples (Section 3.6) were obtained each hour. 
Indirect calorimetry was undertaken for 11 min each hour (Section 3.6). Amino acid 
analysis was by automated ion exchange chromatography with fluorometric 
detection (Section 3.13).
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4.4 Results
4.4.1 Indirect Calorimetry
Resting energy expenditure was 5.42±0.28 kJ/min in the absence of the 
amino acid infusion and increased to 5.87±0.27 kJ/min (P<G.01) during the infusion. 
No change was found in the respiratory quotient (0.73 overall).
4.4.2 Substrates and Hormones
Values of the concentrations of plasma glucose, insulin, glucagon and cortisol 
and of blood D-(-)-3-hydroxybutyrate were stable within each study period, without 
and with amino acid infusion (Table 4.1). During amino acid infusion insulin was 
53% greater (P<0.05) and glucagon 41% greater (P<0.01) compared with 
postabsorptive concentrations. Concentrations of glucose, D-(-)-3-hydroxybutyrate 
and cortisol were not affected by the amino acid infusion.
4.4.3 Amino Acid Concentrations
The mean plasma leucine concentration (Figure 4.1, Table 4.2) in the 
absence of amino acid infusion, from 30 to 270 min, was 157+8 pmol/1; a rise 
(P<0.05) of 16% occurred from 90 to 270 min. During amino acid infusion leucine 
increased by nearly 80% to a plateau value of 278±17 pmol/1 (P<0.001) between 
330 and 510 min. During fasting the concentration of free leucine in intramuscular 
fluid (167±8 pmol/1 was not different from that in plasma: this increased by 52% 
to 254+21 pmol/1 (P<0.02) during amino acid infusion when there was no statistical 
difference between plasma and intramuscular free leucine concentrations. Total
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Table 4.1. Substrate and Hormone Concentrations in Blood and Plasma in the 
Absence and in the Presence o f Amino Acid Infusion
Postabsorptive Amino acid 
infusion
Blood D-(-)-3-hydroxybutyrate (mmol/1) 0.14+0.03 0.16+0.02
Plasma glucose (mmol/1) 4.7±0.1 4.9±0.1
Plasma insulin (pmol/1) 44+11 68+12“
Plasma glucagon (pmol/1) 36+6 50+6b
Plasma cortisol (nmol/1) 279+37 249±77
Results are means±SEM over time. Statistical significance: ‘P<0.05, bP<0.01.
plasma amino acid concentration was 2890+100 pmol/1 initially and a rise (PcO.OOl) 
of 37% to 3950±140 pmol/1 occurred during amino acid infusion. During infusion 
no change was found in the plasma concentrations of aspartic acid and glutamine; 
reductions occurred in glutamic acid and taurine, amino acids not present in the 
mixture infused.
4.4.4 Plasma and Muscle Free Leucine Pool Enrichments
For both plasma leucine and a-ketoisocaproate, plateau enrichment was 
achieved during the last 180 min of each phase of the study (Figure 4.2, Table
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Table 4.2. Amino Acid Concentrations in Plasma and Intramuscular Water 
(IMW)







Alanine 253±17 1610±200' 467±25' 1900±110'
Arginine 101±9 341±35' 211+17' 473±50'
Aspartic acid 8±2 833±130c 8±2 926+92'
Glutamic acid 82±14 5210+200' 70±12d 5580+350'
Glutamine 673±17 11700±900' 658±8 12100+700'
Glycine 237±12 1450±180' 405±16' 1600±110°
Histidine 92±4 369±20' 138±8' 412+17'
Isoleucine 55±3 59±6 160±6C 145±10
Leucine 157±8 167±12 278±17' 254±21
Lysine 181±19 616±45c 241±20' 679±63'
Methionine 19±1 - 63+2' -
Phenylalanine 54+4 85±9b 103+7' 132+8“
Serine 124+5 833±130c 186±5' 926±92'
Taurine 71±5 20400+1100c 60±3e 19800±1200e
Threonine 128+7 573+66' 181+7' 641+38'
Tryptophan 44+3 4870±1060' 65±5' 7310±890'
Tyrosine 47±3 71±la 48+2 53±5
Valine 254+18 511+54b 380±23' 664±55b
Total amino acids 2890+100 52400±3000c 3950+140' ssoooiieoo“
Values for plasma and IMW at the same time points are compared, and also 
values for plasma at different times (increases: aP<0.05, bP<0.01, 'PcO.OOl; 
reductions: dP<0.02, eP<0.01).
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4.3). The ratio of 13C enrichment in plasma a-ketoisocaproate relative to that in 
plasma leucine was S3±2% in the absence of exogenous amino acids and this was 
maintained (85+3%) during amino acid infusion. The 1SC enrichment in muscle free 
leucine was 4.26+0.59 APE 30 min after the [13C]leucine bolus (time 30 min; and 
was 3.45+0.42 APE at the end of the first phase of the study before infusion of the 
amino acids. This enrichment was unchanged (3.41+0.81 APE) during amino acid 
infusion despite reductions in the enrichment of 18C in both plasma leucine and 
plasma a-ketoisocaproate (Table 4.3). The 13C enrichment of intramuscular free 
leucine was 51+3% of that of plasma leucine in the absence of exogenous amino 
acids and rose to 63±5% (P<0.02) during amino acid infusion. The 18C enrichment 
of intramuscular free leucine was 61±7% of that of a-ketoisocaproate in the 
absence of exogenous amino acids and rose to 74±6% (P<0.02) during their infusion.
4.4.5 Muscle Protein Synthesis
The rate of anterior tibial muscle protein synthesis (Table 4.4, Figure 4.3) 
in the absence of amino acid infusion, calculated on the basis that the mean 13C 
enrichment in plasma a-ketoisocaproate (Table 4.3) should closely represent the 
precursor synthetic pool and provide a best estimate of protein synthesis, was 
0.055±0.003 %/h; the rate increased during amino acid infusion by 35% to 
0.074±0.008 %/h (P<0.05). These values should be considered as the best estimate 
of protein synthesis. When the synthetic rate was calculated on the basis of plasma 
leucine enrichment as representative of the precursor pool enrichment, this minimal 
estimate of muscle protein synthesis was 0.045±0.003 %/h in the absence of amino 
acid infusion, 18% slower (P<0.001) than the plasma a-ketoisocaproate based
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Figure 4.2. Plasma leucine (solid circles) and a-ketoisocaproate (hollow circles) 
enrichments in the absence and in the presence o f mixed amino acid infusion
values; a rise of 40% to 0.063+0.007 %/h CP<0.05) occurred during amino acid 
infusion. In contrast to the a-ketoisocaproate based rates these plasma leucine- 
based values should be considered as minimal estimates of protein synthesis. When 
calculated on the basis of the 18C enrichment in intramuscular free leucine, taken 
as representative of the precursor pool enrichment, this maximal or overestimate 
of muscle protein synthesis was 0.094±0.017 %/h in the absence of amino acid 
infusion (71% faster (NS) than the plasma a-ketoisocaproate based rate). During 
amino acid infusion, the rate of muscle protein synthesis calculated in this fashion
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(0.107±0.017 %/h) showed no significant difference from that calculated in the 
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infusion a rise (PcO.OOl) ^J“ 0.075
of 26% occurred in the 
plasma leucine flux 0-050
(Table 4.5), but this
0.025
increase was less than
Figure 4-3- Skeletal muscle fractional protein synthesis
H i C  t / A U t i C i i U L i b  l t / l i L i l i t /  • , 1  I  i  ■ /* < j  • • 7& in the absence and in the presence o f mixed ammo acid
■ c • , , r infusion calculated from a-ketoisocaproateinfusion rate because of ' ' ^
a reduction (PcO.Ol) of 12% in the rate of appearance of endogenous leucine, a
measure of protein breakdown. Whole-body leucine oxidation increased (P<0.001),
in absolute terms, to almost double the postabsorptive value during amino acid
infusion; as a proportion of plasma leucine flux oxidation rose from 15% to 22%.
The non-oxidative rate of leucine disappearance, i.e. whole-body protein synthesis,
increased (PcO.OOl) by 13% during the amino acid infusion. Net leucine uptake
changed (PcO.OOl) from negative to positive, suggesting that net protein balance
had become positive.
Basal A m ir>° a c 'd s
infused
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4.5 Discussion
This study shows, for the first time, the effects of parenteral infusion of 
mixed amino acids on anterior tibial muscle protein synthesis. Information is also 
provided about the relationships of leucine and a-ketoisocaproate in the plasma 
pool and in muscle intracellular water of anterior tibialis.
In essence the results show that increases in amino acid availability in 
plasma and muscle stimulate muscle protein synthesis, calculated on the basis of 
the enrichments of plasma a-ketoisocaproate or leucine, but not when calculated 
on the basis of intracellular leucine enrichment. The correct interpretation of these 
results depends on knowledge of the relative tracer labelling of muscle leucine- 
tRNA, plasma leucine, intramuscular free leucine, and the keto acid of leucine, 
information not available for man. In previous studies of human muscle protein 
synthesis (Rennie et al, 1982b; Gibson et al, 1987; Halliday et al, 1988; Nair et al, 
1988a; Nair et al, 1988b; Pacy et al, 1989) the plasma a-ketoisocaproate 
enrichment has generally been employed as the basis of calculations, since a 
number of studies of precursor pool labelling of leucine in skeletal and cardiac 
muscle, both in vitro and in vivo, showed tRNA labelling to be nearer to that of 
the extracellular, than to that of the intracellular, amino acid pool (Section 2.3.1). 
In contrast one other study reports the opposite result (Schneible et al, 1981). 
Studies using flooding doses of leucine in the rat in vitro suggest that the 
precursor pool for protein synthesis lies between that of plasma leucine and 
intracellular free leucine (Obled et al, 1989). The substantial transamination of 
leucine in human forearm arteriovenous exchange studies (Cheng et al, 1985;
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Cheng et al, 1987) provides further evidence of rapid entry of extracellular leucine 
to intracellular metabolic processes.
Table 4.3. 13C Enrichment of Free Leucine and its Metabolites in Plasma, 
Muscle and Breath, and the rate o f Increase in Muscle Protein-Bound Leucine
Postabsorptive 
(30-270 min)
Amino add infusion 
(330-510 min)
Plasma leucine (APE) 7.03±0.21 5.41±0.08a
Plasma a-ketoisocaproate (APE) 5.80±0.12 4.60±0.14a
Muscle free leucine (APE)b 3.45±0.42 3.41±0.31
Expired C02 (APE) 0.0129±0.0007 0.0185±0.0009a
103* Protein bound leucine/timec 
(APE/h)
3.20±0.19 3.41±0.35
Statistical significance: aP<0.001. bMuscle free leucine results were obtained at 
either 270 or 510 min of elapsed time. "The rate of increase of protein-bound 
leucine enrichment was calculated from changes calculated over 30-270 min 
and 270-510 min.
The relative increase in the equilibrium between the intramuscular free 
leucine enrichment and that of plasma leucine during amino acid infusion is partly 
a function of the reduced arteriovenous decrement in leucine enrichment that 
occurs when plasma leucine concentration is increased (Cheng et al, 1985; Cheng
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et al, 1987; Layman and Wolfe, 1987) and partly to the increased flux of leucine 
(Cheng et al, 1985; Cheng et al, 1987) in the fed state. The initial (time 30 rain) 
higher intracellular leucine enrichment may have been a transient effect due to the 
bolus of [13C]leucine or to an increase in protein breakdown during the initial 
period of the study. It remains a possibility that the lack of a significant effect of 
amino acid infusion on muscle protein synthesis, calculated on the basis of the free 
muscle leucine labelling, was a type 2 error: this may have occurred as a result 
of taking an insufficiently long period over which to measure the enrichment of 
muscle protein, or to the effect of the relative methodological precision of 
measurements made on small samples of free and protein bound intramuscular 
leucine with a resulting greater variability of the calculated protein synthetic rates. 
Until information is available of the leucyl-tRNA charging of human skeletal 
muscle, rates of muscle protein synthesis derived from plasma a-ketoisocaproate 
enrichment should be viewed as the best available estimates, rates derived from 
plasma leucine enrichment as minimal estimates and rates derived from 
intracellular leucine enrichment as overestimates.
Complete mixtures of amino acids are reported to enhance protein synthesis 
in cell free systems suggesting that there is a direct stimulatory effect of amino 
acids on protein synthesis (Tyobeka and Manchester, 1985). There is, however, no 
known mechanism for this effect and the Kjj, for the charging of tRNA is likely 
to be much lower than the intramuscular concentration of amino acids so that 
tRNA is always fully saturated (Tyobeka and Manchester, 1985). Leucine has been 
reported to stimulate rat muscle protein synthesis in vitro (Buse and Reid, 1975; 
May and Buse, 1989) and whole body protein synthesis in man (Schwenk and
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Raymond, 1987). There is an effect of the branched chain amino acids to control 
initiation of protein synthesis by increasing the proportion of muscle ribosomes as 
polyribosomes (Buse et al, 1979; Flairr et al, 1982b; May and Buse, 1989). 
However, branched-chain ammo acids have no effect on muscle amino acid balance 
(Hagenfeldt et al, 1980; Abumrad ei al, 1982; Eriksson et al, 1983; Morrison et al; 
1988c) or ribosome profile in man (Hammarqvist et al, 1988). Our results showed 
that amino acid infusion caused an inci ease in intramuscular leucine and other 
branched chain amino acid concentrations so that if they were anabolic there was 
scope for the effect to be expressed.
To what extent are the increases in muscle protein synthesis likely to result 
from the small increases in insulin? Many studies in animals both in vitro and 
in vivo (Section 1.8.1) provide evidence of a stimulatory effect of insulin on muscle 
protein synthesis, most sensitive in the range 0-15 mU/1 (Millward et al, 1983). 
Studies in adult man conflict with these animal-based results suggesting that 
insulin may not have an anabolic effect (Gelfand and Barrett, 1987; Pacy et al, 
1989). An increase occurred in glucagon but this hormone certainly does not 
stimulate muscle protein synthesis at the concentrations found and may decrease 
it at pathophysiological concentrations (Preedy and Garlick, 1988).
It remains possible that growth hormone itself induced the reported changes 
as this hormone is shown to have an acute, direct insulin-like effect on rat muscle 
protein synthesis in vitro (Cameron et al, 1988). Insulin-like growth factors, 
expressed by messenger ribonucleic acids in most human foetal tissues including 
muscle (Han et al, 1988), may have exerted a paracrine influence to modulate 
increases in protein synthesis in response to amino acid provision, but during
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Table 4.4. Calculated Values o f Anterior Tibial Muscle Protein Synthetic Rate 
According to Choice o f Leucine Pool to Represent the Precursor Pool for Protein
Synthesis
Precursor pool assigned Postabsorptive Amino acid
infusion
P value
Plasma a-ketoisocaproate (%/h) 0.055±0.003 0.074+0.008 0.05
Plasma leucine (%/h) 0.046+0.003 0.063±0.007 0.05
Intramuscular leucine (%/h) 0.094±0.017 0.107+0.017 NS
NS, non significant.
infusion of the same amount of amino acids in another study we were unable to 
measure any change in plasma insulin-like growth factor 1 concentration (Chapter
5). Since, the anabolic effect of the exogenous amino acids on muscle cannot be 
firmly identified with changes in availability of insulin, glucagon (or cortisol, 
glucose and ketone bodies, none of which changed in concentration), we are 
therefore forced to the conclusion that either the simple increase in intramuscular 
concentration of amino acids or an increase in some other unknown anabolic factor 
caused the observed increase in muscle protein synthesis. The present results 
strongly suggest that a major component in the two fold increase seen in muscle 
protein synthesis in going from the postabsorptive to the fed state (Rennie et al,
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1982b; Halliday et al, 1988) is simply due to an increased availability of amino 
acids.
Table 4.5. Whole-Body Leucine Kinetics
Amino Acids and Muscle Protein Synthesis
Postabsorptive Amino acid infusion Change 
(pmol#kg-1*h_1) (pmol#kg'1#h-1) (%)
Infusion rate - 46.5 --
Flux 121±3 153±5b +26
Protein breakdown 121±3 106±5a -12
Oxidation 13±1 34±2b +88
Protein synthesis 104±2 118±3b +13
Net protein balance -18±1 +12±2b
Statistical significance: “PcO.Ol, bP<0.001.
The values in the postabsorptive state for anterior tibialis mixed protein 
synthesis are somewhat higher than those for quadriceps (0.046±0.003 %/h) 
obtained with identical methods and methods of calculation, by ourselves and other 
workers (Gibson et al, 1987; Halliday et al, 1988). This difference may be due to 
the greater type 1 fibre content of anterior tibial muscle (73±4%) compared with 
quadriceps (47±4%) (Johnson et al, 1973). At present the relative synthetic rates 
for human type 1 and type 2 muscle fibres are not known but it is known that in
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animals muscles with predominantly type 1 fibre composition turn over faster than 
those predominantly type 2 (Goldberg, 1967; Flaim et al, 1980; Preedy and Garlick,
1988).
The absolute values, and the changes that occurred between the 
postabsorptive and amino acid supplemented states in the plasma fluxes of leucine 
and a-ketoisocaproate and the rates of oxidation of leucine are in accord with 
these expected from pr'-ious work (Castsliino et al, 1987; Tessari e: ol, 1987;. The 
most important feature of the results for the present discussion is the net anabolic 
effect of exogenous amino acids due to an increase in non-oxidative leucine 
disappearance (whole body protein synthesis) and a reduction in the appearance 
of leucine from protein breakdown.
Given the fact that skeletal muscle contributes about 50% of lean body mass 
(Forbes, 1987) it is possible to calculate (assuming that muscle contains 180 mg 
protein/g, protein contains 8% leucine and all skeletal muscle is similar to anterior 
tibialis) the contribution of muscle to whole body protein synthesis (non-oxidised 
leucine disappearance); it would be 24 pmol^kg'^h"1 in the postabsorptive state 
and 33 pmol^kg'^h'1 during exogenous amino acid infusion. These estimates would 
be reduced by 16% if skeletal muscle turnover generally reflected that of 
quadriceps. Such calculations suggest that in the postabsorptive state skeletal 
muscle may account for between 20-24% of whole body protein synthesis. The 
relative change, on addition of exogenous amino acids, was twice as great for 
anterior tibialis than for the whole body protein mass suggesting that muscle 
increased its contribution; indeed calculations show that the proportion of whole 
body protein synthesis due to muscle rose to between 23-28%. This is less than the
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contribution previously calculated (Rennie et al, 1982b) because of the revised, 
lower values now routinely obtained for skeletal muscle protein synthesis (Gibson 
et al, 1987; Halliday et al, 1988).
This work provides strong support for the hypothesis that amino acids have 
an anabolic effect by stimulating muscle protein synthesis. This effect of amino 
acids may explain why insulin per se fails increase muscle protein synthesis as 
reductions occur in amino acid c-.ncentration in plasma (Fuka.gu.va ci c l  19.16) and 
muscle (Alvestrand et al, 1988) during hyperinsulinaemia. However, uncertainties 
regarding the correct accessible leucine metabolite to use to define precursor pool 
enrichment remain to be resolved. The biopsy technique provides no information 
about skeletal muscle protein breakdown or intermediary metabolism of leucine by 
the leg. To investigate the effect of amino acids on these aspects of muscle protein 
turnover and amino acid metabolism further studies assessing arteriovenous 
exchange of tracers (Sections 2.6 and 2.7) are indicated (Chapter 5).
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5.1 Summary
A stable isotope technique depending on the use of [16N]phenylalanine and 
[ l - 13C]leucine to assess leg exchange of the tracee amino acids was utilized to 
measure the components of protein turnover of the human leg and the effects of 
exogenous amino acid supply. Eight healthy subjects were studied when 
pos¿absorptive in the basal state and again during infusion of a mixed amino acid 
solution (55 g/1; 1.52 ml*kg'1*h~1). During the basal period leucine oxidation by the 
leg was 4.4+2.0 nmol* 100 g '1*min'1 and this increased threefold during amino acid 
infusion (13,6±3.1 nmol* 100 g^m in"1, mean±SEM, P=0.003). Amino acid infusion 
abolished the net negative balance between incorporation of phenylalanine into, and 
release from, protein (basal, -13.7±1.8; during infusion, -0.8+3.0 
nmol* 100 g '^m in '1, P=0.003); leucine exchange showed a similar pattern 
(basal, -31.8±5.8; during infusion, +3.1+7.1 nmol* 100 g '^m in '1, P=0.001). Basal 
entry of phenylalanine into leg protein (i.e. protein synthesis) was 29.1±4.5 
nmol* 100 g_1*min_1 and this increased during amino acid infusion to 38.3±5.8 
nmol* 100 g_1*min_1 (P=0.09). Leucine entry to protein also increased with amino 
acid infusion 70.0±10.8 vs 87.3±14.1 nmol* 100 g"1*min'1, P=0.11). Release from 
protein of phenylalanine (42.8±4.2 vs 39.1±4.2 nmol* 100 g '^m in '1, P=0.50) and of 
leucine (101.8+9.1 vs 84.2±9.1 nmol* 100 g '^m in '1, P=0.21) was unchanged by 
amino acid infusion. The results suggest that, in the post-absorptive state in man, 
infusion of mixed amino acids, without additional energy substrates, reverses 
negative amino acid balance by a mechanism which includes stimulation of muscle 
protein synthesis but which does not alter protein breakdown. Interpretation of the 
results on whole-body protein turnover suggests that the increase in muscle protein
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synthesis contributes substantially to the wbole-body increase, but the fall in 
whole-body breakdown with exogenous amino acids is independent of changes in 
muscle.
5.2 Introduction
We have shown, using s technique involving muscle biopsy and incorporation 
of [ l - 13C]leucine, that infusion of a mixed amino acid solution alone increases 
human skeletal muscle protein synthesis (Chapter 4). We wished to check this 
result by an independent method and obtain additional information about the 
effects of amino acid infusion on other components of skeletal muscle protein and 
amino acid metabolism, principally protein breakdown and leucine oxidation. 
Investigation of skeletal muscle protein turnover in vivo in man has previously 
been usually studied using tracer incorporation into muscle biopsies (Halliday and 
McKeran, 1975; Rennie et al, 1982b; Gibson et al, 1988; Halliday et al, 1988; Nair 
et al, 1988b; Gibson et al, 1989) but this method measures protein synthesis alone, 
providing no information on protein breakdown or other metabolic processes.
An alternative approach to amino acid metabolism in human muscle is to 
measure arteriovenous exchange of leucine across forearm, with L - [ l - 13C,15N]leucine 
(Cheng et al, 1985; Cheng et al, 1987). This technique provides additional 
information about oxidation, transamination and release from protein of leucine but 
has the disadvantage of requiring mass spectrometric analysis of 15N and 13C 
enrichment of different leucine fragments, a-ketoisocaproate and C02 and the 
proliferation of a number of model dependent assumptions. The conceptually similar 
technique using tracer phenylalanine (Gelfand and Barrett, 1987) has the
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advantage of employing fewer (and a different subset of) modelling assumptions 
and provides a more direct measure of protein breakdown. We have borrowed from 
and modified these techniques by simultaneously employing a leucine tracer 
incorporating only one labelled moiety (L - [ l -13C]leucine) and a stable isotope- 
laLAled phenylalanine tracer (L -[1BN]phenylalanine) in order to provide relatively 
robust estimates of protein breakdown in human muscle. Concurrent to our study 
a conceptually similar technique was evolved by a separate group of workers using 
fp/ieny/-2H2]phenylalaiiiiie and [p/ieny/-2H4]phenylalanine (Thompson et al, 1989).
We have used these methods to investigate the effect of infusion of mixed 
amino acid solution in young healthy subjects. Our aims were (a) to gain a further 
insight into the possible effects of amino acids alone on human skeletal muscle 
protein and amino acid metabolism in vivo and (b) to compare the results obtained 
with the arteriovenous exchange technique with those from muscle biopsy studies 
previously performed under similar conditions, which showed a stimulation of 
protein synthesis (Chapter 4).
5.3 Methods
5.3.1 Subjects
Eight healthy subjects (2 female, 6 male; age 28.5±2.5 years; weight 
72.0+3.6 kg; body mass index 23.5+1.1 kg/m2) were studied.
5.3.2 Protocol
After an overnight fast (15 h) the subjects were investigated during 180 min 
of continued fasting (basal), followed by 180 min of infusion of mixed amino acids
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(Protocol c, Section 3.10.3, Figure 3.3). Cannulas for blood sampling were placed 
in a dorsal hand vein, in a retrograde direction, and in a common femoral vein, 
in an antegrade direction (Section 3.5). A third cannula was placed in a 
contralateral forearm vein for tracer and amino acid infusion.
Priming doses of L - [ l - lsC]leucine (6.87±Q.2Q pmol/kg), L -[l6N]phenylalanine 
(2.75±0.10 pmol/kg) and NaHlsC03 (1.99+0.08 pmol/kg) were administered at time 
0 min. A continuous infusion of L - [ l - 13C]leucine (7.61±0.21 pm ol'kg'1«}!'1) and 
L -[16N]phenylalanine (3.05±0.08 pmol«kg-1«h_1) was established and continued until 
the end of the study. After 180 min of continued fasting a priming dose (97.4 mg 
amino acids/kg over 10 min) of a commercial mixed amino acid solution 
(Synthamin 9, Section 3.3, Table 3.1) was administered with a second priming dose 
of NaH13C 03 (0.97±0.04 pmol/kg). Synthamin 9 was then infused until the end of 
the study at 1.52 m l'k g '^ h '1, providing 83.5 mg« kg'1 «h '1 of mixed amino acids,
46.5 pmol^kg'1 «h-1 leucine and 0.33 g nitrogen «kg'1 «day-1.
Arterialized venous samples were taken before the start of the tracer 
infusion (-15 min) and during each phase of study (Section 3.5, Figure 3.3). 
Femoral venous samples and both arterialized and femoral venous blood samples 
for subsequent determination of 13C enrichment of blood C02 (Section 3.5.1) were 
only taken before the tracer was administered and at the four time points at the 
end of each phase of study.
Ventilated-hood indirect calorimetry (Section 3.6) was undertaken during the 
final 40 min of each phase of study. Leg blood flow (Section 3.8) was measured 
three or four times after each of the last set of four pairs of blood samples during 
each phase of study.
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Table 5.1. Hormones and Substrate Concentrations in Blood and Plasma in 
the Absence and in the Presence o f Amino Acid Infusion
Basal Amino acid 
infusion
Plasma
Insulin (pmol/1) 48±6 56±8a
IGF-I (U/l) 740±80 750±80
Glucagon (pmol/1) 39.4±10 54.0±8.6b
Cortisol (nmol/1) 189±32 201±34
Glucose (mmol/1) 4.8±0.1 4.9±0.1
Blood
Lactate (mmol/1) 0.65±0.08 0.69±0.06
D-(-)-3-Hydroxybutyrate (mmol/1) 0.14±0.03 0.11+0.02
Results are means±SEM. Statistical significance: aP=0.07, bP<0.01. 
IGF-I, Insulin-like growth factor I.
Amino acid concentration analysis was by automated ion exchange 
chromatography with fluorometric detection (Section 3.13).
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5.4 Results
5.4.1 Indirect Calorimetry
Whole-body carbon dioxide production was 0.191±0.011 1/min during basal 
postabsorptive conditions and this increased during amino acid infusion to 
0.208+0.11 1/min (P<0.Q1); whole-body oxygen consumption was 0.247+0.014 1/min 
and also increased during amino acid infusion to 0.275+0.017 1/min (PcO.Ol); thus 
resting energy expenditure was 4.96±0.28 kJ/min during basal conditions and 
increased during amino acid infusion to 5.51+0.34 kJ/min (PcO.Ol). Leg blood flow 
was 2.44±0.23 ml* 100 g ^ m in '1 during the basal phase of study and there was no 
change during mixed amino acid infusion (2.69±0.18 ml#100 g '1#min_1).
5.4.2 Hormones and Substrates
The basal plasma glucagon concentration (Table 5.1) was 39.4±10 pmol/1 
and increased by 37% during mixed amino acid infusion (P<0.01). The basal plasma 
insulin concentration was 48±6 pmol/1 and increased by 14% during amino acid 
infusion (P=0.07, one-tailed). The concentrations of plasma insulin-like growth 
factor I, cortisol, glucose, blood lactate and D-(-)-3-hydroxybutyrate remained 
unaffected by the amino acid infusion.
5.4.3 Amino Acid Arterial Concentrations
The primed amino acid infusion produced a rapid increase in the arterial 
plasma concentration of most amino acids (Table 5.2). The plasma concentrations 
of phenylalanine and leucine (Figure 5.1) were stable dining each phase of study. 
Phenylalanine concentration increased by a mean of 91%, leucine by a mean of
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Figure 5.1. Plasma phenylalanine and leucine concentrations before (-15 to 180 
min) and in the presence (180 to 360 min) o f mixed amino acid infusion (solid 
symbols, arterial; hollow symbols, venous)
77% and total amino acids by a mean of 57% during the amino acid infusion. A 
reduction occurred in the arterial concentration of 3-methylhistidine and there was 
a slight increase in the concentration of glutamine during the amino acid infusion.
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Statistical significance: “P<0.05, bP<0.02, 'PcO.OOl. 
BCAA, branched-chain amino acids.
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5.4.4 Leg Amino Acid Balance
The net effluxes from the leg of both phenylalanine and tyrosine (Table 5.3) 
lessened but remained negative during amino acid infusion, indicating that leg 
protein breakdown still exceeded protein synthesis. The efflux of 3-methylkisudine 
from the leg was unchanged throughout suggesting that the rate of myofibrillar 
protein breakdown was unaffected by amino acid infusion.
5.4.5 Enrichments of Phenylalanine, Leucine and Leucine Metabolites
Plateaux were attained for the enrichments of plasma phenylalanine, leucine 
(Figure 5.2) and a-ketoisocaproate and both whole-blood and expired C02 during 
the final periods of each phase of study.
5.4.6 Leg Protein Turnover
Leg mixed protein breakdown, assessed with either [16N]phenylalanine or 
[ l - 13C]leucine, (Table 5.4) was not altered by infusion of amino acids. Leg protein 
synthesis assessed with phenylalanine (Figure 5.3) increased during infusion of 
amino acid 32% (P=0.09, one-tailed; 95% confidence interval -5.2 to +23.7 
nmol* 100 g '1#min_1). Leg protein synthesis, measured with leucine tracer, showed 
a mean value which was 25% greater during infusion of mixed amino acids 
(P=0.11, one-tailed; 95% confidence interval -15.2 to +49.6 nmol* 100 g'^min"1). 
Oxidation of leucine by the leg increased 3 fold (P<0.01). The balance between 
protein synthesis and protein breakdown became markedly (P<0.01) less negative 
during infusion of amino acids when assessed by both phenylalanine and leucine 
tracer kinetics. The molar ratio of leucine to phenylalanine entry to leg protein was
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2,4 when the subjects were studied during postabsorptive conditions and was 2.3 
when they were infused with amino acids; in skeletal muscle protein the ratio of 
the concentrations of the amino acids is 2.4 (Gelfand and Barrett, 1987).
5.4.7 Whole-Body Leucine and Phenylalanine Kinetics
Whole-body leucine flux (Table 5.5) increased by 24% during the amino acid 
infusion and phenylalanine flux increased by 34%. Assessment of whole-body 
protein breakdown with leucine tracer suggested that it decreased by 14% during 
the amino acid infusion; assessment with phenylalanine tracer suggested a decrease 
of 23%. The molar ratio of leucine to phenylalanine release from protein was 2.4 
(basal) and 2.6 during amino acid infusion. Whole-body oxidation of leucine almost 
doubled and whole-body protein synthesis assessed with leucine increased by 12% 
(P<0.02) during infusion of mixed amino acids. The balance between protein 
synthesis and protein breakdown in the whole-body, assessed with leucine, changed 
from negative to positive, a highly significant result (P<0.01).
5.4.8 Calculated Leg Muscle Fractional Protein Synthetic Rate
With the information that muscle contains 18% protein, protein contains 8% 
leucine and 4.0% phenylalanine (Gelfand and Barrett, 1987), and assuming (on the 
fat content of the subjects, and that the leg is representative of whole-body) that 
75±3% of leg blood flow is distributed to muscle, the basal fractional protein 
synthetic rate may be calculated as 0.052±0.009 %/h, from phenylalanine exchange, 
or 0.052±0.009 %/h, from leucine exchange. The corresponding rates during amino 
acid infusion were 0.074±0.015 %/h and 0.066±0.012 %/h respectively.
Amino Acids and Leg Protein Turnover
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Figure 5.2. Plasma phenylalanine, leucine and a-ketoisocaproate enrichments in 
the absence and in the presence o f mixed amino acid infusion (solid symbols, 
arterial; hollow symbols, venous)
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During the investigations described above we were able to produce, by 
infusion, a 60% increase in the plasma concentrations of total amino acids; all 
indispensable amino acids increased in concentration. Thus we were in a position 
to compare metabolism with and without the presence of extra amino acids. Both 
plasma glucagon and insulin concentrations increased slightly (16 and 14%, 
respectively) but the other hormones and substrates monitored were not altered in 
concentration by the infusion. Thus the factor most likely to have any major 
anabolic effect would be the large change in amino acid concentration. However the 
most striking effect of the amino acid infusion on leg amino acid metabolism was 
a catabolic one, a three fold increase in leucine oxidation. This is likely to have 
been the result of stimulation secondary to the 77% increase in leucine 
concentration and a subsequent increase in a-ketoisocaproate, its keto acid, either 
by mass action or by activation of intra-mitochondrial branched-chain keto acid 
dehydrogenase complex (Section 2.3.1; Khatra et al, 1977; May and Buse, 1989). 
(It has been suggested from studies in man (Nair et al; 1988b) and in pig 
(Ostaszewski and Nissen, 1988) that glucagon at high concentrations stimulates 
whole-body leucine oxidation, and this may be an additional factor which increased 
leucine oxidation by skeletal muscle and other tissues in the present study). The 
net efflux of a-ketoisocaproate from the leg was 26% higher during the amino 
acid infusion showing that net transamination of leucine was increased more than 
decarboxylation by the amino acid infusion. However the present results confirm 
and extend previous findings that the majority of leucine transaminated in muscle
5.5 Discussion
157
Amino Acids and Leg Protein Turnover
is oxidised in situ and not exported to liver as cx-ketoisocaproate as in the rat (Elia 
and Livesey, 1983).
The unidirectional uptake by the leg of both leucine and of phenylalanine 
(i.e. protein synthesis) was increased by the infusion of amino acids. A substantial 
degree of variation in the measured response to the infusion was seen in the 
different individuals, due both to analytical and biological factors. Nevertheless 
the finding that the average leg protein synthetic rate increased in response to 
amino acid infusion is in agreement with the results from a previous study in 
which protein synthetic rate, indicated by incorporation of tracer into percutaneous 
muscle biopsies, was found to increase by 35% (Chapter 4).
The modest increase in insulin during amino acid infusion may theoretically 
have stimulated skeletal muscle protein synthesis, although in adult man no such 
effect of insulin alone on skeletal muscle protein synthesis could be found by 
techniques similar to these used here (Gelfand and Barrett, 1987). In contrast we 
found an effect of insulin on muscle protein synthesis assessed by phenylalanine 
arteriovenous exchange at fast rates of amino acid supply (Chapter 6), but we have 
evidence that in diabetic man protein synthesis studied by the biopsy incorporation 
technique is unaffected by acute insulin in the presence of amino acids (Chapter
7). We previously concluded that the rise in protein synthesis observed during 
amino acid infusion was either a direct effect of the increased amino acid 
availability (Chapter 4), or due to increases in an unidentified systemic or 
paracrine growth factor secondary to increased amino acid concentration.
It is possible that the increase in the plasma concentrations of both leucine 
and phenylalanine which occurred during amino acid infusion may have caused an
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Statistical significance: “P<0.02, bP<0.01, CP<0.001. 
BCAA, Branched chain amino acids.
increase in tracer exchange between the plasma and intramuscular compartments
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(Layman and Wolfe, 1987). If during basal conditions tracer exchange between 
plasma and intracellular fluid was incomplete and a marked difference existed 
between the intracellular tracee enrichment and that of plasma, such a difference 
would be less when amino acid concentrations were raised by exogenous infusion 
and amino acid transport was stimulated. Consequently protein breakdown and 
protein synthesis may have been significantly underestimated during basal 
conditions but underestimated to a lesser extent during mixed amino acid infusion. 
If this potential source of error had occurred to a marked extent the present 
results may overestimate the stimulatory effect of amino acid infusion on protein 
83rnthesis.
Apart from the measurements of net transamination and oxidation we have 
more confidence in the results for protein metabolism derived from phenylalanine 
than leucine data. This is for a number of reasons. For the leucine-based results 
(e.g. the derived leg protein synthesis value calculated from 14 separate analyses: 
blood flow, packed cell volume, arterial and venous concentrations and enrichments 
of leucine, a-ketoisocaproate and C02) the analytical variation in the calculated 
protein synthetic rate was greater than when phenylalanine data, for which only 
6 separate analyses were required, were used. A further potential problem with the 
leucine-based results is the possibility that the use of plasma a-ketoisocaproate as 
a measure of the precursor pool enrichment for leucine oxidation and the weighted 
mean of leucine and a-ketoisocaproate as the precursor pool for protein synthesis 
may cause a systematic error in the leucine-based results if one of these estimates 
of precursor pool enrichment is incorrect. There is also the possibility of a 
systematic error in the calculation of leucine oxidation which may occur to a
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Figure 5.3. Leg protein synthesis before and during mixed amino acid infusion 
assessed with phenylalanine exchange
substantial extent in leg adipose tissue (Frick and Goodman, 1980) in addition to 
muscle, whereas protein synthesis will occur predominantly in muscle. For 
phenylalanine similar problems do not arise as adipose tissue is not a significant 
site for its metabolism. It therefore appears likely that the interpretation of the 
results of leg protein turnover measured with phenylalanine in an exchange model 
may be more secure than those obtained from measures with leucine. Although the 
leucine technique, particularly when a L - [ l - 13C,1BNlleucine tracer is used (Cheng 
et al, 1985; Cheng et al, 1987) potentially provides additional information about 
amino acid intermediary-metabolism (e.g. unidirectional transamination rates) by 
the leg, the stable isotope-labelled phenylalanine technique is also more analytically
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robust, obviating the need for isotope ratio mass spectrometry of C02 and providing 
more secure information.
Table 5.4. Compì:nents o f Leg Phenylalanine caid Leucine Metabolism; Effects
o f Amino Acid Infusion
Phca v'iâianine turnover Leucine turnover
Basal Amino acid
infusion
Basal Amino acid 
infusion
(nmol *100 g 1#min *) (nmol *100 g'^m in'1)
Breakdown 42.8±4.2 39.1±4.2 101.8±9.1 84.2±9.1
Synthesis 29.1±4.5 38.3±5.8b 70.0±10.8 87.3+14.l a




Statistical significance: “P=0.12, bP=0.09, CP<0.01, dP<0.001.
When amino acids are administered intravenously in the form of a primed 
continuous infusion the intravenous amino acid pool expands rapidly and a new 
plateau for amino acid concentration may be obtained within 45 min (Figure 5.1). 
However, the intramuscular amino acid pool may expand in size more slowly, being 
limited by the transport kinetics of amino acids. Studies of the effect of amino acid
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infusion for only 90 rain (Lundholm et al, 1987) suggest that equilibration of 
concentration between plasma and muscle is not totally complete within this short, 
period although when amino acids were infused for 240 min equilibration did seem 
to occur (Chapter 4). Such observations suggest that disappearance from the 
plasma space of non-oxidised/non-transaminated leucine carbon and of 
phenylalanine into leg skeletal muscle after 135-180 min of amino acid infusion 
predominantly represents incorporation of the amino acid into protein. Nevertheless 
we cannot exclude the possibility that tracer uptake across the leg may in part 
represent equilibration of the amino acids between plasma and muscle on 
expansion of the intramuscular free amino acid pool and, consequently, protein 
synthesis may have been overestimated during amino acid infusion in the present 
study. However our previous finding of an increase in skeletal muscle protein 
synthesis, determined by leucine incorporation into protein (Chapter 4), is not 
dependent on the particular modelling-assumptions adopted in the present work 
and the agreement of the of the two results suggests that the design of the present 
study was adequate. An additional piece of evidence providing support for the 
nature of the results is the concurrence between the ratios of influx and efflux of 
tracer leucine and phenylalanine and their relative concentrations in muscle 
protein.
The effects of amino acid infusion on whole-body protein turnover 
determined with leucine are in agreement with our previous study (Chapter 4) 
which showed increases in whole-body protein synthesis and oxidation, a reduction 
in whole-body protein breakdown, and a change in whole-body protein balance 
from negative to positive. The reduction in whole-body protein breakdown during
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Table 5.5. Components o f Whole-Body Leucine and Phenylalanine Kinetics; 
Effects of Amino Acid Infusion
Leucine turnover Phenylalanine turnover
Basal Amino acid Basal Amino a
infusion infusion
(pmol®kg"1*h'1) (pinol* kg"1 »h-1)
Flux 119±3 148±5C 50.0±2.1 66.9+2.6b
Infusion -- 46 - 28.2





Statistical significance: “P<0.02, bP<0.01, CP<0.001.
amino acid infusion was confirmed by the phenylalanine-based data.
The present investigation suggests that infusion of mixed amino acids 
neither decreased total mixed skeletal muscle protein breakdown (indicated by the 
leucine and phenylalanine results) or reduced myofibrillar protein breakdown
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(indicated by the lack of change in 3-methylhistidine efflux), findings in agreement 
with those from a previous study (Tracey et al, 1S88). Thus the decrease in whole- 
body protein breakdown must occur in non-skeletal muscle tissue, such as the liver, 
a tissue in which protein breakdown is inhibited by amino add availability 
(Mortimore et al, 1987).
The calculated fractional leg skeletal muscle protein synthetic rates for 
postabsorptive subjects (phenyiaianine-based 0.052±0.009 %/h; leucine-based 
0.052+0.009 %/h) are very close to these for anterior tibial muscle determined in 
biopsy samples and calculated with plasma a-ketoisocaproate as precursor pool 
for protein synthesis (0.055+0.003 %/h, Chapter 4). However, the rates for anterior 
tibialis, when calculated with a-ketoisocaproate as precursor pool (Chapter 4), are 
about 20% higher than the rates for quadriceps muscle (Gibson et al, 1987) 
measured with identical means; the rates from quadriceps will be more 
representative of the average skeletal muscle protein synthetic rates of the whole- 
leg than anterior tibialis. The rates obtained with the arteriovenous exchange 
technique should be viewed as minimal estimates of muscle protein synthesis since 
the use of the plasma amino acid tracer enrichment in the calculations may result 
in an overestimate of the enrichment of the precursor pool for protein synthesis 
and correspondingly underestimate protein synthesis.
Nevertheless, the results provide further evidence that nutritionally driven 
anabolism in the whole-body receives a major input from skeletal muscle. The 
present study confirms our previous findings that infusion of mixed amino acid 
solution without addition hormones or energy substrates increases skeletal muscle 
protein synthesis and leucine transamination and oxidation. In contrast, it also
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suggests that amino acid infusion does not alter either mixed protein breakdown 
or myofibrillar protein breakdown of skeletal muscle of the leg. A major part of the 
anabolic effect of feeding, in the whole-body, may be due simply to an increased 
supply of amino adds on muscle protein synthesis, but the decrease in whole-body 
protein breakdown must occur in non-muscle tissue.
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6.1 Summary
Leg exchange and plasma kinetics of [1EN]phenylalanine and [ l - 13C]leucine 
were used to assess the effect of insulin during amino acid sufficiency on leg and 
whole-body protein turnover. Eight healthy subjects were studied ilrst curing amino 
infusion aione and then during infusion of glucose and insulin (0.29 
nmol*m'2,min'’ ) with additional amino acids. Insulin strongly stimulated the 
positive leg amino acid balance seen with amino acids; phenylalanine uptake into 
leg protein (protein synthesis) rose during insulin plus amino acids (amino acids 
alone, 47.3±11.5 nmol*(100 g leg)-1*min_1; insulin + amino acids, 73.1±7.3 
nmol* 100 g-1*min-1, P=0.022) but with no reduction in leg phenylalanine release 
(protein breakdown) (44.7±8.1 vs 40.0±7.9; both nmol* 100 g '^m in '1). Leucine entry 
to leg protein increased slightly with insulin (129+26 vs 146+21 
nmol* 100 g_1*min_1) possibly obscured by a fourfold elevation in leucine oxidation 
(P=0.012). Leg protein breakdown (leucine release) was reduced by insulin (120+17 
vs 84±10 nmol* 100 g-1*min"1, P=0.024). Whole-body protein synthesis (non-oxidative 
leucine-carbon disposal) increased with insulin (114±4 vs 126±4 pmol^kg'^h'1, 
P=0.0048); whole-body protein breakdown (as appearance of either endogenous 
leucine or phenylalanine) fell with insulin (leucine, 118±5 vs 99±6; phenylalanine, 
45+2 vs 32±5; both pmol*kg'1*lr1, both P<0.02). The results suggest that insulin, 
given with sufficient amino acids, markedly stimulates leg and whole-body protein 
balance by mechanisms including stimulation of protein synthesis and inhibition 
of protein breakdown.
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6.2 Introduction
Insulin is well recognised to exert a protein anabolic effect in man, the 
anabolic effect probably including modulation of both protein synthesis and 
breakdown. A stimulatory effect on. protein synthesis has been shown in animal 
tissues both in vitro and in vivo (Section 1.8.1), but the post-receptor mechanisms 
of insulin stimulation of protein synthesis have not been fully elucidated (Kahn and 
White, 1988). Studies of animal tissue extracts in vitro suggest that insulin 
deficiency may cause impaired transcription, leading to a decrease in mRNA 
production (Dilimann, 1988) and impaired initiation of translation due to a 
reduction in the proportion of total ribosomes as polyribosomes (Section 1.8.1; 
Kimball and Jefferson, 1988). Insulin also stabilizes lysosomes and decreases rat 
muscle (Furuno and Goldberg, 1986) and liver protein breakdown (Mortimore et al, 
1987) in vitro (Kettelhut et al, 1988), but is not generally considered to affect the 
rate of myofibrillar protein breakdown (Smith and Sugden, 1986), a cytoplasmic 
rather than lysosomal process (Furuno and Goldberg, 1986).
Despite the readily apparent stimulatory effect of insulin on protein 
synthesis in animal tissues both in vivo and in vitro, demonstration of such an 
effect in vivo in man has proved elusive, either for muscle (Pacy et al, 1989), or 
in the whole-body (Castellino et al, 1987; Tessari et al, 1987). Furthermore, in 
those studies where arterial amino acid concentrations were maintained at post- 
absorptive values, with insulinaemia the major variable, no stimulatory effect of 
insulin on protein synthesis was apparent, either for forearm (Gelfand and Barrett, 
1987) or whole-body (Castellino et al, 1987; Tessari et al, 1987). One explanation 
for the apparent failure of insulin to stimulate protein synthesis is a possible
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constraint caused by an insulin-induced reduction in amino acid concentrations both 
in plasma and in muscle (Alvestrand et al, 1988). The importance of prevailing 
amino acid concentration is demonstrated by our findings, by two independent 
methods, that increased amino acid availability alone stimulates skeletal muscle
as well as whole-body protein synthesis in healthy young subjects (Chapters 4 and
5).
The present studies were undertaken to assess the acute effects of insulin 
on protein metabolism both of skeletal muscle and of the whole-body in healthy 
subjects under conditions of amino acid replacement designed to provide a 




Eight healthy subjects (2 female, 6 male; mean age 33, range 24-42 years, 
weight 68.7±3.9 kg; body mass index 23.6±1.3 kg/m2) with no intercurrent or 
chronic illness and with normal hepatic, renal and thyroid function were studied. 
Three additional male subjects (age 29-30 years, weight 72.0+3.0 kg, body mass 
index 24.3±1.5 kg/m2) were studied without tracer (see below).
6.3.2 Protocol
After an overnight fast (15 h), from 08-30 h the subjects received only water 
and no food by mouth until the study was complete. Their leg and whole-body
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Table 6.1. Hormones and Substrate Concentrations in Plasma and Blood; 






Insulin (pmol/1) 57±7 597±44c
IGF-I (U/l) 650±80 630±80
Glucagon (pmol/1) 34±3 49±8a
Cortisol (nmol/1) 167±44 242±56
Glucose (mmol/1) 5.1+0.1 4.9±0.1
Blood
Lactate (mmol/1) 0.54±0.03 0.91±0.07c
D-(-)-3-Hydroxybutyrate (mmol/1) 0.15±0.04 0.05±0.01b
Statistical significance: “P=0.08, bP<0.05, CP<0.001; IGF-I, Insulin-like growth 
factor I.
phenylalanine and leucine kinetics were investigated during 180 min with amino 
acid, but no insulin, infusion (amino acids alone), followed by 180 min of infusion 
of glucose and insulin to produce euglycaemic hyperinsulinaemia (the insulin 
infusion period) (Protocol d, Section 3.10.4, Figure 3.4). They were continuously
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infused with the mixed amino acid solution (Synthamin 14, Section 3.3, Table 3.1) 
throughout, but at an increased rate during insulin infusion, estimated from our 
experience to maintain a sufficiency of amino acids, in plasma and in muscle, 
during both phases of study (Chapter 7).
Cannulas for blood sampling was placed in a dorsal hand vein, in a 
retrograde direction, and in a common femoral vein, in an antegrade direction 
(Section 3.5). Before sampling arterialized venous blood, the hand was placed for 
a minimum of 15 min in a temperature-regulated (75-80°C) chamber. A third 
cannula was placed in a contralateral forearm vein for tracer and amino acid 
infusions.
Priming doses of L -[1BN]phenylalanine (3.06±0.13 pmol/kg), L - [ l - 13C]leucine 
(7.55±0.28 pmol/kg) and NaH13C03 (3.06+0.32 pmol/kg) were administered and a 
continuous infusion of a mixture of L -[1BN]phenylalanine (3.38±0.12 pmol • kg'1 “h"1) 
and L - [ l - 13C]leucine (8.28±0.30 pmol* kg'1 »h"1) was established and continued until 
the end of the study. A priming dose (51.6 mg amino acids/kg over 10 min) of the 
commercial amino acid solution was administered at the beginning of the study; 
it was then infused until the end of the basal period at a rate of 0.52 ml*kg_1*h_1, 
providing 44.2 mg*kg"1*h'1 of mixed amino acids, 15.0 pmol phenyl­
alanine »kg'1» h '1, 24.6 pmol leucine* kg'1 «h '1 and 0.17 g nitrogen »kg'1 »day'1. The 
subjects were studied over 180 min (amino acids alone) and then during a primed 
intravenous infusion of neutral human insulin (Humulin S, Eh Lilly and Co. Ltd, 
Basingstoke, U.K.) of 0.29 nmol *m~2* min"1 (40 mU^m'^min"1) for 180 min (the 
insulin infusion period) (Section 3.9.2). Glucose solution (1 mol/1) was infused at 
varying to maintain euglycaemia (Section 3.3). During the insulin infusion period,
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Figure 6.1. Arterial (solid symbols) and venous (hollow symbols) phenylalanine, 
leucine and a-ketoisocaproate concentrations before and during insulin infusion 
with continuous amino acid infusion
the amino acid infusion rate was increased to 1.96 m l'kg '^h"1 providing 
167 mg^kg'^h'1 of mixed amino acids, 56.5 pmol phenylalanine^kg'^h'1 and 92.7
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pmol leucine»kg“1 • h '1. The amino acid infusion rates were chosen following a 
separate set of studies in eight diabetic patients in whom intracellular amino acid 
concentrations were measured by percutaneous biopsy after 4 h periods of insulin 
infusion and amino add infusion at identical rates to these used in this study; in 
those studies the intramuscular free leutine and total free amino add 
concentrations were depressed below normal during insulin infusion even though 
the plasma amino adds were greater than those during insulin deficiency (Chapter
7). We did not feel justified, given the extensive nature of the study, to carry out 
muscle biopsies to check the intramuscular concentrations of amino acids in this 
study.
Arterialized venous samples were taken before the start of the tracer 
infusion, at intermediate times (45, 90 min) and at the end (135, 150, 165, 
180 min) of the first phase of study, and at intermediate times (225, 270 min) 
and at the end (315, 330, 345, 360 min) of the second phase of study. Femoral 
venous samples and blood samples for subsequent determination o f13C enrichment 
and total concentration of blood C 02 were taken only before the tracer was 
administered and at the four time points at the end of each phase of study. 
Arterialized blood for hormone analysis was obtained on two occasions during the 
final phases of each study.
At each sampling point, expired air was collected into evacuated glass tubes 
for storage prior to 13C analysis of C 02 (Section 3.6). Gas exchange was determined 
during the final 40 min of each phase of study with a ventilated-hood indirect 
calorimeter (Section 3.6). Leg blood flow (BF) was measured three or four times 
after each of the last four blood samples during each phase of study (Section 3.8).
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Three additional subjects did not receive tracer amino acids; samples were 
only taken during the insulin infusion period to determine the effect of changes in 
substrate oxidation during euglycaemic-hyperinsulinaemia on the background rates 
of 13C02 production by the leg and the whole-body.
Amino acxd concentrations in extracts of plasma were determined with an 
automated amino acid analyser using ion-exchange chromatography for separation 
and elution of amino acids, derivatization with ninhydrin and photometric detection 
for quantification (Section 3.13).
The average rate for all muscle in the leg of muscle was calculated from 
the phenylalanine and leucine based entry rates on the basis that muscle contains 
18% protein, protein contains 4% phenylalanine and 8% leucine (Gelfand and 
Barrett, 1987) and that bone, skin and fat accounted for negligible protein turnover 
and sampled blood flow. Bone was assumed to occupy 10% of leg volume and 
whole-body fat composition was taken as representative of that of the leg 
(21.5±3.3% in the subjects studied, which compares well with a reported value of 
17.9% for thighs in sedentary males (Haggmark et al, 1978).
6.4 Results
6.4.1 Gas Exchange and Leg Blood Flow
Whole-body carbon dioxide production was 0.185±0.008 1/min during basal 
conditions and this increased during insulin infusion (0.236±0.13 1/min, P<0.001); 
whole-body oxygen con sumption was 0.245+0.012 1/min and increased during insulin 
infusion (0.281±0.012 1/min, P=0.003); the respiratory quotient increased (0.76±0.02
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Table 6.2. Arterial Plasma Amino Acid and a-Ketoisocaproate Concentrations; 






Alanine 275±32 42Q±28d 800±43d
Glutamate 61±6 59±6 46±6b
Glutamine 591±26 622±26a 527±23d
a-Ketoisocaproate 35±4 38±3 28±3a
Isoleucine 51±5 105±15d 180±15d
Leucine 128±7 207±lld 276±18‘
Phenylalanine 49±2 87±4d 161±9d
Tyrosine 62±5 59±4 51±3a
Valine 231±13 302±13d 438±26d
BCAA 410±22 613±24d 893±57d
Total 2780±80 3830±100d 5280±250d
Statistical significance: aP<0.05, bP<0.02, CP<0.01, dP<0.001.
BCAA, Branched chain amino acid.
Comparisons are amino acids alone vs pre-study, and insulin-plus-amino acids 
vs amino acids alone.
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vs 0.84±0.02, P=0.003). Resting energy expenditure calculated from gas exchange 
was 4.9Q±0.23 kJ/min during the low insulin condition and increased 20% during 
insulin infusion (5.74+0.26 kJ/min, PcO.OOl). Leg blood flow was 
2.95±0.29 mi® 100 g ' ‘ rain-1 during the low insulin period and increased 60% with 
insulin infusion (4.74±0.54 ml® 100 g '^m in '1, P=0,003).
6.4.2 Hormones and Substrates
The plasma insulin concentration of 57+7 pmol/1 during infusion of amino 
acids alone and increased (PcO.OOl) to 597±44 pmol/1 during insulin infusion (Table
6.1). Plasma glucagon concentration was 34±3 pmol/1 in the low insulin phase and 
increased by 50% during insulin infusion (P=0.084). The concentrations of plasma 
insulin-like growth factor I and cortisol were unaffected by the insulin infusion and 
the arterial plasma glucose concentration was stable (5.0±0.1 mmol/1) throughout 
the study. The glucose infusion rate was increased over the period of the insulin 
infusion reaching 36.1+4.6 pmoPkg'^min"1 during the final sampling period. 
Uptake of glucose by the leg increased during insulin infusion (0.07±0.10 vs 
6.08±0.93 pmol®100 g '^m in '1, PcO.OOl). Blood lactate concentration increased by 
68% during insulin infusion (PcO.OOl) but no change occurred in leg lactate balance 
(-0.06±0.08 vs -0.07+0.10 pmol®100 g '^m in'1). A 67% reduction occurred in blood 
D-(-)-3-hydroxybutyrate concentration during insulin infusion (Pc0.05).
6.4.3 Amino Acid Arterial Concentrations
The primed amino acid infusion during the initial low insulin period 
produced a 38% increase in the arterial plasma concentration of total amino acids
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(Table 6.2). The arterial plasma concentrations of phenylalanine and leucine were 
stable during this initial phase (Figure 6.1, Table 6.2). During the insulin infusion 
period, when extra amino acids were infused, phenylalanine concentration initially 
increased by 85% and remained stable during the sampling period; leucine initially 
increased by 33% but then showed a slow steady decrease throughout the insulin 
infusion period (by 3% during the last hour). Reductions also occurred in the 
arterial concentrations of a-ketoisocaproate, glutamate, glutamine and tyrosine 
during the insulin infusion (Table 6.2).
6.4.4 Leg Amino Acid Balance
The net leg balance of phenylalanine was just positive during the low 
insulin period and became markedly positive during insulin infusion, indicating 
that leg protein synthesis exceeded protein breakdown (Table 6.3). An increased 
net efflux from the leg of the gluconeogenic precursor amino acids alanine and 
glutamine, and also of a-ketoisocaproate, occurred during the combined 
insulin/amino acid infusion.
6.4.5 Enrichments o f Phenylalanine, Leucine and Leucine Metabolites
Plateaux were attained for the enrichments of plasma phenylalanine, leucine 
and a-ketoisocaproate (Figure 6.2) and both whole blood, and expired 1SC02 during 
the final periods of each phase of study. The 13C enrichment of expired C02 was 
0.0195±0.0014 APE during the initial period and 0.0271±0.0024 APE during insulin 
infusion. The mean value in the three subjects who did not receive tracer was
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Table 6.3. Leg Net Balance o f Amino Acids and a-Ketoisocaproate; Effects of 
Insulin During Continuous Amino Acid Infusion
Amino Acids Insuhn plus
Alone Amino Acids












Statistical significance: aP<0.05, bP<0.01, CP<0.001. 
BCAA, branched chain amino acids.
0.0008±0.0004 APE during insulin, glucose and amino acid infusion suggesting that
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whole-body leucine oxidation may have been overestimated only by about 3% 
during this period. The leg production rate of 13C02 was 0.72±0.19 
nmol *100 g a in in '1 during the initial period, and 2.58±0.40 nmol *100 g '^m in '1 
during insulin infusion; however, in the three subjects who did not receive tracer 
it was only -G.02±0.09 nmol* 100 g_1*min-1, suggesting that no substantial 
systematic error occurred in the estimates of leg leucine oxidation due to changes 
in substrate metabolism by the leg.
6.4.6 Leg Protein Turnover and Amino Acid Metabolism
Leg protein breakdown, assessed with [ l - 13C]leucine (Table 6.4) was 
decreased by 30% by infusion of insulin with amino acids, but an average reduction 
of only 9% (non-significant) could be observed using tracer phenylalanine exchange 
as an index. However, leg protein synthesis assessed with tracer phenylalanine 
(Figure 6.3) showed an increase of 55% during infusion of insulin (P=0.022), yet 
assessment with leucine tracer showed leg protein synthesis was, on average, only 
13% greater during insulin infusion (non-significant). Oxidation of leucine by the 
leg increased over four fold (P=0.0029) with insulin i.e. approximately in proportion 
to the increase in supply of leucine. The balance between protein synthesis and 
protein breakdown assessed with both leucine and phenylalanine became markedly 
more positive during infusion of insulin, although the increase assessed by tracer 
leucine showed the smaller change. For entry to leg protein, the molar ratio of 
leucine to phenylalanine was 2.7 when the subjects were studied during low insulin 
conditions and was 2.0 when they were infused wdth insulin; in skeletal muscle 
protein this ratio is 2.4 (Gelfand and Barrett, 1987).
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6.4.7 Whole-Body Leucine and Phenylalanine Kinetics
Whole-body leucine flux increased by 35% during the period of insulin-plus- 
amino acid infusion; whole-body phenylalanine flux increased by 47%. Assessment 
oi whole-body protein breakdown with leucine tracer showed a decrease (P=0.004) 
of 16% during the insulin infusion; assessed with phenylalanine tracer the decrease 
(P=0.C13) was 29%. The molar ratio of leucine to phenylalanine release from 
protein was 2.6 in low insulin conditions and 3.1 during high insulin-plus-amino 
acids. Whole-body oxidation of leucine doubled and non-oxidative leucine 
disappearance, i.e. whole-body protein synthesis increased (P=0.005) by 11% during 
the high insulin phase. The balance between protein synthesis and protein 
breakdown in the whole-body, assessed with leucine, changed from negative to 
positive (PcO.001).
6.4.8 Calculated Leg Muscle Fractional Protein Synthetic Rate
During the low insulin period, the muscle protein synthetic rate was 
0.086±0.021 %/h, calculated from phenylalanine exchange, and 0.095±0.020 %/h 
calculated from leucine exchange. The corresponding rates during insulin infusion 
were 0.137+0.018 %/h and 0.110±0.020 %/h.
6.5 Discussion
The present results using either phenylalanine or leucine tracer suggest 
that whole-body protein breakdown is less during infusion of insulin combined 
with amino acids than during infusion of a lesser dose of amino acids alone, results
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consistent with these of other workers (Castellino et al, 1987; Tessari et al, 1987). 
After insulin plus extra amino acid infusion, a modest increase was found in the 
rate of whole-body protein synthesis, measured by leucine turnover. A net anabolic 
effect on leg protein balance was indicated by results obtained with both tracers 
used but there were apparent discrepancies between them regarding components 
of the net anabolic effect; for the phenylalanine based results, a marked increase 
occurred in muscle protein synthesis with smaller effects on protein breakdown but 
for the leucine based results there was only a minor increase in the rate of muscle 
protein synthesis, although a marked reduction occurred in the rate of muscle 
protein breakdown. It is unlikely that these results have arisen purely as artifacts 
of the investigative and analytical techniques employed as similar discrepancies 
between phenylalanine- and leucine-derived limb protein turnover during combined 
insulin plus amino acid infusion have been reported in preliminary form by other 
workers who employed radiolabelled phenylalanine and leucine to assess protein 
turnover (Luzi et al, 1989). They reported that a combined insulin and amino acid 
infusion caused a marked increase in phenylalanine uptake but only a minimal 
increased in leucine uptake; the extent of the apparent discrepancy they observed 
between the results using the two different tracer amino acids would have been 
greater if leucine metabolism (ie transamination and oxidation) had been 
stimulated by exogenous amino acid provision, as in the present study. It is, of 
course, possible that our methods obscured the true extent of the decrease in 
muscle protein breakdown with phenylalanine and likewise of the increase in 
protein synthesis with leucine, causing type 1 errors, but, even if this were the 
case, there remains a substantial discrepancy in the apparent magnitude of the
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Figure 6.2. Plasma phenylalanine, leucine and a-ketoisocaproate enrichments before 
and during insulin infusion with continuous amino acid infusion (arterial, solid 
symbols; venous, hollow symbols)
changes in protein turnover induced by insulin with amino adds when assessed 
by leucine and phenylalanine tracers.
184
Amino Acids, Insulin and Leg Protein Turnover
Before attempting to interpret the present results, whether concordant or 
discrepant, in physiological terms, some of the uncertainties associated with them 
need to be identified, their sizes estimated and their possible effects on the derived 
data recognised. The points to be considered are (a) the attainment or not, at 
metabolically active sites, of plateau conditions for the tracers of interest during 
each of the two periods of investigation, (b) the extent to which measurements of 
tracer concentrations and enrichment in accessible compartments represented those 
at the sites of metabolism within tissues, and (c) the relative robustness of the 
results obtained in allowing the construction of a qualitatively accurate account of 
intracellular events. The principles of using tracer labelled amino acids to 
investigate human amino acid and protein metabolism in vivo and of using the 
enrichment of a-ketoisocaproate as a measure of leucine labelling in the 
metabolically active compartment of the body, have been extensively discussed by 
others (Matthews et al, 1982; Horber et al, 1989; Layman and Wolfe, 1987; 
Schwenk et al, 1985a) and in Chapters 2 and 4. We have employed both primary 
pool stochastic models with venous sampling used to define precursor pool 
enrichment (for both whole-body phenylalanine metabolism and leg exchange and 
metabolism of phenylalanine and leucine) and a reciprocal pool model with arterial 
a-ketoisocaproate sampling for whole-body leucine metabolism. Accordingly, it 
needs to be considered whether or not the routine assumptions used were made 
less tenuous by the experimental circumstances of our study.
The infusion of insulin, glucose and additional amino acids in the second 
phase of the study resulted in marked changes in the plasma concentrations of 
the two tracee amino acids and a-ketoisocaproate. Phenylalanine concentration
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Table 6.4. Leg Phenylalanine and Leucine Metabolism; Effects o f Insulin 
During Amino Acid (AA) Infusion
Phenylalanine metabolism Leucine metabolism
AA Insulin AA Insulin
Alone + AA Alone + AA
(nmol® 100 g'^min"1) (nmol* 100 g '1#min J)
Breakdown 44.7±8.1 40.0±7.9 120±17 84+10d
Synthesis 47.3±11.5 73.1±7.3a 129±26 146+21
Oxidation - 14±4 65±10b
Balance 2.6±6.1 33.1±5.8C 
(Synthesis-Breakdown)
8±15 62±15a
Statistical significance: “PcO.Ol, bP<0.001, CP<0.05, dP<0.02.
showed an initial rise, but both concentration and enrichment of phenylalanine 
had stabilized by the end of the period from which the measurements were taken 
for calculations of whole-body and leg flux; however, in the case of leucine an 
initial rise was followed by a continuous slow (3% per h) decline in concentration 
during insulin infusion. Nevertheless, the calculated changes for whole-body protein 
breakdown are qualitatively similar with the two tracers, suggesting that even if 
a new steady state had not been attained for leucine, it was sufficiently close to
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fulfil the basic requirement for the use of the stochastic whole-body turnover 
model. It is, however, possible that although the plasma amino acid concentrations 
and labelling were in a quasi-steady state their intracellular counterparts might 
have still been changing at the time of sampling. If this were the case the 
increased uptake of amino acids apparent during insulin infusion might have 
represented an expansion of the intracellular pool rather than incorporation of 
amino acid into protein which, accordingly, would have been overestimated. Some 
evidence in favour of this comes from the observation of the increased net uptake 
of both phenylalanine and leucine by leg tissues during hyperinsulinaemia. Such 
uptake could be interpreted as showing the existence of a concentration gradient 
from plasma to some part of the intracellular fluid, and indeed we have evidence 
of such a gradient from studies we carried out with infusion of insulin plus amino 
acids in type 1 diabetic patients (Chapter 7). In those subjects the intramuscular 
concentrations of both leucine and total amino acids, determined by biopsy, were 
slightly lower during the insulin infusion period than during infusion of amino 
acids alone, despite marked increases in the plasma amino acid concentrations 
(Chapter 7). Thus a concentration gradient did exist, but there was no evidence of 
expansion of the intracellular pool at the time of sampling. If normal subjects show 
similar responses then the chance of pool size changes artefactually elevating 
calculated rates of protein synthesis becomes minimal, although changes in 
breakdown could be underestimated.
The reliability of the results for whole-body protein synthesis crucially 
depends on the measurements of leucine oxidation, and on the assumption that 
the precursor pool for each process is similar. If the enrichment of the leucine
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Figure 6.3. Leg muscle protein synthesis assessed by phenylalanine exchange; effect 
of insulin during continuous amino acid infusion
entering protein synthesis is greater than that entering leucine oxidation then 
synthesis will be over-estimated, and vice versa. There are suggestions from in 
vitro studies of rat muscle that the precursor pool tracer specific activity (ie of 
tRNA) for synthesis is near to that of the extracellular pool, is higher than the 
intracellular free pool (Section 2.3.1) and is unaffected by insulin (Airhart et al, 
1982; Stirewalt et al, 1985). Recent studies in pigs (Watt et al, 1989) suggest that 
the provision of exogenous amino acids by infusion brings the tRNA labelling in 
muscle from a value intermediate between the extra and intracellular free pools, 
to a value closer to the extracellular value; the best (most easily sampled) 
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(Watt P.W and Rennie M.J., unpublished results). Thus, if protein breakdown is 
inhibited by insulin, and the rate of exchange of label among precursor pools is 
increased by amino acid infusion, then there remains a theoretical possibility that 
the apparent increases in protein synthesis after insulin and additional amino acids 
could have been the result of a closer approximation to the true value than could 
be observed at a lower rate of amino acid infusion without insulin. It seems likely 
that this did occur to some extent in the studies described here, possibly more so 
for phenylalanine where a marked increase in the plasma concentration occurred 
than for leucine. If this had occurred it would resulted in overestimates of the 
effect of insulin on protein synthesis when assessed by phenylalanine but not with 
leucine, but at the present time we cannot judge to what effect such an effect may 
have affected the results.
We have attempted to minimise the influence of the latter problem in 
calculating the whole-body rates by using the labelling of a-ketoisocaproate to 
estimate precursor enrichment. There is however a possibility that even these 
calculations underestimate protein synthesis in lean tissue because of a change 
of the site of leucine oxidation, from skeletal muscle, under low insulin conditions 
to adipose tissue under high insulin conditions (Frick and Goodman, 1980). Within 
adipose tissue the intracellular leucine pool is probably so small that almost all 
leucine undergoing decarboxylation would derive from plasma and therefore have 
a relatively high enrichment, possibly higher than that of a-ketoisocaproate; thus 
any tendency of the leucine metabolic model to produce overestimates of leucine 
oxidation should occur to a greater extent during infusion of insulin which 
stimulates decarboxylation of a—ketoisocaproate in adipose tissue (Frick and
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Goodman, 1980). This of' course is not simply a problem affecting whole-body rates 
but also the rates of synthesis in the leg, in which there are certainly metabolically 
active interfascicular fat depots. Accordingly, assessments of leg protein turnover 
with leucine might fail to reflect true increases in protein synthesis which occurred 
with insulin, because of diversion of leucine to oxidation in intercalated adipose 
tissue of the leg.
Are there any specific problems affecting the results obtained for leg 
metabolism? The basis of the leg metabolism calculations is different from that 
of the whole-body, and with consequent differences in the methodology and 
assumptions underlying use of phenylalanine and leucine tracers. For the leucine- 
based results, the equations used to assess protein synthesis depend on a greater 
number of analyses than for phenylalanine. These analyses include measurements 
of arterial and venous concentrations and enrichments not only of an amino acid, 
as for phenylalanine, but also of the metabolites a-ketoisocaproate and C02. Thus 
analytic variation could have a greater influence on the leucine than the 
phenylalanine based leg protein synthesis results. In addition, in modelling leg 
protein turnover with leucine a greater number of assumptions are employed than 
for phenylalanine with a correspondingly greater possibility of introducing 
systematic errors. For example, leg leucine oxidation is calculated from the 
enrichment of venous a-ketoisocaproate but leg protein turnover from the combined 
enrichment of venous a-ketoisocaproate and leucine, i.e. predominantly represented 
by leucine. However, except for the possibilities of underestimating both protein 
synthesis and breakdown to a lesser extent due to increased tracee concentration 
(particularly for phenylalanine) and overestimating leucine oxidation in lean leg
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Table 6.5. Whole-Body Leucine and Phenylalanine Kinetics; Effects o f Insulin 
During Amino Acid (AA) Infusion
Leucine metabolism Phenylalanine metabolism
AA Insulin AA Insulin
Alone + AA Alone + AA
(pmol#kg"1#h_1) (pm ol'kg-^h'1)
Flux 142±5 192±6‘ 60.0±2.3 88.7±4.7C
Infusion 25.0 93.0 15.0 56.5
Breakdown 118±5 99±6b 45.5±2.3 32.2±4.7a
Oxidation 28±2 66±3C — -




Statistical significance: aP<0.02, bP<0.01, CP<0.001. 
All comparisons are effects due to insulin.
tissue, by falsely attributing to it rates more properly occurring in adipose tissue, 
it seems unlikely that the increased availability of insulin and amino acids would 
have added any further errors. These arguments suggest to us that the leg
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metabolic model should provide at least qualitative indications of the experimental 
perturbations.
The main feature of the results which is internally inconsistent, and difficult 
for us to explain, is the lack of any apparent effect of insulin in causing a fall in 
breakdown of leg protein as indicated by phenylalanine tracer exchange; whole- 
body protein breakdown, measured by both leucine and phenylalanine, and leg 
protein breakdown measured by leucine tracer exchange, all appeared to fall with 
insulin infusion. The finding is also at variance with the results of previous 
workers (Gelfand and Barrett, 1987; Luzi et al, 1989). This may have occurred due 
to the rise in amino acid concentration leading to less underestimation of protein 
breakdown. It should be born in mind however that insulin does no appear to 
decrease myofibrillar protein breakdown (Smith and Sugden, 1986; Kettelhut et al, 
1988).
Phenylalanine catabolism (hepatic hydroxylation) does not occur in muscle 
or fat, so the problems associated with the possible sites of leucine oxidation do 
not apply. However, one possibly important factor could be the large rise in 
availability in blood of the branched-chain amino acids which might influence the 
exchange of tracer phenylalanine by membrane transport effects, possibly including 
both cis and trans effects (Stein, 1986). In addition to competitive cis-inhibition of 
phenylalanine entry, with resultant increases in leucine entry, there may have been 
frans-stimulation of phenylalanine efflux, due simply due to the carrier moving 
more rapidly across the membrane when loaded than empty, and thus increasing 
the chances of phenylalanine being picked up for exit (Christensen and Kilberg, 
1987). Such an effect might explain the apparent lack of inhibition of insulin on
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leg protein breakdown, measured with tracer phenylalanine in the presence of 
exogenous amino acids.
As skeletal muscle protein turnover should show a single physiological 
response to the perturbations of amino acid availability, which of the two sets of 
tracer-derived results most closely reflect protein turnover? The greater increase' 
in phenylalanine than leucine concentration will have caused artefactual 
overestimation of phenylalanine tracer-derived protein turnover values (both 
synthesis and breakdown), but the error in estimating the true precursor for 
leucine will have caused underestimation of the insulin associated increase in 
protein synthesis for the leucine based results. Furthermore the compound nature 
of the final leucine based estimate may have caused a Type 2 error in concluding 
that the leucine based synthesis did not rise. Accordingly it seems that the true 
extent of the effects of the insulin plus amino acids on leg synthesis lies 
somewhere between the two observed changes, i.e. a 15-30% increase. For reasons 
connected with transport phenomena the effects of insulin plus amino acids on 
breakdown are probably most accurately reflected by the leucine based results, i.e. 
a fall occurred.
Thus, after dealing with all the methodological considerations it still seems 
reasonable to suggest that the present results will bear interpretation in the light 
of the major differential features between the two phases of the study. These were 
that in the initial phase of the study, insulin was at low (postabsorptive) 
concentrations concurrent with an elevation of plasma amino acids about 38% 
above normal postabsorptive values, and during the second phase, plasma insulin 
increased due to the exogenous insulin infusion to high physiological concentrations
193
Amino Acids, Insulin and Leg Protein 'Turnover
concurrent with a further increase of plasma amino acids to about double the 
postabsorptive concentration, i.e. of the same order as the maximal insulin and 
amino acid concentration values observed after a large mixed meal. The arterial 
plasma concentration of most indispensable amino acids was increased but for the 
femoral venous concentrations a less marked increase occurred, i.e. there was an 
increased amino acid balance greater than the increase in arterial supply.
What are the likely mechanisms of the anabolic effect? Analysis of the 
exchange of both amino acid tracers suggested that skeletal muscle protein 
synthesis increased, although the increase was greater on the basis of the 
phenylalanine tracer exchange. Skeletal muscle protein breakdown decreased 
significantly on the basis of leucine leg exchange. Furthermore, the same general 
pattern was seen for the whole-body, this consonance reinforcing the likelihood of 
the presumed effects and providing yet more evidence of the substantial 
contribution of muscle to whole-body protein metabolism.
So far as we know these observations are the first to provide evidence that 
under favourable conditions, insulin has a stimulatory effect on skeletal muscle and 
whole-body protein synthesis in man. They are thus in agreement with the results 
of a substantial amount of work in whole animals, in perfused organs and in 
isolated tissues and extracts from them (Kimball and Jefferson, 1988). The results 
may also hold the key to the puzzle as to why a stimulatory effect of insulin on 
protein synthesis, either in muscle or the whole-body, has been so difficult to 
observe in studies of normal and diabetic subjects previously. It now seems that 
(a) although insulin may, at all values of blood (and probably muscle) free amino 
acid concentration inhibit protein breakdown, as shown here by the leucine results
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and also by previous studies of regional and whole-body metabolism (Castellino et 
al, 1987; Gelfand and Barrett, 1987; Tessari et al, 1987), and that (b) amino adds 
alone stimulate protein synthesis (Chapters 4 and 5), (c) stimulation by insulin 
require ,̂ a concurrently high amino acid availability, sufficient to maintain their 
blood and intracellular concentrations at high physiological values. We have 
previously shown by muscle biopsy studies in type 1 diabetic patients (Chapter 7) 
that modest extra provision of exogenous amino adds during insulin infusion is 
insuffident to prevent a fall in the intramuscular concentration of amino acids and 
that for some amino adds (e.g. tyrosine and methionine) insulin causes their fall 
to undetectable values. Even in the present study, there was evidence of a slow 
drift downwards of plasma amino acids during the insulin infusion despite a high 
constant rate of amino acid provision; for some amino adds (e.g. tyrosine, cysteine) 
the fall was to values below those observed before the study commenced.
It could be argued that the present results do not actually demonstrate an 
effect of insulin, but simply reflection a further elevation of the powerful anabolic 
drive provided by elevated blood amino acids. The arguments for and against this 
cannot yet be more than indirect, because of the current lack of definitive 
information on dose-responses of amino adds, or for that matter insulin, on protein 
synthesis in man. Nevertheless the following evidence seems to us to indicate an 
additional effect of insulin in the presence of high amino add concentrations. First, 
a decrease occurred in the intramuscular concentration of leucine in type 1 
diabetics studied during conditions equivalent to these reported here, despite 
similar increases in plasma leudne in the two studies (Chapter 7). Secondly, the 
stimulatory effect of amino adds on muscle and whole-body protein synthesis is,
195
Ammo Acids, Insulin and Leg Protein Turnover
in our hands, independent of the delivery of amino acids between rates of 44-88 
mg» kg'1 »h '1, as shown by the results obtained from the eariy phase of this study 
and of our previous results in normal man (Chapters 4 and 5); this point is 
reinforced by the reported similarity of the extent of stimulation of whole-boay 
synthesis by a range of delivery rates of amino acids in normal man, with low 
physiological insulin availability (Casteliino et al, 1987; Tessari et al, 1987). 
Thirdly, the effect is in contrast to the marked dependence of leucine oxidation on 
its delivery, shown here and elsewhere (Castellino et al, 1987; Tessari et al, 1987; 
Chapter 5), and suggests that the mechanism of the stimulation of synthesis is a 
non-linear function of amino acid availability, such as might occur by a covalent 
modification of initiation or translation factors of the synthetic apparatus (Pain, 
1986; Kimball and Jefferson, 1988). Lastly, a fall in plasma tyrosine occurred, 
despite an increase of 3.8 fold in tyrosine supply with only a 15% decrease in the 
likely rate of release from protein breakdown.
Although the balance of the evidence available from the present work 
strongly suggests that in the presence of sufficient amino acids insulin stimulates 
protein synthesis in muscle and the whole-body, the present findings cannot be 
considered conclusive; further studies designed to confirm the results and allay our 
worries concerning pool sizes, transport inhibition, differential sites of oxidation, 
and the reasons for the different behaviour of leucine and phenylalanine tracers, 
and transport inhibition will need to be carried out before definitive statements can 
be made on the mechanisms of the net protein anabolic effects of insulin in man.
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Inability to Stimulate Protein Synthesis by Insulin
7.1 Summary
Despite its anabolic effects on protein balance, acute administration of 
insulin has been reported to have no effect on skeletal muscle or whole-body 
protein synthesis in man. However, insulin also reduces plasma and intramuscular 
amino acid availability, which may limit protein synthesis. We have therefore 
measured the acute effects of insulin on skeletal muscle (anterior tibialis) protein 
synthesis and whole-body leucine turnover in eight insulin-withdrawn Type 1 
(insulin dependent) diabetic patients. They were studied initially when insulin 
deficient, but during infusion of mixed amino acids at a rate sufficient to raise 
plasma amino acids by 30% ie to 4 mmol/1 in total; measurements were continued 
when insulin was infused together with an increased rate of amino acids to 
maintain insulinopenic plasma amino acid concentrations. Using 
a -k e to [l-13C]isocaproate in plasma as an index of the intracellular precursor 
labelling, incorporation of [ l - 13C]leucine into skeletal muscle protein was 
0.068±0.007 %/h during insulin withdrawal and was unaltered during insulin 
infusion. Also calculated on the basis of a-ketoisocaproate labelling, non-oxidized 
whole-body leucine disappearance (ie whole-body protein synthesis) was 
110±4 pmol»kg~1»h~1 during insulin withdrawal; this also was unchanged during 
insulin infusion. Despite stable or increased plasma concentrations of most amino 
acids, the intramuscular concentrations of a number of amino acids decreased 
during insulin infusion. This may have limited any anabolic effect of insulin on 
protein synthesis. Alternatively, pre-existing high intramuscular amino acids may 
have maximally stimulated muscle protein synthesis, so that the further elevation 
was obscured, especially with the tendency to depletion of precursor amino acids.
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7.2 Introduction
Insulin has a protein anabolic effect in mammals. Insulin deficiency in 
immature streptozotocin-diabetic rats depresses skeletal muscle protein synthesis, 
both in vitro and in vivo, which is corrected by replacement of insulin (Section
1.8.1). However, insulin stimulation of protein sjmthesis is difficult to reproduce in 
animals not rendered insulin deficient (McNurlan and Garlick, 1989). Muscle 
protein synthesis in postabsorptive insulin-deficient Type 1 diabetic patients is 
reported as neither below that in healthy subjects nor responsive to insulin (Pacy 
et al, 1889). Furthermore, although close arterial infusion of insulin (which caused 
no systemic fall in plasma amino acids) increased the net protein balance of the 
forearm in postabsorptive healthy men (Gelfand and Barrett, 1987), local protein 
synthesis was unaffected; the anabolism appeared to be entirely the effect of 
insulin in reducing forearm protein breakdown.
Studies in man suggest that the availability of amino acids, which is 
reduced by insulin in plasma (Castellino et al, 1987; Tessari et al, 1987; Alvestrand 
et al, 1988) and in muscle (Alvestrand et al, 1988), is a major factor modulating 
rates of whole-body (Castellino et al, 1987; Tessari et al, 1987; Chapters 4 and 5) 
and muscle (Chapters 4 and 5) protein synthesis. Other factors which reduce (eg 
3-hydroxybutyrate (Nair et al, 1988b)) or increase (eg glucagon (Nair et al, 1987b; 
Almdal and Vilstrup, 1988)) amino acid oxidation may indirectly regulate protein 
synthesis by changing amino acid availability. Infusion of insulin plus glucose, 
together with amino acids sufficient to maintain plasma concentrations, had no 
effect on whole-body protein synthesis but appeared to reduce whole-body protein
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breakdown (Castellino et al, 1987; Tessari et al, 1987) thereby improving protein 
balance. These results raise doubts about any physiologically important role in man 
for insulin in controlling whole-body protein synthesis. Nevertheless 
hyperaminoacidaemia during hyperinsulinaemia was accompanied by a rise in 
whole-body protein synthesis (Tessari et al, 1987; Chapter 6) and muscle protein 
synthesis (Chapter 6).
These results collectively suggest that any effect of insulin on protein 
synthesis might only be demonstrable when insulin-induced muscle amino acid 
deficiency, by inhibition of protein breakdown, did not constrain muscle protein 
synthesis. The present work was undertaken to investigate the acute effects of 
insulin infusion on skeletal muscle protein synthesis, determined directly with the 
biopsy technique, in type 1 diabetic subjects. The constraint on protein synthesis 
from insufficient amino acid availability was minimized by continuous infusion of 




Eight Type 1 diabetic male patients, in good health and free of major 
diabetic complications despite diabetes for 14±3 years, were studied. Biochemical 
tests indicated good diabetic control (HBA1 8.6±0.7%, normal <8.5%) and normal 
renal, hepatic and thyroid function. Five were completely, and three partially, 
deficient in C-peptide (0.13, 0.21 and 0.43 nmol/1 during hyperglycaemia and
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ketosis). Their total daily insulin was 52+6 U. Three additional age-matched 
subjects were studied without tracer to check for effects of the metabolic 
interventions on baseline 13C 02 enrichments.




210-270 min 450-510 min
Free insulin (pmol/1) 33(14,75) 449(403,499)b
Glucagon (pmol/1) 53(30,95) 69(47,100)
Cortisol (nmol/1) 300(145,624) 306(170,548)
Insulin-like growth 
factor I (mU/ml) 560(330,970) 500(320,790)




Data given as means, with 95% confidence limits in parenthesis. 
Statistical significance: “PcO.Ol, bP<0.001.
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7.3.2 Protocol
Each subject was studied over 240 min after overnight insulin withdrawal 
and then for a further 240 min during insulin and glucose infusion (Protocol b, 
Section 3.10.2, Figure 3.2). During the period prior to the study all subjects were 
prescribed high-fibre diets in which carbohydrate supplied over 50% and fat 30-40% 
of total energy. They were given half of their usual dose of short-acting insulin, 
with no intermediate or long-acting insulin, at 18.00 hours prior to the study day; 
they then fasted until the end of the study.
At 09.00 hours a cannula was inserted retrogradely into a dorsal hand vein 
for collection of arterialized venous blood samples (Section 3.5) and a contralateral 
forearm vein cannula was placed for all infusions. Priming doses of 
L - [ l - 13C]leucine (6.84±0.25 pmol/kg) and sodium [13C]bicarbonate (2.83±0.33 
pmol/kg) were then administered (time 0 min) and a continuous infusion of 
L - [ l - 13C]leucine (7.59±0.32 pmol • kg'1 »h '1) commenced via a contralateral forearm 
vein cannula. At the same time a priming dose of Synthamin 14 mixed amino acid 
solution (29 pmol leucine/kg, 52 mg amino acids/kg) was given over 10 min 
(Section 3.3, Table 3.1); Synthamin 14 was then continuously infused at a rate 
providing leucine 25 pmol* kg'1 »h"1 until the end of the period of insulin 
withdrawal (time 270 min). A priming dose (Section 3.9.2) of Humulin S neutral 
human insulin (Section 3.3) was then given followed by a continuous infusion at 
0.29 nmol «m'2» min'1 (40 mU^m'^min"1) and the rate of Synthamin 14 was 
increased to provide leucine at 93 pmol*kg'1 »h '1 until time 510 min. Glucose was 
infused when the plasma glucose concentration fell to 5 mmol/1.
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Table 7.2. Plasma Amino Acid Concentrations Before and During Amino Acid 












Alanine 266±24 423+92° 791+190d
Arginine 133±21 203±26d 304+39d
Asparagine 44±3 47±3b 29±2d
Glutamic acid 61±8 60±25 48+23°
Glutamine 632+45 695±140c 612±94b
Glycine 229+23 369±40d 588±59d
Histidine 99±5 141±8d 200±15d
Isoleucine 110±15 183±19d 274±25d
Leucine 211±24 333±32d 407+39°
Lysine 202+12 257±18° 328±32b
Methionine 27±2 52±6d 103±12d
Phenylalanine 64±2 96±4d 161±7d
Serine 131±17 191±28c 251+34d
Taurine 66+6 64±5 47±3d
Threonine 145±18 198+28° 247+37'
Tryptophan 48±4 60+3 96±6d
Tyrosine 57±3 54±4a 41±3d
Valine 320±32 431±37d 588±60°
Total amino acids 2950+150 4000±240d 5120± 350d
Comparisons are 30-270 min vs -15 min and 330-510 min vs 30-270 min. 
Statistical significance: aP<0.05, bP<0.02, 'PcO.Ol, dP<0.001.
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Thirty min after priming with [ l - 13C]leucine and beginning the mixed amino 
acid infusion (ie elapsed time 30 min), a percutaneous muscle biopsy was obtained 
from the tibialis anterior, a second muscle biopsy was taken from the same or 
the contralateral leg 240 min later at the end of the insulin withdrawal period, 
and a third biopsy from the leg contralateral to that first biopsied at time 510 min, 
the end of the insulin infusion period (Section 3.7).
Blood samples were obtained before tracer administration, at the time of the 
first muscle biopsy (30 min), and every 60 min thereafter (Section 3.5). Coincident 
samples of expired air were collected for subsequent determination of 13C'02 
enrichment (Section 3.6). Total carbon dioxide production and oxygen consumption 
were determined for 11 min every 60 min with a ventilated-hood indirect 
calorimeter (Section 3.6).
In all subjects we avoided interference with the estimation of [ l - 13C]leucine 
oxidation from oxidation of maize-derived dextrose, which has a high natural 
abundance of 13C, by the use of potato starch glucose, which does not (Section 3.3). 
In the three control subjects who did not receive 13C tracer, breath samples were 
obtained to measure possible background changes, including the effects of increased 
amino acid oxidation, in the 13C enrichment of expired C 02.
An automated amino acid analyzer with fluorometric detection (Section 3.13) 
was used to measure concentrations of amino acids from plasma and intramuscular 
water, the latter calculated on the assumption that 13% of the muscle biopsy 
water was extracellular (Bergstrom et al, 1974).
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Plasma a-ketoisocaproate 18C enrichment was used to calculate whole-body 
leucine rates of appearance (Ra) and of disappearance (Rd) with non-steady state 
equations (Section 2.3.2).
Mean and SEM values are presented; for D-(-)-3-hyaroxybutyrate and 
hormones, which showed log-normal distributions, the values were transformed to 
their natural logarithms before analysis; the means and 95% confidence intervals 
presented are the antiloge transformations.
7.4 Results
7.4.1 Indirect calorimetry
During insulin withdrawal carbon dioxide production was 204±7 ml/min and 
increased by 11% during insulin infusion (PcO.Ol); respiratory quotient was 
0.72±0.01 and increased to 0.75+0.01 (PcO.Ol); calculated heat production was 
5.69±0.26 kJ/min and increased by 5% to 6.00±0.26 kJ/min during insulin 
replacement (PcO.Ol).
7.4.2 Hormones and Substrates
Blood bicarbonate before infusion was 23.1+0.5 pmol/1 and remained in the 
range 22-25 throughout. Plasma hormone concentrations were stable within each 
phase of the study (Table 7.1. During insulin infusion, plasma free insulin 
concentration increased from low (33 pmol/1) to high physiological values 
(449 pmol/1). Plasma glucagon, cortisol and insulin-like growth factor 1 were 
unchanged. Plasma glucose and blood D-(-)-3-hydroxybutyrate were stable during
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Table 7.3. Effect o f Insulin on Intramuscular Free Amino Acid Concentrations 
During Amino Acid Infusion
Amino acid Insulin Withdrawn





Alanine 1920±140 2090±180 3340±160d
Arginine 608±104 598±112 607±113
Asparagine 897±44 914+71 850±67
Glutamic acid 4750±300 4820±460 3050±210c
Glutamine 13400+800 13200±1900 11600±900a
Glycine 1510+100 1570±90 1640±110
Histidine 597±72 652±95 562±85“
Isoleucine 149±17 175+31 173+33
Leucine 298±32 341+9 282+50‘
Lysine 1808±257 2214±286 1376±344
Phenylalanine 95±8 105±8 145+9d
Serine 690±75 670±86 650±84
Taurine 17600±900 17700±1300 16100±1100
Threonine 769±56 729+68 705±68
Tyrosine 89±6 81±4b 21±7d
Valine 448±79 444±79 492±100
Total amino acids 45200+1300 45000±2100 41200±170a
Comparisons are 30 min vs 270 min and 270 min vs 510 min.
t̂atistica îgnificance^P^OjOS^P^OjO^^P^O^O^^P^O^OO^^^
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insulin withdrawal and decreased during insulin infusion. During the final 60 min 
of insulin infusion the rate of glucose infusion was 2.17±0.64 mg »kg'1 »min"1.
7.4.3 Amino and Keto Acid Concentrations
Mean plasma leucine concentration (Figure 7.1: Table 7.2) was
211±24 pmol/1 before the start of the primed amino acid infusion. The plasma 
leucine concentration increased by 13% throughout the period when leucine kinetics 
were calculated during insulin withdrawal (P<0.02); mean plasma leucine was 
337±33 pmol/1 during this period. The plasma leucine concentration decreased by 
18% throughout the period when leucine kinetics were calculated during insulin 
infusion (P<0.01); the mean concentration during this period (407±39 pmol/1) was 
21% higher than during insulin withdrawal (P<0.01). Plasma a-ketoisocaproate 
concentration was 53±9 pmol/1 during insulin withdrawal and was not significantly 
different during insulin infusion (43±7 pmol/1). The total concentration and 
concentrations of most individual amino acids in plasma (Table 7.2) were increased 
by the amino acid infusion given at a faster rate during insulin administration. 
Exceptions were asparagine, glutamic acid, glutamine, tyrosine (Figure 7.1) and 
taurine which all decreased. The concentration of free leucine in intramuscular 
water (Figure 7.1, Table 7.3) was not different from the plasma concentration 
before insulin, ie at 30 or at 270 min. During insulin infusion the intramuscular 
leucine concentration decreased (when sampled at the end, ie at 510 min) and 
was actually lower than both the plasma value at the same time (P<0.01) and the 
preceding intramuscular value (P<0.01). Despite the general increase in plasma 
amino acid concentrations when insulin plus additional amino acids were infused
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a reduction was found in the concentration of total amino acids in intramuscular 
water. The biggest change occurred for tyrosine which decreased from 81±4 pmol/1 
to a mean of only 21±7 pmol/1; it was reduced below detectable values in three 
subjects (Figure 7.1).
7.4.4 Plasma and Muscle Free Leucine Pool Enrichments
For both plasma a-ketoisocaproate and for plasma leucine plateaux of 13C 
enrichment were observed during insulin withdrawal and significantly reduced 
plateaux were found during insulin replacement (Table 7.4, Figure 7.2). However, 
leucine enrichment in muscle was unchanged. No differences occurred in the ratios 
of enrichment of free leucine and its metabolite in plasma or muscle or between 
them as a result of insulin administration.
7.4.5 Muscle Protein Synthesis
Mixed skeletal muscle protein synthesis (k„) was 0.068±0.007 %/h during 
insulin withdrawal (Figure 7.3) and was unchanged (0.071±0.006 %/h) during 
insulin replacement. If muscle protein synthesis rates were calculated on the basis 
of the enrichment of plasma or intracellular leucine (Table 7.5), they tended to be 
lower or were higher than on the basis of the plasma a-ketoisocaproate labelling, 
respectively, but no effects of insulin-plus-glucose were seen. From the present 
a-ketoisocaproate based results it can be calculated that there was a 83% 
likelihood of detecting an increase of 30% in skeletal muscle protein synthesis 
during insulin infusion (a = 0.05, two-tailed test); thus the chance of a Type II 
error was only 17%. Individual subjects showed different changes in k, during
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Figure 7.1. Upper panel: plasma (solid line) and intramuscular (dotted line) 
leucine concentrations. Lower panel: plasma and intramuscular tyrosine 
concentrations
insulin infusion but on stepwise regression analysis no correlation was found 
between the changes in k, and changes in the concentration of
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D-(-)-3-hydroxybutyrate, changes in the respiratory quotient or the absolute glucose 
infusion rate during hyperinsulinaemia.
7.4.6 Whole-Body Leucine Kinetics
Expired C02 13C enrichment was 0.0188+0.0013 atoms % Excess (APE) 
during insulin withdrawal and was higher during insulin infusion 
(0.0298±0.0012 APE, PcO.001). The corresponding mean values were 0.0002±0.Q001 
and 0.0009+0.0005 APE in three subjects not infused with 13C tracer leucine, 
suggesting that leucine oxidation may have been overestimated by only 3% during 
the latter period due to 53C 02 released from oxidation of the infused glucose.
Leucine oxidation was 35±3 pm ol'kg '^h '1 during insulin withdrawal and 
increased by 84% during insulin replacement (P<0.001) (Table 7.6). Whole-body 
leucine turnover was stable during the final 180 min of each phase of the study 
(Figure 7.4). Total leucine appearance (Table 7.6) was 150+5 pmol*kg"1#h_1 during 
insulin withdrawal and increased 18% during insulin replacement (P<0.01); 
endogenous leucine appearance (protein breakdown) was 125±5 jimol*kg_1*h-1 and 
decreased by 33% (P<0.01). On the basis of plasma a-ketoisocaproate labelling,
total leucine disappearance (Figure 7.4) was 145±5 pm ol'kg '^h '1 during insulin
withdrawal and increased by 28% during insulin replacement (P<0.01); the
non-oxidized component of Rd (whole-body protein synthesis) was
110+4 pm ol'k g '^ h '1 and was not significantly different during insulin replacement 
(117±4 pmol»kg~1»h~1). However if the plasma leucine labelling was used instead 
of a-ketoisocaproate and the non-steady equations were applied, then whole-body 
protein synthesis increased from 96.3+5.4 to 119.1+7.1 pmoHkg"1* ^ 1 (PcO.Ol). On
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Table 7.4. Enrichments o f Plasma and Intramuscular Free Leucine and 
a-Ketoisocaproate, and Their Ratios, During [ l - I3C]Leucine Infusion
Insulin Insulin
Withdrawn Infused
(90-270 min) (330510 min)
Plasma leucine (APE) 5.01±0.21 4.19+0.18*
Plasma a-ketoisocaproate (APE) 4.70+0.31 4.19+0.23“
Intramuscular leucine (APE)d 3.82±0.27c 3.33±0.32c
Plasma a-ketoisocaproate/plasma leucine 0.94+0.05 0.99±0.03
Intramuscular leucine/plasma leucine 0.76±0.04 0.80+0.07
Intramuscular leucine/plasma 
a-ketoisocaproate 0.82±0.05 0.80±0.06
Comparisons are 330-510 vs 270-90 min. Statistical significance: aP<0.02, 
bP<0.001. ‘Intramuscular leucine enrichment was significantly different (P<0.02) 
from plasma leucine and plasma a-ketoisocaproate at 90-270 and 330-510 min. 
intramuscular leucine was measured at 270 min and 510 min.
this basis there was also a reduction in whole-body protein breakdown which was 
highly significant (P<0.001) but it was only by 23% of the pre-insulin value (results 
not shown).
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Figure 7.2. Plasma leucine (solid line) and a-ketoisocaproate (broken line), and 
intramuscular free leucine (hollow circles) 13C enrichments
7.5 Discussion
In the investigations described here plasma free insulin was increased by 
insulin infusion from low to high physiological concentrations over four hours. 
During insulin infusion, increased infusion of amino acids resulted in indispensable 
amino acids being maintained at, or slightly above, plasma concentrations seen 
before insulin. Despite the increased supply of amino acids no significant increase 
occurred in skeletal muscle protein synthesis during insulin replacement, 
irrespective of the precursor used as the basis of the calculations.
A number of possibilities might explain this negative result. Although it is 
possible that in the adult human body the capacity for modulation of muscle
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protein synthesis by insulin is absent, this seems unlikely, especially in view of the 
extensive evidence from animal studies (Section 1.8.1). Alternatively, insulin may 
have been ineffective on account of a post-receptor defect of protein metabolism in 
the diabetic patients (whose glucose metabolism was markedly insulin resistant, 
as indicated by the low respiratory quotients and glucose disposal rates), but the 
possible nature of such an effect is presently unknown.
That the rates of anterior tibialis muscle protein synthesis found in the 
present study during insulin withdrawal tended to be faster (P=0.12) than those 
in 7 healthy postabsorptive subjects studied by identical means (Chapter 4) may 
offer a further possibility. It seems that at low concentrations of insulin muscle 
protein synthesis was not pathologically reduced in these diabetic subjects and may 
even have been elevated, a result in accordance with the results from Halliday’s 
group (Pacy et al, 1989): thus skeletal muscle protein synthesis may have been 
already maximally stimulated in the diabetic patients and further increase by 
insulin may not have been possible. This would be in marked contrast to the 
situation in immature rats in which muscle protein synthesis is reduced at low 
insulin concentrations (Section 1.8.1).
There is also the slight possibility that if insulin were initially totally 
absent, instead of present at very low concentrations (Table 7.1), it might have 
been possible to observe an impairment of basal skeletal muscle protein synthesis 
in our patients, since in the rat at least sensitivity of protein synthesis to insulin 
is already maximal over 0-10 mU/1 (Millward et al, 1983). Evidence against this 
comes from our findings that two subjects in whom insulin was not detectable by 
our assay had muscle protein synthetic rates comparable with those of the other
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subjects in whom it was. Nevertheless this argument cannot be conclusive since the 
range of insulin sensitivity of protein synthesis in adult man is unknown and may 
differ markedly from that in young rats and other animals.
The possibility of limitation of intracellular amino acid availability remains 
to be considered. Amino acid infusion at an increased rate did not prevent an 
insulin-induced reduction in the muscle water concentration of certain amino acids, 
most markedly for tyrosine. This reduction may have acted as a constraint on 
muscle protein synthesis (even though the affinity of tRNA for amino acids is very 
high in vitro (Tyobeka and Manchester, 1985)) or the normal stimulatory effect 
(Chapter 4) of amino acids on muscle protein synthesis may have been reduced. 
The amino acid mixture used contained only a small quantity of tyrosine, whose 
relative insolubility limits its delivery by infusion. Although not indispensable in 
the whole-body in adults, usually being produced in liver from phenylalanine, it is 
essential in muscle which cannot synthesize it; the ratio between protein-bound and 
free tyrosine is high, so that the "safety factor" for tyrosine availability is small 
(Waterlow et al, 1978b). Decreases in the plasma tyrosine may have limited uptake 
of tyrosine into the limb since its net uptake depends upon the plasma 
concentrations (Lundholm et al, 1987). Its uptake, by the insulin-independent 
L-system transporter (Yudilevitch and Boyd, 1987; Hundal et al, 1989), may also 
have been competitively inhibited by the relatively high concentrations of the 
branched-chain amino acids, phenylalanine and tryptophan; furthermore these 
amino acids may have depleted muscle tyrosine by trans-stimulation (Stein, 1986) 
of the L-system.
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In comparison to healthy postabsorptive subjects (Chapter 4), the patients 
with diabetes we studied had markedly raised plasma amino acid concentrations 
during insulin withdrawal, partly, presumably, as a result of increased protein 
breakdown as well as amino acid infusion. It seems likely that elevated amino acid 
availability initially may have contributed to the elevated muscle protein synthetic 
rates we measured in the insulin withdrawn state, since we have shown previously 
that muscle protein synthesis in healthy postabsorptive men increased by an 
average of 35% during infusion of mixed amino acids alone (Chapter 4), and we 
have recently confirmed the effect by arterio-venous tracer amino acid flux 
measurements in a separate group of subjects (Chapter 5). It is difficult to choose 
which of two possible effects, ie stimulation by an initially high intramuscular 
amino acid concentration or limitation by removal of muscle essential amino acids 
was most important for the lack of a further stimulation by insulin, but both could 
conceivably have been involved. In any event, our present and previous findings 
are consistent with the proposition that, in man, availability of amino acids rather 
than of insulin, is important in maintaining rates of skeletal muscle protein 
synthesis, and that insulin is less so.
A number of other substrates which could have influenced muscle protein 
synthesis changed in response to insulin infusion. 3-Hydroxybutyrate apparently 
stimulates muscle protein synthesis, but by only 10% as its concentration increases 
over a fourfold range from 0.5 mmol/1 (Nair et al, 1988b): we found that insulin 
caused a small decrease in 3-hydroxybutyrate, making it unlikely that such a 
change would have relieved a previously stimulatory effect on skeletal muscle 
protein synthesis. In rat diaphragm and heart muscle in vitro, glucose increases
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Figure 7.3. Individual and mean skeletal muscle protein synthesis rates during 
insulin withdrawal and replacement with continuous amino acid infusion
protein synthesis (Hedden and Buse, 1982) and deficiency of glucose results in 
increased leucine oxidation (Hedden and Buse, 1982). Plasma glucose was elevated 
during insulin withdrawal but muscle was unlikely to have been able to utilize it 
efficiently because of lack of insulin and little sparing of amino acid catabolism 
could have occurred. Other factors not otherwise considered in our patients include 
elevations of fatty acids and medium-chain triglycerides, the latter being reported 
to improve forearm balance of amino acids (Wicklmayr et al, 1987).
In addition a number of hormones may have altered in concentration during 
insulin infusion. Growth hormone (not measured) may have been initially elevated 
but the patients were in good diabetic control, and plasma insulin-like growth
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factor I was in the normal range making this unlikely. Paracrine and systemic 
growth factors other than insulin-like growth factor I may influence protein 
synthesis in ways not accessible to our analyses. During insulin infusion plasma 
free insulin increased into the high physiological range but nevertheless remained 
beneath the threshold necessary to stimulate insulin-like growth factor receptors. 
However insulin-like growth factor I was measured in plasma only and any local 
muscle-cell changes would not have been apparent. We suggest that this is unlikely 
not only because of a lack of any anabolic effect, but also because increases in 
insulin-like growth factor I normally require considerable exposure to insulin 
(Glaser et al, 1987).
Marked changes in the rates of muscle protein synthesis were evident 
between patients; increases occurred in three, but in two patients there were 
decreases. Stepwise regression analysis showed these changes not to correlate 
either with indices of insulin sensitivity or changes in the plasma 
3-hydroxybutyrate. Although it is not possible with the present study design to 
identify specific factors which induced increases in protein synthesis in particular 
individuals during insulin infusion, the occurrence of the increases suggests that 
there may have been some stimulation of protein synthesis by a combination of 
insulin and some unidentified factor.
The muscle biopsy technique used, although invasive, enables measurement 
of muscle protein synthesis with few inherent assumptions. The plasma enrichment 
of a-ketoisocaproate during infusion of leucine tracer is assumed to represent the 
labelling of leucyl-tRNA within cells: we have recently obtained good evidence that 
for pig muscle, with and without infusion of amino acids, it comes closer to the
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Figure 7.4. Upper panel: whole-body total leucine appearance (solid line) and 
endogenous leucine appearance (broken line). Lower panel: total leucine 
disappearance and non-oxidized leucine disappearance
leucyl-tRNA than do a number of other possible indices such as plasma or 
intracellular leucine (Watt et al, 1989). Only circumstantial evidence concerning
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this question is currently available in man, but it is consistent with our approach 
(Matthews et al, 1982; Schwenk et al, 1985a). Given the present study conditions, 
in which plasma leucine concentration was high throughout both phases of 
investigation, tracer exchange between plasma and the intracellular fluid was likely 
to be rapid; certainly, we observed ratios of the enrichment of plasma 
a-ketoisocaproate/leucine, intramuscular leucine/plasma leucine and intramuscular 
leucine/a-ketoisocaproate much closer to unity in the diabetic patients than in. 
healthy subjects studied without infusion of amino acids (Chapter 4). There is, 
therefore, less variation in the magnitudes of rates of muscle protein synthesis in 
the diabetic patients than in healthy subjects (Chapter 4) when different precursor 
pools are used to calculate the muscle protein synthesis rate.
The rates of whole-body protein leucine kinetics are in agreement with 
values published by other workers (Nair et al, 1983; Tessari et al, 1986a; Nair et 
al, 1987a). The apparent lack of stimulation by insulin of whole-body protein 
synthesis in the diabetic patients is consistent with results from healthy subjects 
showing that rates of protein synthesis correlated only with plasma leucine 
(Castellino et al, 1987; Tessari et al, 1987). In the present study the observed lack 
of insulin stimulation of skeletal muscle is consistent with a lack of change in 
whole-body protein synthesis. That leucine oxidation increased with insulin infusion 
is also in agreement with previous work in which plasma leucine was maintained 
during insulin infusion (Castellino et al, 1987). Although insuhn deficiency 
increases leucine oxidation in perfused hind-limbs, from fasted or fed rats, its 
replacement reduces leucine oxidation in the fed preparation but markedly 
increases it in the fasted preparation (Hutson et al, 1980). Also, insulin has been
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Table 7.5. Anterior Tibialis Muscle Protein Synthetic Rates (kj Calculated on 
the Basis o f Enrichment o f Various Possible Precursors
Possible Insulin Insulin
Precursor Withdrawn Infused
(k8, %/h) (k„ %/h)
Plasma leucine 0.063±0.007 0.071+0.007
Plasma a-ketoisocaproate 0.068±0.007 0.071±0.006
Intramuscular leucine 0.084+0.010E 0.091±0.007a
Statistical significance: aP<0.05 in comparison with plasma leucine or 
a-ketoisocaproate based synthetic rates.
shown to increases leucine oxidation in adipose tissue in vitro (Frick and Goodman, 
1980). It appears likely that the increased leucine oxidation we observed during 
insulin infusion occurred in muscle and adipose tissue. The extent of leucine 
oxidation in different human tissues in vivo is not well documented although the 
distribution of the a-keto acid dehydrogenase (Khatra et al, 1977) suggests muscle 
to be a m^or site, and our own arterio-venous measurements suggest that it must 
be the major one in healthy man (Cheng et al, 1985; Chapter 5).
The measurement of muscle protein synthesis uses fewer uncheckable 
assumptions than the assessment of whole-body protein synthesis with the tracer
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Total Flux 150±5 176±5a
Infusion 25 93
Breakdown (Endogenous Ra) 125±5 83±5b
Total Rd 145±5 185±4b
Synthesis (Non-Ox Rd) 110±4 117±4
Oxidation 35±3 68±4b
Statistical significance: aP<0.01, bP<0.001.
Ra = rate of appearance and Rd = rate of disappearance.
dilution technique. In addition to uncertainties of precursor pool labelling (Chapter 
4), changes in insulin action result in alterations of plasma and intramuscular 
leucine concentration with the result that whole-body protein synthesis, calculated 
with steady state equations, tends to be overestimated during insulin withdrawal 
with the opposite effect during insulin replacement. Although not independently 
validated the equations that we used take account of the changing tracee
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concentrations. A further source of error which may have caused underestimation 
of protein synthesis during the present study conditions is recycling of tracer, 
which may leads to increased plasma tracee enrichment and underestimation of 
both flux and protein synthesis despite coincident underestimation of leucine 
oxidation; however this is usually only a problem in more prolonged infusions 
(Schwenk et al, 1985b). In the present investigations a bicarbonate recovery value 
of 0.81 was used, derived from intravenous tracer-bicarbonate infusion in healthy 
postabsorptive subjects. As determined from the appearance of tracer-carbon 
labelling in glucose by incorporation of the carbons during gluconeogenesis, the 
proportion of bicarbonate fixed during infusions of leucine tracer from oxidation of 
leucine carboxyl-carbon within mitochondria is greater than occurs during infusion 
of bicarbonate for the same degree of plasma bicarbonate labelling. Therefore, 
general use of a bicarbonate recovery value of 0.81 may lead to additional 
underestimation of leucine oxidation and thus, overestimation of protein synthesis. 
During provision of glucose, which stimulates insulin secretion and inhibits 
gluconeogenesis, fixation of tracer-carbon from bicarbonate by gluconeogenesis is 
reduced (McMahon et al, 1989) and under these conditions the figure of 0.81 may 
markedly overestimate leucine oxidation exacerbating the underestimation of 
protein synthesis. Changes also occur in the whole-body bicarbonate pool during 
insulin withdrawal and insulin replacement inducing additional errors in estimates 
of bicarbonate fixation and leucine oxidation. We probably avoided one source of 
error in glucose infusion: if maize derived glucose had been infused 13C02 released 
from maize glucose oxidation would have led to an overestimation of leucine 
oxidation and a further corresponding underestimation of whole-body protein
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synthesis during hyperinsulinaemia. Such factors collectively result in 
underestimation of whole-body protein synthesis by the tracer-leucine dilution 
technique during hyperinsulinaemic conditions and may induce qualitative errors 
in the interpretation of the effects of insulin action on whole-body protein 
synthesis, both in our work and that of others (Castellino et al, 1987; Tessari et 
al, 1987).
Comparison of the present whole-body leucine metabolism results with those 
from studies in non-diabetic men, in which where whole-body protein synthesis was 
not stimulated by insulin (Castellino et al, 1987; Tessari et al, 1987), are consistent 
with a lack of any fundamental difference in sensitivity of amino acid metabolism 
to insulin between diabetic and non-diabetic subjects (Tessari et al, 1986a). Similar 
conclusions might be drawn by comparing the skeletal muscle leucine incorporation 
results reported here for Type 1 diabetic subjects with the reported lack of effect 
of insulin on forearm arteriovenous uptake of phenylalanine in healthy man 
(Gelfand and Barrett, 1987). In contrast, our experience with the arteriovenous 
exchange technique in healthy man suggests that when amino acids are adequately 
replaced during insulin infusion there was a stimulatory effect of insulin on both 
whole-body and muscle protein synthesis, the latter apparent when assessed with 
phenylalanine but not with leucine (Chapter 6). Possible explanations include: the 
possibility that differences do exist between type 1 diabetic patients and healthy 
subjects (see Chapter 8), possibly due to either insulin resistance in type 1 diabetic 
patients or that they were studied immediately after a period of insulin 
withdrawal. A second possibility is that the average rate of skeletal muscle protein 
synthesis was not increased during the 4 h of insulin replacement, the period
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would included a period before insulin had any effect and possibly a period when 
reduced amino acid availability constrained protein synthesis. A third possibility 
is that one or other model of protein metabolism (ie leucine incorporation assessed 
by biopsy and amino acid uptake assessed by amino acid exchange) may be 
deficient; the different methods used in the two investigations, and the differences 
in the subjects studied may make comparisons invalid.
To conclude, in the present study we could not show any acute anabolic 
effect of systemic insulin infusion on skeletal muscle protein synthesis in insulin- 
withdrawn adult diabetic patients. It appears possible that reduced intracellular 
concentrations for a number of amino acids during insulin infusion, in particular 
tyrosine, may have constrained muscle protein synthesis. The hypothesis that such 
a deficiency of amino acids, particularly tyrosine, is the reason why protein 
synthesis is not stimulated by insulin needs to be further investigated using amino 
acid mixtures including tyrosine dipeptides (Albers et al, 1988) to increase its 
availability.
In the meantime the likelihood that increased total amino acid availability 
maintains muscle protein synthesis in diabetic subjects and that acute treatment 
with insulin does not stimulate it further must weaken the perception that the 
generally anabolic effect of insulin includes stimulation of muscle protein synthesis. 
It may be however, that in normal healthy subjects or in diabetic patients with 
physiological amino acid concentrations, insulin does stimulate muscle protein 
synthesis, if sufficient substrate is supplied; the fact that Type 1 insulin dependant 
diabetic children may grow normally suggests that this is so.
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8.1 Summary
To assess whether leg and whole body protein metabolism is insulin 
resistant in type 1 diabetic patients this was measured with [16N]phenylalanine and 
[ l - 13C]leucine models. Eight type 1 diabetic patients were studied twice and eight 
healthy nondiabetic control subjects were studied once during hypoinsulinaemic 
conditions and again during infusion of insulin (0.29 m nol'm '^m in'1). Studies in 
the diabetic patients were undertaken both without amino acid infusion (-I-AA and 
+I-AA) and in both groups with infusion of a mixed amino acid solution (-I+AA and 
+I+AA). In the insulin withdrawn diabetic patients insulin alone abolished the 
negative leg phenylalanine balance due to a 42% reduction (P<0.05) in muscle 
protein breakdown and no change in muscle protein synthesis. In the amino acid 
infused diabetic patients insulin combined with additional amino acids increased 
phenylalanine-based muscle protein synthesis (-I+AA 33.1+8.0 vs +I+AA 45.7±7.5 
nmol» 100 g-1*min-1, P -0.077) and reduced muscle protein breakdown 41% (43.8±7.1 
vs 25.9±3.7 nmol» 100 g'^min"1, P<0.05). Leg leucine oxidation was unchanged by 
insulin alone but was increased during insulin infusion with additional amino acids 
(-I+AA 10.3±2.6 vs +I+AA 40.8±8.5 nmol» 100 g '^m in '1, P<0.01). In the diabetic 
patients insulin and amino acid stimulated phenylalanine-based leg protein 
synthesis (45.7±7.5 nmol» 100 g '^m in '1) and leg glucose uptake (1.60±0.28 
pmol» 100 g^'m in-1) were impaired in comparison to the nondiabetic subjects 
(protein synthesis: 73.1±7.3 nmol» 100 g a in in '1, P=0.021; glucose 3.37±0.28 
pmol» 100 g_1»min"\ P=0.040). These results suggest that in type 1 diabetic 
patients: a) infusion of insulin only stimulates leg protein synthesis when combined
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with a substantial provision of amino acids, and b) muscle protein synthesis 
exhibits impaired sensitivity to insulin, as does glucose uptake.
8.2 Introduction
Type 1 diabetic patients have both a deficiency of endogenous insulin 
secretion and a well documented insensitivity to insulin by glucose disposal in the 
whole-body (DeFronzo et al, 1982; Del Prato et al, 1983; Pernet et al, 1984) and 
specifically in muscle (Butterfield and Wnichelow, 1964; Hother-Nielsen et al, 1987; 
Beek-Nielsen, 1989; Bogardus, 1989). Lipid metabolism in type 1 diabetes is also 
relatively insulin resistant (Jensen et al, 1989). In addition there is an impaired 
effect of insulin on whole-body protein metabolism assessed by leucine-tracer 
dilution techniques in type 1 diabetic patients, in comparison to nondiabetic 
subjects, in whom there are decreased reductions in the rates of whole-body protein 
breakdown and leucine oxidation during euglycaemic hyperinsulinaemia (Tessari 
et al, 1986a; Tessari et al, 1988). In man insulin is thought to exert a protein 
anabolic effect in the whole-body predominantly by reducing the rate of protein 
breakdown (Section 1.8.1; Chapter 6; Chapter 7). The anabolic effect in the whole- 
body may also include modulation of protein synthesis when amino acids are 
maintained at comparable concentrations by exogenous infusion (Chapter 6). 
Assessment of human muscle protein metabolism in vivo in healthy subjects using 
a phenylalanine-tracer-based arteriovenous exchange technique suggests that insulin 
reduces the rate of protein breakdown (Gelfand and Barrett, 1987) but does not 
alter protein synthesis. However, when amino acid availability is increased by 
amino acid infusion, insulin predominantly exerts its anabolic effect by increasing
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protein synthesis (Chapter 6). In contrast direct assessment of muscle protein 
synthesis in vivo in type 1 diabetic subjects with a biopsy technique suggests that 
there is no effect of insulin on muscle protein synthesis when hypoaminoacidaemia 
develops (Pacy et al, 1989), and when hypoaminoacidaemia is prevented by 
continuous infusion of a mixed amino acid solution (Chapter 7). It, therefore, 
appears possible that insulin resistance in type 1 diabetic patients, demonstrated 
for glucose metabolism and for whole-body proteolysis, extends to amino acid 
metabolism, particularly protein synthesis, in skeletal muscle.
These studies were designed to assess by tracer exchange the acute effects 
of insulin and of amino acids, separately and in combination, on both skeletal 
muscle and whole-body protein turnover and amino acid metabolism in type 1 
diabetic patients. In addition an aim was to compare the anabolic effects of insulin 




Eight patients with type 1 diabetes were studied (Table 8.1). Their diabetes 
was maintained under good control with insulin two to four times daily. Seven had 
no overt diabetic complications and one patient had laser-treated retinopathy. They 
had no additional illness, their biochemical tests of hepatic, renal and thyroid 
function were normal and their only medication was insulin. Six were connecting- 
peptide negative and two were deficient (0.08 and 0.13 nmol/1 during
Insulin Resistance of Protein Synthesis in Type 1 Diabetes
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hyperglycaemia and ketosis). Eight non-diabetic subjects (Table 8.1, Chapter 6), 
matched for age, sex, body mass index and body fat composition (determined from 
skinfold thickness at four sites (Dumin and Womersley, 1974)), were also 
investigated with the same protocol: these results are described in detail in 
(Chapter 6).






Age (years) 32(22-43) 33(23-42)
Sex (Female:Male) 2:6 2:6
Body mass index (kg/m2) 26.2+1.2 23.6+1.3
Body fat (%) 23.8±2.6 21.5±3.3
Duration of diabetes (years) 10.7±1.8
Insulin dose (U/day) 61±4.5
Glycated haemoglobin (%, normal <8.5) 9.4±0.8
Data are means (ranges) or means±SEM.
No differences existed between diabetic patients and controls.
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8.4.2 Protocol
The diabetic patients were investigated on two occasions a minimum of 21 
days apart. They were given only half of their usual dose of short-acting and no 
intermediate or long-acting insulin at 5 pm on the evening prior to each study. 
On each occasion, after an overnight fast (15 h). they were studied during 180 min 
of continued insulin withdrawal followed by 180 min of euglycaemic 
hyperinsulinaemia (the insulin replacement period) (Protocol d, Section 3.10.4, 
Figure 3.4). In random order, on one study day hypoaminoacidaemia was allowed 
to develop during insulin replacement and on the other day this was prevented by 
infusion of a commercial mixed amino acid solution (Synthamin 14, Section 3.3, 
Table 3.1) given at an increased rate during insulin infusion. The nondiabetic 
subjects were studied after an overnight fast (15 h) with an identical protocol to 
that used during the amino acid infusion studies in the diabetic patients (Chapter 
6).
A cannula for blood sampling was placed, in a retrograde direction, in a 
dorsal hand vein, and a second sampling cannula, in an antegrade direction, in a 
common femoral vein (Section 3.5). A third cannula was placed in a contralateral 
forearm vein for tracer, amino acid and glucose infusions.
Priming doses of L -[1BN]phenylalanine (-AA 2.71±0.13, +AA 2.58±0.10 
pmol/kg), L - [ l - 13C]leucine (-AA 6.62±0.28, +AA 7.29±0.37 pmol/kg) and NaH13COs 
(-AA 1.81+0.11, +AA 2.79±0.10 pmol/kg) were administered and a continuous 
infusion of a mixture of L -[15N]phenylalanine (-AA 2.94±0.12, +AA 2.76+0.12 
]imn1«kg~1»b~1) and L - [ l - 13C]leucine (-AA 6.36±0.24, +AA 6.84±0.24 pmoDkg’^h"1) 
was established and continued until the end of the studies. A priming dose (51.6
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mg amino acids/kg over 10 min) of a commercial mixed amino acid solution 
(Synthamin 14, Section 3.3, Table 3.1) was administered at the beginning of the 
study of amino acid infusion; Synthamin 14 was then infused until the end of the 
period of insulin withdrawal at a rate of 0.52 ml»kg_1*h_1, providing 44.2 mg of 
mixed amino acids • kg"1 »h '1, 15,0 pmol phenylalanine* kg'1 »h"1, 24.6
pmol leucine* kg'1 »h '1 and 0.17 g nitrogen »kg'1 »day"1. Then a primed intravenous 
infusion (Section 3.9.2) of neutral human insulin (Humulin S, Section 3.3) was 
administered at 0.29 nmol*m'2*min'1 (40 mU^m'^min'1) for 180 min (the insulin 
infusion period). Glucose solution (1 mold, Section 3.3) was infused where plasma 
glucose fell to 5 mmol/1 to maintain euglycaemia (5 mmol/1). During the insulin 
infusion period, the amino acid infusion rate was increased to 1.96 ml »kg'1 »h"1 
providing 167 mg* kg'1 »h '1 of mixed amino acids, 56.4 pmol phenylalanine• kg“1 • h"1 
and 93 pmol leucine* kg"1 »h '1. The amino acid infusion rates were chosen following 
separate set of studies in eight diabetic patients in whom intracellular amino acid 
concentrations were measured by percutaneous biopsy after 4 h periods of identical 
amino acid and insulin infusion; in those studies the intramuscular free leucine 
and total free amino acid concentrations (Table 7.3, Figure 7.1) were lower during 
insulin infusion than the values during insulin deficiency even though the plasma 
values (Table 7.2, Figure 7.1) were greater (Chapter 7).
Blood sampling, breath sampling and indirect calorimetry were as described 
in Chapter 6 (Section 6.3). Amino acid concentrations in sulphosalicylic acid 
extracts of plasma were determined in duplicate by reverse-phase high performance 
liquid chromatography (Section 3.13).
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Figure 8.1. Upper panel: Arterial plasma phenylalanine concentrations. Lower panel: 
Arterial plasma leucine concentrations (circles, without amino acids; squares, with 
amino acids)
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8.4 Results
8.4.1 Gas Exchange and Leg Blood Flow
In the diabetic patients whole-body carbon dioxide production and whole- 
body oxygen consumption (Table 8.2) were greater during insulin replacement with 
amino acids than at all other times (P<0.02). The respiratory quotient was 
increased by infusion of insulin and glucose, both during hypoaminoacidaemia 
(P<0.02) and during hyperaminoacidaemia (P<0.05). Resting energy expenditure 
calculated from gas exchange was unchanged by either insulin replacement alone 
or by amino acid replacement alone but increased (P<0.02) during insulin 
replacement combined with amino acids. In the non-diabetic subjects energy 
expenditure was not different from the diabetic patients when the results were 
normalized by expression as kJ*(kg lean body massl'^min"1 (results not shown). 
Basal respiratory quotient was not different in the nondiabetic controls but was 
higher (P<0.05) during with insulin plus amino acid infusion. Leg blood flow (Table 
8.2) was unaltered by insulin or amino acid infusion: in the nondiabetic subjects 
blood flow during amino acid infusion alone was not different from that in the 
diabetic patients but this was faster during insulin plus amino acid infusion 
(4.74±0.29 vs 3.29±0.26 ml* 100 g^m in”1, P<0.05).
8.4.2 Hormones
During insulin withdrawal the plasma free insulin concentration (Table 8.3) 
was 37±9 pmol/1 in the absence of amino acids. Insulin was apparently increased 
(PcO.Ol) during infusion of amino acids alone despite negative c-peptide assays in
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Table 8.2. Indirect Calorimetry and Leg Blood. Flow; Effect of Insulin 'Without 
(-AA) and With (+AA) Amino Acid Infusion
Insulin Insulin insulin Insulin
Withdrawn Infusion íV i h drawn Infused
-AA +AA -AA +AA
VC02 (1/min) 0.206±0.008 0.213±0.011 0.214±0.008 0.243±0.011b
V 02 (1/min) 0.284±0.013 0.270±0.017 0.288±0.014 0.312±0.013b
Respiratory
quotient
0.72+0.01 0.79±0.02a 0.75+0.02 0.78±0.02°
REEC (kJ/min) 5.64±0.25 5.47±0.34 5.74±0.27 6.27±0.26
Leg blood flow 
(ml* 100 g a in in '1)
3.26±0.41 3.08±0.43 3.63±0.34 3.29±0.26
Statistical significance: “P<0.05 effect of insulin replacement, bP<0.02 different 
from all other groups. CREE, resting energy expenditure.
6 of 8 of the diabetic patients: this anomalous result may possibly have been due 
to an effect of amino acids on non-specific binding in the insulin assay or may 
have arisen by chance. During infusion plasma free insulin concentration increased 
to 529±65 and 561±54 pmol/1 in the absence and in the presence of amino acids. 
Plasma total insulin concentrations were similar in the nondiabetic subjects (Table 
6.1). In the diabetic subjects plasma glucagon concentration (Table 8.3) was
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decreased 28% (P<0.01) by insulin in the absence of amino acid infusion but not 
in the presence of amino acid infusion. In the nondiabetic subjects plasma glucagon 
was lower than in the diabetic patients during amino acid infusion alone (34±3 vs 
50±7 pmol/1, P<0.05) but was not different during insulin and amino acid infusion. 
The concentration of total plasma insulin-like growth factor I was reduced (P<0.05) 
In insulin during amino acid infusion. Similar values were found in the nondiabetic 
subjects compared to the diabetic patients. Cortisol was unaffected by either insulin 
or amino acid infusion and was not different in the two groups studied.
8.4.3 Substrates
The arterial plasma glucose concentration in the diabetic patients (Table 8.3) 
was reduced to a similar extent by insulin in the absence and in the presence of 
amino acids; during amino acid infusion alone plasma glucose concentration was 
much lower (P<0.001) in the nondiabetic subjects (Table 6.1) than in the diabetic 
patients but did not differ dining the euglycaemic clamp. Whole-body net insulin- 
stimulated glucose uptake in the diabetic patients was decreased by amino acid 
infusion (-AA 18.1±4.0 vs +AA 14.8±2.9 pmoDkg'^min'1, P<0.05). In the 
nondiabetic subjects the rate was higher than in the diabetic patients during amino 
acid infusion (36.1±4.6 vs 14.8±2.9 pmoDkg'^h'1, P<0.01). Insuhn-stimulated leg 
glucose uptake in the diabetic patients was similar without and with amino acid 
infusion (-AA 1.46±0.51 vs +AA 1.60±0.28 pmol»100 g '^m in '1): in both studies 
the rate of leg glucose uptake was much higher (-AA P<0.05, +AA PcO.OOl) 
during insuhn infusion than was the case during insulin withdrawal when it was 
not different from zero. In the nondiabetic subjects insulin stimulated leg glucose
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Table 8.3. Hormone and Substrate Concentrations; Effects o f Insulin Without 














Insuhn (pmol/1) 37±9 529±65d 61+7' 561±54d
IGF-P (U/l) 680+60 640±80 680±60 610±70a
Glucagon (pmol/1) 48+5 34±5C 51+7 50+5
Cortisol (nmol/1) 241±60 276+25 335±72 253+27
Glucose (mmol/1) 10.9±1.5 5.2±0.2C 11.8±1.5 6.1±0.7d
Blood
Bicarbonate (mmol/1) 24.4±0.6 26.6+0.3' 24.8±0.7 26.4±0.6d
Lactate (mmol/1) 0.76±0.05 0.93±0.08a 0.63±0.05 0.89±0.06'
3-OHButf (mmol/1) 0.68±0.20 0.05+0.02b 0.55±0.14 0.10±0.06'
Statistical significance: Effect of insulin, aP<0.05, bP<0.02, 'PcO.Ol, dP<0.001. 
eIGF-I, Insulin-like growth factor I; f3-OHBut, D(-)3-hydroxybutyrate.
uptake was faster than in the diabetic patients (3.37±0.52 vs 1.60+0.28 
pmol»100 g_1»min_1, P<0.05).
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The arterial blood bicarbonate concentrations in the diabetic patients were 
only modestly depressed during insulin withdrawal; there was an increase with 
insulin replacement. The initial arterial blood bicarbonate concentration was higher 
(P<0.05) in the nondiabetic subjects than in the diabetic patients. In the diabetic 
patients blood lactate concentration (Table 8.3) increased during insulin infusion 
both in the absence and in the presence of additional amino acids. Net release of 
lactate by the leg tended to reduce during insulin infusion (-I-A A  -0.42±0.16 vs 
+I-AA -0.31±0.10; -I+AA -0.43±0.09 vs +I+AA -0.40±0.16 pmol#100 g^m in"1). 
Similar concentrations of blood D-(-)-3-hydroxybutyrate were found during insulin 
withdrawal in the diabetic patients in the absence and presence of amino acid 
provision; in the nondiabetic subjects (Table 6.1) the concentration was lower 
(P<0.05) during amino acid infusion alone than in the diabetic patients. During 
insulin infusion D-(-)-3-hydroxybutyrate concentrations in the absence and in the 
presence of amino acid infusion were similar in the diabetic patients (Table 8.3) 
and in the nondiabetic subjects.
8.4.4 Amino Acid and Keto Acid Arterial Concentrations
The pre-study arterial plasma concentrations of phenylalanine (-AA 42±3, 
+AA 45±1 pmol/1) and leucine (-AA 125±12, +AA 132±13 pmol/1) were not 
different on the two days. At the time of sampling during the initial insulin 
withdrawal phases arterial phenylalanine, leucine (Figure 8.1) and 
a-ketoisocaproate (-AA 43.3±4.1 pmol/1) concentrations were stable; these were 
73% (PcO.OOl) higher and 60% higher (P<0.001) and unchanged (40.1±1.7 pmol/1), 
respectively, with amino acid infusion during insulin withdrawal. During infusion
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of insulin alone phenylalanine concentration decreased (PcO.OOl) by 15% and was 
stable during the sampling period; leucine concentration decreased 45% (PcO.OOl) 
and also remained stable during sampling; a-ketoisocaproate concentration 
decreased 47% (PcO.OOl) to 2.2.9±1.9 umol/1. Compared to the insulin withdrawal 
period, insubn infused with extra amino acids resulted in a 87% increase (PcO.OOl) 
in arterial phenylalanine concentration, a 27% increase (PcO.OOl) in leucine 
concentration and a 37% decrease (PcO.OOl) in a-ketoisocaproate concentration; 
all were stable during final sampling. During amino acid infusion alone the arterial 
plasma leucine and a-ketoisocaproate concentrations tended to be lower in the 
nondiabetic controls but during insulin and amino acid infusion there were no 
differences from the diabetic patients.
8.4.5 Leg Amino Acid and Keto Acid Balance
The leg net fluxes of both phenylalanine and leucine (Table 8.4) were 
negative during insulin withdrawal. Infusion of insulin alone improved (PcO.Ol) 
phenylalanine balance and leucine balance followed a similar pattern. During 
insulin infusion with additional amino acids phenylalanine leg uptake changed 
(Pc0.05) and became markedly positive indicating that leg protein synthesis 
exceeded protein breakdown; leucine balance also became positive but the leg 
a-ketoisocaproate balance became markedly negative at the same time.
8.4.6 Enrichments o f Phenylalanine, Leucine and Leucine Metabolites
Plateaux were attained for the enrichments of plasma phenylalanine and 
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Figure 8.2. Upper panel: Arterial plasma phenylalanine 1SN  enrichment. Lower 
panel: Arterial plasma leucine I3C enrichment (circles, without amino acids; squares, 
with amino acids)
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C02 (not shown) during the final periods of each phase of study. During insulin 
withdrawal the 13C enrichment of expired C02 was 0.016±0.001 Atoms Percent 
Excess (APE) both without and with amino acids. During insulin infusion this 
increased (both P<0.001) to 0.022±0.002 and 0.025±0.0Q1 APE, respectively. In 
three subjects who did not receive tracer (Chapter 6) the 1SC enrichment of expired 
C02 was 0.0008±0.0004 APE during insulin, glucose and amino acid infusion 
suggesting that whole-body leucine oxidation may have been overestimated by 
about 3% during this period. The leg production rate of 13C02 was not different 
from zero in the three subjects who received no tracer (Chapter 6) suggesting that 
a systematic error in the estimates of leucine oxidation, due to changes in 
substrate metabolism by the leg, did not occurred.
8.4.7 Leg Protein Turnover and Amino Acid Metabolism
Compared with the insulin withdrawal state, insulin infusion alone reduced 
(P<0.05) protein breakdown assessed with [1BN]phenylalanine by 42% but assessed 
with [ l - 13C]leucine exchange the effect was only a 20% reduction (P=0.18, non­
significant) in the diabetic patients. There was no effect of insulin alone on protein 
synthesis (assessed with phenylalanine or leucine) or leucine oxidation by leg 
tissues.
Compared to insulin withdrawal without amino acids, when amino acids 
were infused in the diabetic patients protein synthesis assessed with phenylalanine 
was 66% higher (P=0.077); a similar pattern was seen with leucine (+54%, P<0.05). 
No change occurred in the rate of muscle protein breakdown, leucine oxidation or 
net protein balance as a result of amino acid infusion alone. In the nondiabetic
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subjects the rates of leg protein breakdown, synthesis and leucine oxidation during 
infusion of amino acids alone (Table 6.4) were not different from these in the 
diabetic patients.
In the diabetic patients infused with amino acids during insulin withdrawal 
the effect of insulin with additional amino acids was a 41% reduction (P<0.05) in 
muscle protein breakdown assessed with phenylalanine and 32% (P<0.05) assessed 
with leucine. A trend was seen to increased muscle protein synthesis assessed by 
phenylalanine (+38%, P=0.07). No such effect on muscle protein synthesis was 
observed with the leucine model and the increased leucine balance was largely 
accounted for by a four fold increase (P<0.02) in leucine oxidation by the leg. In 
the nondiabetic subjects during insulin infusion with additional amino acids muscle 
protein synthesis assessed by phenylalanine exchange was 60% faster (P<0.05) than 
in the diabetic patients (73.1±7.3 vs 45.7±7.5 nmol» 100 g '^m in '1). A similar 
pattern was shown in the leucine exchange based rates which were 54% higher in 
the nondiabetic subjects (146±21 vs 94.8±21.9 nmol»100 g'^min"1, P=0.112). The 
rates of protein breakdown and leucine oxidation in muscle were not different from 
the diabetic patients in the nondiabetic control subjects.
8.4.8 Whole-Body Leucine and Phenylalanine Kinetics
In the diabetic patients the effect of insulin alone was to reduce whole-body 
protein breakdown by 13% (PcO.OOl) and whole-body protein synthesis by 20% 
(P<0.001) assessed with leucine (Table 8.5). Insulin alone induced a 18% increase 
(P<0.01) in whole-body leucine oxidation and a 18% deterioration in the negative
243
Insulin Resistance of Protein Synthesis in Type 1 Diabetes
balance between synthesis and breakdown. Whole-body protein breakdown assessed 
with phenylalanine decreased 19% (PcO.Ol).
Amino acid provision without insulin in the diabetic patients reduced whole- 
body protein breakdown by 19% assessed with phenylalanine (Pc0.02) but not with 
leucine. Increases occurred in whole-body protein synthesis (+11%, P<0.05) and in 
leucine oxidation (+32%, PcO.Ol) and the net balance between protein synthesis 
and breakdown (PcO.OOl), all assessed with [ l - 13C]leucine. In the nondiabetic 
subjects studied during amino acid infusion alone indices of whole-body protein 
turnover (Table 6.5) were not different from these in the diabetic patients.
In the diabetic patients the effect of insulin with increased amino acid 
infusion was a 27% reduction (PcO.Ol) in the rate of whole-body protein 
breakdown, a two fold increase (PcO.OOl) in whole-body leucine oxidation and no 
change in the rate of whole-body protein synthesis assessed with leucine. The net 
balance between whole-body protein synthesis and breakdown was improved 
(PcO.OOl) and became markedly positive during the combined infusion. In the 
nondiabetic subjects during the combined insulin with amino acid infusion whole- 
body protein synthesis was 14% faster (Pc0.05) than in the diabetic patients (126±4 
vs 111±5 pmoDkg'^h"1); there were no differences in the rates of protein 
breakdown or leucine oxidation.
8.5 Discussion
During the insulin withdrawal periods the degree of insulin deficiency was 
relatively modest on the basis of the glucagon, bicarbonate and (i-hydroxybutyrate 
concentrations in the type 1 diabetic patients. Under these circumstances infusion
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Table 8.4. Leg Phenylalanine and Leucine Metabolism; Effects of Insulin 
Infusion Without (-AA) and With (+AA) Amino Acid Infusion
Insulin Insulin Insulin Insuhn
Withdrawn Infused Withdrawn Infused
-AA +AA —AA +AA
Phenylalanine turnover (nmol* 100 g~1#min'-1)
Breakdown 31.1±5.2 18.0±2.1a 43.8±7.1 25.9±3.7a




Leucine turnover (nmol* 100 g'^•min'1)
Leucine net flux -13.3±10.1 1.6+5.9 6.3±15.4 88.0±17.8C
KICd net flux 10.2+4.5 -14.9±7.9 1.3±5.6 -24.6±4.1b
Breakdown 72.4+10.1 57.8±8.4 104.1+13.9 70.9±8.4“
Synthesis 65.8±14.5 46.6±8.8 101.5+17.1“ 94.8±21.9




Statistical significance: Effect of insulin, “P<0.05, bP<0.01, 'PcO.OOl. 
dKIC, a-ketoisocaproate.
of insulin alone in insulin-withdrawn has no acute net anabolic effect on either
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skeletal muscle protein turnover or on whole-body protein turnover. This result is 
in keeping with results from previous studies in diabetic patients (Nair et al, 1983; 
Robert et al, 1985; Tessari et al, 1986a; Umpleby et al, 1986; Nair et al, 1987a; 
Pacy et al, 1989; Section 1.8.1). In contrast to the effects of insulin, infusion of 
amino acids in the insulin withdrawn diabetic patients was anabolic by increasing 
protein synthesis, assessed with leucine, both in muscle and in lean tissues, similar 
to the effects seen in nondiabetic patients (Chapters 4 and 5). Compared to 
infusion of amino acids alone the main effects of insulin, with additional amino 
acids designed to maintain comparable amino acid availability at a tissue level, 
was to improve skeletal muscle phenylalanine balance due to reduced muscle 
protein breakdown; there was only a trend to increased muscle protein synthesis 
with the phenylalanine-based model and no increase was seen with the leucine- 
based model. In addition, no increase occurred in whole-body protein synthesis 
during insulin infusion with additional amino acids.
These results in the diabetic patients are in contrast to the results in the 
nondiabetic subjects in whom infusion of insulin with amino acids did exert an 
anabolic effect by increasing protein synthesis both in muscle and in lean tissues 
of the whole-body (Chapter 6). As a result of these differing responses to insulin 
by the diabetic patients and the nondiabetic subjects the rates of both skeletal 
muscle protein synthesis assessed with phenylalanine and whole-body protein 
synthesis assessed with leucine were faster in the nondiabetic subjects. These 
observations suggest that protein synthesis in patients with type 1 diabetes under 
the study conditions we used is resistant of to acute stimulation by insulin.
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Table 8.5. Whole-Body Leucine and Phenylalanine Kinetics; Effects o f Insulin 
Without (-AA) and With (+AA) Amino Acid Infusion
Insulin Insuhn Insulin Insulin
Withdrawn Infused Withdrawn Infused
-AA +AA -AA +AA
Leucine kinetics (pmol»kg~1#h *)
Flux 119±6 104±5d 137±7 174±6d
Infusion - — 25 93
Breakdown 119±6 104±5d 112±7 82±6C
Oxidation 22±2 26±2C 29±2 64±2d
Synthesis 97±4 78±4d 108±6 l l l± 5 d
Balance
(Synthesis-Breakdown)
-22±2 -26±2C -4±2 29±2d
Phenylalanine kinetics (pmol'kg 1#h‘-1)
Flux 48.5±2.5 39.5±1.7C 52.4±3.4 76.6±6.6C
Infusion - - 15.0 56.4
Breakdown 48.5±2.5 39.5±1.7C 37.5±3.3 20.2±1.7a
Statistical significance: Effect of insulin, ‘PcO.Ol, bP<0.02, CP<0.01, dP<0.001.
During infusion of insulin alone changes occurred in the concentrations of 
amino acids and other metabolites and hormones, eg (3-hydroxybutyrate, glucose,
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lactate, bicarbonate and glucagon; it is most unlikely that insulin directly reduced 
protein synthesis. Most of these metabolites altered to a similar extent when 
insulin was infused with amino acids. It is unlikely that these alterations per se 
would have accounted for the changes in protein metabolism: there is evidence that 
P-hydroxybutyrate stimulates protein synthesis (Nair et al, 1988b) and that acid- 
base alterations also affect protein turnover (Rodriguez et al, 1989). Paradoxically 
plasma insulin-like growth factor I concentrations decreased during insulin infusion 
as insulin-like growth factor I is said to be depressed in diabetic ketoacidosis 
(Glaser et al, 1987). The probable explanation is that insulin-like growth factor I 
is almost totally bound to carrier proteins and the small binding protein 
concentration is rapidly decreased by insulin (Suikkan et al, 1989).
In the studies where insulin was infused alone its apparent lack of effect 
on protein synthesis, both in muscle and in whole-body, may have arisen in part 
due to differences between the concentrations and enrichments of the tracee in the 
accessible vascular compartment and at a tissue level. A reduction was observed 
in the plasma concentrations of both tracers. As transmembrane transport of amino 
acids by leg tissues is dependent on their concentrations (Lundholm et al, 1987), 
transport of the tracer between plasma and intracellular water, the site of protein 
synthesis, may have been reduced during insulin infusion alone. If this had 
occurred to a substantial extent, and there may have been a greater decrement in 
enrichment within cells during insulin infusion alone than dunng insulin 
withdrawal: as a result protein synthesis may have been substantially 
underestimated. This effect of insulin, to reduce amino acid concentrations with a 
resultant underestimation of protein synthesis, is directly opposite to the situation
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during infusion of amino acids alone. In contrast under these circumstances, both 
in the present study and in studies described in previous chapters, increased amino 
acid transport may have resulted in overestimation of the effects of amino acids 
on both whole-body and muscle protein synthesis (Sections 4.5 and 5.5). It is not 
possible to ascertain to what extent this may have occurred, and indeed it may 
have been to a negligible extent.
It is likely that leucine oxidation was overestimated in the present studies 
as a result of stimulation of leucine oxidation by insulin in adipose tissue (Frick 
and Goodman, 1980). Adipose tissue is not a site of amino acid storage and leucine 
undergoing oxidation there would have originated directly from plasma and would 
have been more highly enriched than leucine entering protein synthesis which 
would have been diluted from unlabelled amino acids released from muscle protein. 
This possibility may explain the discordant results for leg protein synthesis during 
combined insulin and amino acid infusion obtained with phenylalanine and leucine, 
ie that muscle protein synthesis tended to increase with insulin when assessed 
with the former but not the latter tracer, analogous to the situation in nondiabetic 
subjects (Section 6.5). In addition the possibility that the elevated concentrations 
of the branched-chain amino acids resulted in competitive inhibition of 
phenylalanine transport by the muscle L-system transporter and also that both cis- 
and ¿rans-stimulation occurred which may explain the discordant results (Section 
6.5). The greater increases for phenylalanine than for leucine concentration, with 
the possibility of increased tracer exchange of phenylalanine, may have resulted in 
a relative overestimation of the effect of insulin plus amino acids on muscle protein 
synthesis assessed with phenylalanine (Section 6.5).
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The phenyl alanine-based model for assessing leg protein synthesis is subject 
to fewer sources of analytical error and to fewer inherent assumptions than the 
leucine-based model and is, therefore, more robust. This may have been a 
particularly important factor in the present studies of diabetic patients as a much 
greater variation was seen in measures of muscle protein synthesis than was the 
case in the nondiabetic subjects. This may have been due to clinical factors on 
account of a heterogeneous response by the diabetic patients to insulin withdrawal 
and also to laboratory factors. The variation may have obscured clinically 
significant changes in protein turnover. The possibility exists that the effects of 
insulin with additional amino acid were due simply to the increased arterial 
concentrations of amino acids which stimulated protein synthesis directly but this 
is unlikely. Intramuscular amino acid concentrations were lower in a separate 
group of type 1 diabetic patients studied with a similar protocol (Chapter 7).
The comparisons between the diabetic patients and the nondiabetic subjects 
is not subject most of the uncertainties noted above and discussed in detail in 
sections 4.5, 5.5 and 6.5. However, possible reasons for the differences in the 
results between the groups need to be considered. There was a trend to increased 
fat mass in the type 1 diabetic patients (Table 8.1). As protein turnover occurs 
predominantly in lean tissues normalising protein turnover to total body weight 
may have led to underestimation of protein turnover in the diabetic patients. The 
small differences in fat mass are not sufficient to explain the differences in protein 
turnover between the groups. Increases occurred in leg blood flow in the healthy 
subjects but not in the diabetic patients. Insulin is shown to increase muscle blood 
flow by adrenergic mechanisms (Laing et al, 1982) but it is not known if type 1
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diabetic patients have a diminished muscle blood flow response to insulin. The 
concentrations of glucagon and cortisol tended to be higher in the diabetic patients 
than in the nondiabetic subjects. There is little evidence that elevated cortisol 
would have decreased protein synthesis (Wemerman et al, 1989) and there is no 
evidence that glucagon would have had such an effect at the concentrations found 
in the present study.
The resistance of protein synthesis to insulin is not unexpected as resistance 
of glucose metabolism to insulin occurred both in the present study and has been 
well documented by others (DeFronzo et al, 1982; Del Prato et al, 1983; Pemet et 
al, 1984). The site of insulin resistance of glucose metabolism predominantly 
appears to be in muscle (Butterfield and Whichelow, 1964; Hother-Nielsen et al, 
1987; Beck-Nielsen, 1989; Bogardus, 1989) and, in addition, liver where suppression 
of glucose release by insulin is deficient (DeFronzo et al, 1982).
In contrast to the relative insensitivity of protein synthesis to insulin in 
diabetic patients, the rates of muscle protein synthesis during amino acid infusion 
were not different in the diabetic patients and in the nondiabetic subjects when 
insulin was at basal levels, a finding in keeping with the relatively normal glucose- 
stimulated glucose uptake in type 1 diabetic subjects.
The respiratory gas exchange ratio in the diabetic patients was lower than 
in the nondiabetic subjects during insulin infusion with amino acids indicating 
that glucose oxidation was reduced and lipid oxidation was increased. However, 
plasma p-hydroxybutyrate concentrations were not different in the two groups 
during insulin infusion, an observation which in contrast does not support the 
possibility that lipid metabolism was insulin resistant in these diabetic patients.
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Although lipolysis is exquisitely sensitive to suppression by insulin there is a 
relative insensitivity in patients with type 1 diabetes (Jensen et al, 1989).
Tessari and colleagues (Tessari et al, 1986a; Tessari et al, 1988) have shown 
that whole-body proteolysis in patients with type 1 diabetes is resistant to 
suppression by insulin. This did not appear to be the case in our study but our 
study conditions and protein turnover models were different and we infused amino 
acids with insulin. Therefore, direct comparisons are not possible between these 
studies.
In summary amino acid stimulation of protein synthesis in muscle and 
whole-body was normal in patients with type 1 diabetes. In contrast insulin 
stimulation of protein synthesis, in the presence of a sufficiency of amino acids, 
was reduced suggesting that insulin resistance extends to amino acid metabolism 
in addition to glucose and lipid metabolism in subjects with type 1 diabetes. Our 
finds need to be confirmed with further studies employing a combination of 
pancreatic and adrenal clamp techniques to enable selective manipulation of 
elements of the hormone and substrate milieu.
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The studies described above are subject to a number of prominent 
uncertainties and limitations. The most important is that serious errors may have 
ansen by calculation of indices of protein turnover and amino acid metabobsm from 
the tracee enrichments in the accessible vascular compartment. At the present time 
the evidence supporting this approach is only circumstantial. As discussed in 
section 4.5, qualitative mistakes may have arisen in the present studies, 
particularly that the anabolic effects of amino acids on protein synthesis may have 
been overestimated.
A second problem is that the coefficients of variation of the measures of 
muscle protein turnover were large. This was due to errors compounding in the 
calculations based on small arteriovenous differences and also that the degree of 
insulin deficiency in the hypoinsulinaemic diabetic patients was variable. It is 
likely that the forearm would have been a better site to study muscle metabolism; 
at the antecubital fossa it would have been possible to retrogradely cannulate 
muscle veins rather than sampling drainage from the complete leg as was the case 
in our studies. It remains to be tested if this approach would have decreased the 
variation in the results. The coefficients of variation for muscle protein synthesis 
calculated from tissue enrichments in samples obtained by biopsy were lower than 
these determined by the arteriovenous exchange technique. However, it may not 
be valid to directly compare the results from the two techniques as the 
arteriovenous exchange technique determines protein turnover at a point in time, 
whereas the biopsy technique gives an integrated result during a period of time.
Additional elements of the studies to be considered are that the time scale 
of our protocols may not have been optimal to show insulin and/or amino acid 
effects, and that the relative content of amino acids in the commercial amino acid 
solution that we used was not ideal as the plasma phenylalanine concentration
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increased during the combined insulin and amino acid infusion and, in contrast, 
the concentration of tyrosine and other amino acids in plasma and intramuscular 
water decreased.
Despite the qualifications that must be applied to our results we showed 
that insulin invariably decreased whole-body protein breakdown. The magnitude 
of the reduction is consistent with the concept that insulin regulates lysosomal 
proteolysis, which accounts for about 30% of protein breakdown, and has little 
effect on other systems for proteolysis. The minimal effect that we found by insulin 
on muscle protein breakdown in healthy subjects is compatible with the knowledge 
that myofibrillar protein breakdown is not subject to insulin regulation.
Stimulation of protein synthesis by insulin appeared to be dependent on a 
rapid amino acid supply. Our results suggest that under such conditions insulin 
is anabolic by increasing protein synthesis both in muscle and in lean tissues of 
the body. However, the relatively modest effects of insulin on protein synthesis in 
the nondiabetic subjects and the lack of such effect in the type 1 diabetic patients 
is consistent with the hypothesis that factors other than insulin must predominate 
in the regulation of protein synthesis. We can only speculate on the nature of these 
factors at the present time but they probably include an interaction between 
insulin and other hormones, the substrate milieu and neural influences.
Our observation that muscle protein synthesis in type 1 diabetic patients is 
insensitive to modulation by insulin needs to be verified by additional studies in 
which hormonal influences are regulated by means of a combination of pancreatic 
and adrenal clamps. The finding does, however, suggest that insulin effects on 
protein metabolism in type 1 diabetic patients follows the pattern of resistance 
documented for glucose and palmitate metabolism.
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Increase in anterior tibialis muscle protein synthesis in 
healthy man during mixed amino acid infusion: studies of 
incorporation of [l-13C]leucine
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S U M M A R Y
1. Anterior tibial muscle protein synthesis in seven 
healthy postabsorptive men was determined from 
increases in muscle protein bound leucine enrichment 
during a primed continuous infusion of L-[l-l3C]leucine. 
Biopsies were taken 30 min after the beginning of leucine 
infusion (when plasma 13C enrichment was steady), 240 
min later during continued fasting and again after 240 min 
of infusion of a mixed amino acid solution which 
increased plasma total amino acid concentrations by 37%. 
The mean enrichment of 13C in plasma a-ketoisocaproate 
was used as an index of the enrichment of the precursor 
pool for leucine metabolism.
2. Anterior tibial muscle mixed protein synthetic rate 
during fasting was 0.055 ( s d  0.008) %/h and this increased 
by an average of 35% during infusion of mixed amino acid 
to 0.074 ( s d  0.021) %/h {P< 0.05).
3. Whole-body protein breakdown (expressed as the 
rate of endogenous leucine appearance in plasma) was 
121 ( s d  8) //mol h"1 kg-1 during fasting and decreased 
(RC0.01) by an average of 12% during amino acid in­
fusion. Leucine oxidation was 18 ( s d  3) //mol h"1 kg-1 
during fasting and increased [P <  0.001) by 89% during 
amino acid infusion. Whole-body protein synthesis (non- 
oxidative leucine disappearance) was 104 ( s d  6) //mol h 1 
kg 1 during fasting and rose by 13% [P<  0.001) during 
mixed amino acid infusion.
4. ,3C enrichment of muscle free leucine was only 61 
( s d  19) % of that in plasma a-ketoisocaproate and this 
increased to 74 ( s d  16) % {P< 0.02) during mixed amino 
acid infusion.
5. The results suggest that increased availability of 
amino acids reverses whole-body protein balance from 
negative to positive and a major component of this is the 
increase in muscle protein synthesis.
Correspondence: M. J. Rennie, Department of Physiology, 
The University, Dundee DD1 4HN, U.K.
Key words: amino acids, leucine, muscle protein synthesis, 
protein turnover.
Abbreviations: APE, atoms per cent excess; KIC, a-keto­
isocaproate.
IN T R O D U C T IO N
Studies of quadriceps muscle protein synthetic rates in 
man have shown increases during mixed oral feeding [1, 
2], and studies in a variety of disease states [2-4] and 
during leg immobilization [5] have shown reductions from 
normal in muscle protein synthesis, but the mechanisms 
remain obscure.
In model-dependent studies of amino acid exchange 
across human limbs, an apparent increase in protein 
synthesis but no change in protein breakdown occurred 
during mixed oral feeding which should elevate insulin 
secretion [6, 7], but, paradoxically, insulin infusion in fast­
ing subjects not only did not induce an increase in indirect 
indices of protein synthesis but reduced protein break­
down [8],
The individual contributions of amino acids, energy 
(i.e. equivalents of carbohydrate and lipids) and other 
paracrine and endocrine hormones in the control of 
skeletal muscle protein synthesis in man are not known. It 
is known that in man, infusion of substantial amounts of 
either leucine [9] or mixed amino acids [10, 11] increased 
whole-body protein synthesis but only a mixed amino acid 
infusion reduced whole-body protein breakdown, and 
although the branched-chain amino acids and leucine in 
particular are said to have anabolic effects on animal 
muscle no data exist for human muscle. We have begun 
to tackle these problems by examining the effect of amino 
acid supply on skeletal muscle protein synthesis.
The aim of the study reported here was to apply stable 
isotope tracer technology to study the effects on the 
skeletal muscle protein synthetic rate in postabsorptive
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man of an intravenous infusion of mixed amino acids 
without additional fuel substrates or hormones. A sub­
sidiary aim was to assess the contribution of skeletal 
muscle to whole-body protein turnover and to examine 
the changes induced by provision of amino acids.
M E T H O D S
Subjects
Seven healthy men [age 24.5-39.5 years; weight 
67.8-77.4 kg (101-114% ideal body weight [12, 13 [ ) J  
were studied at the Department of Medicine, Ninewells 
Hospital and Medical School, University of Dundee. 
Each subject gave written consent after a full explanation 
of the study. The study protocol was approved by the 
Tayside Health Board Committee on Medical Ethics.
Tracers
L-[l-l3C]Leucine and sodium [13C]bicarbonate (both 
99%) were obtained from Tracer Technologies Incorpo­
rated, Newton, MA, U.S.A. Immediately before admini­
stration the tracers were mixed in sterile NaCl solution 
(150 mmol/1) and were sterilized by passage through 0.22 
/mi filters (Millipore SA, Molsheim, France).
Experim ental design
The subjects were studied after a 15 h overnight fast; 
they received no food throughout the study, during which 
they were semi-recumbent in a thermoneutral environ­
ment (25-27°C). Arterialized venous blood samples were 
taken from a 1.7 mm outer diameter cannula (Venflon, 
Viggo AB, Helsingborg, Sweden), placed retrogradely in 
a dorsal hand vein and maintained patent by slow infusion 
of NaCl solution (150 mmol/1); before sampling the hand 
was warmed by insertion into a thermostatic chamber at 
75°C [14]. Priming doses of L-[l-l3C]leucine [7.17 ( s d  
0.51) /imol/kg] and NaH'-’CO, [1.86 ( s d  0.08) /¿mol/kg] 
were given, and a constant infusion of l -[ l - l:’CJlcucine 
[7.39 ( s d  0.24) /rmol h"1 kg“1] was established, via a 1.7 
mm outer diameter cannula in a contralateral forearm 
vein; infusions were delivered and controlled with IMED 
928 volumetric infusion pumps (IMED Ltd, Abington, 
Oxon, U.K.). Thirty minutes later (elapsed time 0 min) 
anterior tibial muscle was biopsied using 6.5 mm Tilley 
Henckel ethmoid punches (S. Murray and Co, Sheffield, 
U.K.) via a 10 mm long skin incision made using 5 ml of 
20 g/1 lignocaine anaesthesia, subcutaneously infiltrated 
to the fascia [15]. The biopsies were from the most muscu­
lar aspect of the skin at a depth of 10 mm below the fascia. 
Samples were immediately frozen in liquid nitrogen and 
stored at — 194°C until analysis. A  second biopsy was 
taken 240 min later (elapsed time 240 min), from either 
the ipsilateral leg (40 mm distant from the initial biopsy 
site) or the contralateral leg. A third anterior tibial biopsy 
was taken 240 min after the second biopsy (elasped time 
480 min), from the leg contralateral to the first biopsy. 
After the second biopsy was taken a priming dose of a
commercial preparation of mixed amino acids (Synthamin 
9, Travenol Laboratories Ltd, Thetford, Norfolk, U.K.) 
was infused intravenously (83.5 mg of amino acids/kg 
over 10 min), with a second bolus of NaHl3CO, [0.94 
( s d  0.03) /<mol/kg[; amino acids were then continuously 
infused until the end of the study at a rate of 1.52 ml h"1 
kg“1 providing 83.5 mg of amino acids h"1 kg-1, 46.5 /rmol 
of leucine h"1 kg"1 and 0.33 g of nitrogen day'1 kg"1. Each 
litre of Synthamin 9 contained the following L-amino 
acids: alanine 11.38 g, arginine 6.32 g, glycine 5.66 g, 
histidine 2.64 g, isoleucine 3.30 g, leucine 4.02 g, lysine 
3.19 g, methionine 2.20 g, phenylalanine 3.08 g, proline 
3.74 g, serine 2.75 g, threonine 3.21 g, tryptophan 0.99 g, 
tyrosine 0.22 g, valine 3.19 g, total amino acids 55.0 g.
Arterialized venous samples were taken before, 30 min 
after the start of the tracer infusion (time 0) and every 60 
min thereafter for 480 min. Every 60 min, total C02 pro­
duction, total 0 2 consumption and resting energy ex­
penditure were determined over 11 min with a ventilated 
hood, indirect calorimeter [16], Every 60 min expired 
breath was collected into a 2 litre plastic bag and an 
aliquot was transferred into 20 ml evacuated glass tubes 
(Vacutainer, Becton Dickenson, Rutherford, NJ, U.S.A.) 
for subsequent determination of 13C enrichment in C02 
(see below).
13C analysis
Enrichment with l3C in leucine in plasma and neutral­
ized perchloric acid extracts of freeze-dried, ground 
muscle were determined after the procedure described 
below. Urea, which otherwise interfered with gas 
chromatography-mass spectrometry, was removed by 
incubation (37°C, 15 min) with jack-bean urease; amino 
acids were extracted (plasma samples only) with metha- 
nolic HC1 (4:1, v/v), the solvent removed by evaporation, 
and then the residue redissolved in pyridine before 
preparation of t-butyldiemethylsilyl derivatives by reaction 
with lV-methyi-/V-(t-butyldimethylsilyl)trifluoroacetamide 
(Regis Chemical Company, Morton Grove, IL, U.S.A.) 
[17]. Gas chromatography-mass spectrometry was 
carried out on a Finnigan 1020B instrument (Finnigan 
MAT Ltd, Hemel Hempstead, U.K.), fitted with a 20 m 
x0.2 mm inner diameter OV-i WCOT chemically 
bonded fused silica column (Pierce UK Ltd, Cambridge, 
U.K.), with temperature programmed from 110 to 270°C 
at 15°C/min after a 1 min lag. Decane was used as solvent. 
The injector temperature was 280°C and injection, in the 
splitless mode, was complete in 30 s. The carrier gas was 
helium at 50 kPa. The mass spectrometer was operated in 
the electron impact mode with an ionization energy of 70 
eV. [ l -13C]Leucine enrichment was determined by moni­
toring m/z 302 and 303. The enrichment in a-ketoiso- 
caproate (KIC) was determined by analogous methods 
using o-trimethylsilyl quinoxalinol derivates [18] and 
monitoring rn/z 232 and 233.
Enrichment of 13C in expired CO, was measured with 
an automated Finnigan MAT breath gas analysis system 
attached to a Finnigan MAT Delta D isotope ratio mass 
spectrometer [19]. To determine the 13C enrichment in
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protein-bound leucine, protein from freeze-dried, ground 
muscle samples was repeatedly washed with perchloric 
acid, acid-hydrolysed (6 mol/1 HC1) and leucine was sep­
arated by preparative gas chromatography [20], Leucine- 
C02 was liberated by ninhydrin and its 1 :'C enrichment 
determined using the breath gas system optimized for 
small quantities of C02 [21],
M etabolite  and horm one concentration assays
Amino acid concentrations were determined in plasma 
and muscle sulphosalicylic acid or perchloric acid extracts 
with an amino acid analyser (LC5000, Biotronik GmbH, 
München, F.D.R.) using ion-exchange chromatography 
and fluorimetric detection of o-phthaldehyde derivatives 
with norvaline as internal standard. Intracellular free 
amino acids were extracted from freeze-dried, ground 
muscle samples with 0.5 mol/1 perchloric acid; calculation 
of the values for intracellular concentration and enrich­
ment was made on the assumption that 13% of the water 
content, by weight, of the muscle sample was extracellular
[22]. Concentrations of plasma glucose were determined 
with a Glucose Analyser 2 (Beckman Instruments, Irvine, 
CA, U.S.A.) and of blood d -( — )-3-hydroxybutyrate by an 
nicotinamide-adenine dinucleotide-linked enzyme assay
[23]. Plasma hormone concentrations were measured at 
180, 240, 420 and 480 min by radioimmunoassay, insulin 
by a double-antibody kit (Ire-Medgenix Sa, Brussels, Bel­
gium), glucagon by a double-antibody kit (Radioassay 
Systems Laboratories Inc., Carson, CA, U.S.A.) and corti­
sol by a solid-phase primary antibody kit (Immunodiag- 
nostic Systems Ltd, Washington, U.K.).
Calculations
Muscle protein synthetic rates were calculated from the 
increase in incorporation of L-[l-13C]leucine into the pro­
tein-bound leucine pool, assuming that the mean 13C 
enrichment in plasma KIC from 0 to 240 min and 300 to 
480 min reflected that in the precursor pool, in the abs­
ence and in the presence of amino acid infusion, respect­
ively [1], The components of plasma leucine turnover 
were calculated from the mean plasma KIC enrichment 
from 60 to 240 min and 300 to 480 min [1], Leucine oxi­
dation was calculated from whole-body 13C02 excretion 
and plasma KIC enrichment [1]; during an additional 
study without tracer 13C, enrichment in expired C02 was
only 0.00018 ( s d  0.00015) atom per cent excess (APE) 
during amino acid infusion.
Statistical analysis
Mean values and their s d  are presented. Results from 
the two phases of the study were compared with the 
Student’s f-test for paired data.
RESULTS 
Ind irect calorim etry
Resting energy expenditure was 5.42 ( s d  0.28) kJ/min 
in the absence of the amino acid infusion and increased to 
5.87 ( s d  0.27) kJ/min (PCO.Ol) during the infusion. No 
change was found in the respiratory quotient (0.73 over­
all).
Substrates and hormones (Table I )
Values of the concentrations of plasma glucose, insulin, 
glucagon and cortisol and of blood d -( -  )-3-hydroxy- 
butyrate were stable within each study period, without and 
with amino acid infusion. During amino acid infusion 
insulin was 53% greater (PC0.05) and glucagon 41% 
greater (P<0.01) compared with postabsorptive con­
centrations. Concentrations of glucose, d -( -  )-3-hydroxy- 
butyrate and cortisol were not affected by the amino acid 
infusion.
Am ino acid concentrations (Fig. 1 and Table 2)
The mean plasma leucine concentration (Fig. 1) in the 
absence of amino acid infusion, from 0 to 240 min, was 
157 ( s d  22) //mol/I; a rise (PC0.05) of 16% occurred 
from 60 to 240 min. During amino acid infusion leucine 
increased by nearly 80% to a plateau value of 278 ( s d  46) 
/tmol/1 (P<  0.001) between 300 and 480 min. During 
fasting the concentration of free leucine in intramuscular 
fluid was not different from that in plasma at 167 ( s d  22) 
//mol/1; this increased by 52% to 254 ( s d  55) //mol/1 
(P<0.02) during amino acid infusion when there was no 
statistical difference between plasma and intramuscular 
free leucine concentrations. Total plasma amino acid con­
centration was 2890 ( s d  260) //mol/I initially and a rise 
[P<  0.001) of 37% to 3950 ( s d  370) //mol/l occurred 
during amino acid infusion. During infusion no change
Table 1. Substrate and hormone concentrations in blood and plasma in the absence and in the
presence o f amino acid infusion
Results are means (s d ) over time (see the text). Statistical significance: *P <  0.05, **p<  0.01.
Postabsorptive Amino acid 
infusion
Blood d -( -  )-3-hydroxybutyrate (mmol/1) 0.14(0.08) 0.16(0.04)
Plasma glucose (mmol/1) 4.7 (0.3) 4.9 (0.3)
Plasma insulin (m-units/1) 6.2 (4.0) 9.5 (4.4)*
Plasma glucagon (pmol/1) 35.6(14.5) 50.2(16.8)**
Plasma cortisol (nmol/1) 279(99) 249(204)













Fig. 1. Plasma concentration of leucine (•) and l3C 
enrichment of plasma leucine (o) and K1C (■). Results are 
means with bars indicating s d . L-[l-13C]Leucine was 
infused in the absence ( -  30 to 240 min) and in the 
presence (240 to 480 min) of a mixed amino acid infusion 
see the Methods section).
was found in the plasma concentrations of aspartic acid 
and glutamine; reductions occurred in glutamic acid and 
taurine, amino acids not present in the mixture infused.
Plasma and muscle free leucine pool enrichments
For both plasma leucine and KIC, plateau enrichment 
was achieved during the last 180 min of each phase of the 
study (Fig. 1, Table 3). The ratio of 13C enrichment in 
plasma KIC relative to that in plasma leucine was 83 ( s d  
4) % in the absence of exogenous amino acids and this 
was maintained [85 ( s d  7) %] during amino acid infusion. 
The l3C enrichment in muscle free leucine was 4.26 ( s d  
1.56) APE 30 min after the [l3C]leucine bolus (time 0 
min) and was 3.45 ( s d  1.10) APE at the end of the first 
phase of the study before infusion of amino acids. This 
enrichment was unchanged [3.41 ( s d  0.81) APE] during 
amino acid infusion despite reductions in the enrichment 
of L'C in both plasma leucine and plasma KIC (Table 3). 
The 1 ’C enrichment of intramuscular free leucine was 51
( s d  7) % of that of plasma leucine in the absence of 
exogenous amino acids and rose to 63 ( s d  14) % 
(P< 0.02) during amino acid infusion. The 13C enrich­
ment of intramuscular free leucine was 61 ( s d  19) % of 
that of KIC in the absence of exogenous amino acids and 
rose to 74 ( s d  16) % (P<  0.02) during their infusion.
M uscle prote in synthesis (Table 4)
The rate of anterior tibial muscle protein synthesis in 
the absence of amino acid infusion, calculated on the basis 
that the mean l3C enrichment in plasma KIC (Table 3) 
should closely represent the precursor synthetic pool and 
provide a best estimate of protein synthesis, was 0.055 ( s d  
0.008) %/h; the rate increased during amino acid infusion 
by 35% to 0.074 ( s d  0.021) %/h (PC0.05). These values 
should be considered as the best estimate of protein 
synthesis. When the synthetic rate was calculated on the 
basis of plasma leucine enrichment as representative of 
the precursor pool enrichment, this minimal estimate of 
muscle protein synthesis was 0.045 ( s d  0.008) %/h in the 
absence of amino acid infusion, 18% slower (P< 0.001) 
than the plasma-KiC-based values; a rise of 40% to 0.063 
( s d  0.019) %/h (P<0.05) occurred during amino acid 
infusion. These values should be considered as minimal 
estimates of protein synthesis. When calculated on the 
basis of the l3C enrichment in intramuscular free leucine 
taken as representative of the precursor pool enrichment, 
this maximal or overestimate of muscle protein synthesis 
was 0.094 ( s d  0.044) %/h in the absence of amino acid 
infusion [71% faster (NS) than the plasma-KIC-based 
rate]. During amino acid infusion, the rate of muscle 
protein synthesis calculated in this fashion [0.107 ( s d
0.044) %/h] showed no significant difference from that 
calculated in the absence of exogenous amino acids.
W hole-body leucine kinetics (Table 5)
During the infusion a rise (P<  0.001) of 26% occurred 
in the plasma leucine flux, but this increase was less than 
the exogenous leucine infusion rate because of a reduc­
tion (P<0.01) of 12% in the rate of appearance of 
endogenous leucine, a measure of protein breakdown. 
Whole-body leucine oxidation increased (P <  0.001), in 
absolute terms, to almost double the postabsorptive value 
during amino acid infusion; as a proportion of plasma 
leucine flux leucine oxidation rose from 15% to 22%. The 
non-oxidative rate of leucine disappearance, i.e. whole- 
body protein synthesis, increased (P<0.001) by 13% 
during the amino acid infusion. Net leucine uptake 
changed (7J< 0.001) from negative to positive, suggesting 
that net protein balance had become positive.
D IS C U S S IO N
This study shows, for the first time, the effects of 
parenteral infusion of mixed amino acids on anterior 
tibial muscle protein synthesis. Information is also pro­
vided about the relationships of leucine and KIC in the
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Table 2. A m ino acid concentrations in  plasma and in tram uscular water ( IM W )
Results are means ( s d ). Values for plasma and IMW at the same time points are compared, and 
also values for plasma at different times (increases: *P<0.05, **P<0.01, ***P<0.001; reductions:
HR< 0.02, UHP<0.01).
Amino acid concn. (/rmol/l)









Alanine 253(44) 1610(540*** 467(66)*** 1900(300)***
Arginine 101 (23) 341 (92)*** 2U (46)*** 473(131)***
Aspartic acid 8(4) 833 (344)*** 8(4) 926 ¡243)***
Glutamic acid 82(38) 5210 (520)*** 70(31)11 5580 (92O) ***
Glutamine 673(44) 11700(2300)*** 658 (57) 12100 ( 1900)***
Glycine 237(33) 1450 ¡480)*** 405 ¡43)*** 1600 (290)***
Histidine 92(11) 369 (54)*** 138 ¡21)*** 412 (46)***
Isoleucine 55(7) 59 ¡17) 160 ¡16)*** 145(27)
Leucine 157(22) 167 (32) 278 ¡46)*** 254(55)
Lysine 181 (49) 616 ¡119)*** 241 (54 )*« 679(166)***
Methionine 19(2) — 63(6)*** —
Phenylalanine 54(10) 85 (23)** 103(l9)*** 132(20)*
Serine 124(14) 833 ¡344)*** 186 ¡14)*** 926 ¡243)***
Taurine 71 (13) 20400 ¡2900)*** 60 (9)1111 19800 ¡3300)***
Threonine 128(18) 573(174)*** 181 (18)*** 641 ¡101)***
Tryptophan 44(8) 4870 (2800)*** 65(13)*** 7310 ¡2350)***
Tyrosine 47(7) 71 (2 )* 48(5) 53(14)
Valine 254(48) 511 ( 142)** 380 (60)*** 664(145)**
Total amino acids 2890(260) 52400 (7900)*** 3950(370)*** 55900 ¡4300)***
Table 3. I3C enrichm ent o f free leucine and its metabolites in plasma, muscle and breath, and the 
rate o f increase in muscle protein-bound leucine
Results are means (s d ). Statistical significance: *P<  0.001.
Postabsorptive 
(0-240 min)
Amino acid infusion 
(300-480 min)
Plasma leucine (APE) 7.03 (0.56) 5.41 (0.20)*
Plasma KIC (APE) 5.80 (0.33) 4.60(0.36)*
Muscle free leucine (APE)t 3.45(1.10) 3.41 (0.81)
Expired CO, (APE) 0.0129(0.0019) 0.0185 (0.0023)*
103 x Protein leucine/time (APE/h)£ 3.20 (0.50) 3.41 (0.93)
tMuscle free leucine results were obtained at either 240 or 480 min of elapsed time.
:tThe rate of increase in enrichment of protein-bound leucine was calculated from changes calculated over 
0-240 min and 240-480 min.
Table 4. Calculated values o f an terio r tib ia l muscle prote in synthetic rate according to choice o f 
leucine pool to represent the precursor pool for prote in synthesis
Results are means (s d ). Statistical significance: *P<0.05. Abbreviation: NS, not significant.
Precursor pool assigned Postabsorptive Amino acid infusion P  value
Plasma KIC (%/h) 0.055 (0.008) 0.074(0.021) 0.05
Plasma leucine (%/h) 0.046(0.008) 0.063(0.019) 0.05
Intramuscular leucine (%/h) 0.094 (0.044) 0.107(0.044) NS
plasma pool and in muscle intracellular water of anterior 
tibialis.
In essence, the results show that increases in amino 
acid availability in plasma and muscle stimulate muscle 
protein synthesis, calculated on the basis of the enrich­
ments of plasma KIC or leucine, but not when calculated
on the basis of intracellular leucine enrichment. The 
correct interpretation of these results depends on know­
ledge of the relative tracer labelling of muscle leucine 
tRNA, plasma leucine, intramuscular free leucine and the 
keto-acid of leucine, information not available for man. In 
previous studies of human muscle protein synthesis [1-5]
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Table 5. W hole-body leucine kinetics
Results are means ( s d ). Statistical significance: *P <  0.01, **p<  0.001.
Rate (//mol h 'kg ') Change
(%)
Postabsorptive Amino acid infusion
Infusion rate — 46.5 —
Flux 121 (8 ) 153(13)** + 26
Protein breakdown 121 (8 ) 106(13)* - 1 2
Oxidation 18(3) 34(6)** + 88
Protein synthesis 104(6) 118(8)** + 13
Net protein balance -18 (3 ) + 1 2 (6 )**
we used the plasma leucine or K1C enrichments as the 
basis of our calculations, since six studies [24-29] of 
precursor pool labelling of leucine in skeletal and cardiac 
muscle, both in vitro and in vivo, showed tRNA labelling 
to be nearer to that of the extracellular, than to that of the 
intracellular, amino acid pool, but one other study reports 
the opposite result [30]. The substantial transamination of 
leucine in human forearm arteriovenous exchange studies 
[6, 7] provides further evidence of rapid entry of extra­
cellular leucine to intracellular metabolic processes.
The relative increase in the equilibrium between the 
intramuscular free leucine enrichment and that of plasma 
leucine during amino acid infusion is partly a function of 
the reduced arteriovenous decrement in leucine enrich­
ment that occurs when plasma leucine concentration is 
increased [6, 7, 31] and partly to the increased flux of 
leucine [6, 7] in the fed state. The initial (time 0 min) 
higher intracellular leucine enrichment may have been a 
transient effect due to the bolus of [ l - l3C]leucine or to an 
increase in protein breakdown during the initial period of 
the study. It remains a possibility that the lack of a signifi­
cant effect of amino acid infusion on muscle protein 
synthesis, calculated on the basis of the free muscle leu­
cine labelling, was a type 2 error: this may have occurred 
as a result of taking an insufficiently long period over 
which to measure the enrichment of muscle protein, or to 
the effect of the relative methodological precision of 
measurements made on small samples of free and protein- 
bound intramuscular leucine with a resulting greater 
variability of the calculated protein synthetic rates. Until 
information is available on the leucyl-tRNA charging of 
human skeletal muscle, rates of muscle protein synthesis 
derived from plasma KIC enrichment should be viewed as 
the best available estimates, rates derived from plasma 
leucine enrichment as minimal estimates and rates 
derived from intracellular leucine enrichment as overesti­
mates.
Complete mixtures of amino acids are reported to 
enhance protein synthesis in cell-free systems, suggesting 
that there is a direct stimulatory effect of amino acids on 
protein synthesis [32]. There is, however, no known 
mechanism for this effect and the Km for the charging of 
tRNA is likely to be much lower than the intramuscular 
concentration of amino acids so that tRNA is always fully 
saturated [32]. Leucine has been reported to stimulate rat 
muscle protein synthesis in vitro [33] and whole-body pro­
tein synthesis in man [9], but this may occur by indirect
and unknown mechanisms. Branched-chain amino acids 
have no effect on muscle amino acid balance [34] or ribo­
some profile in man [35], However, our results showed 
that amino acid infusion caused an increase in intra­
muscular leucine and other branched-chain amino acid 
concentrations so that if they were anabolic there was 
scope for the effect to be expressed.
To what extent are the increases in muscle protein 
synthesis likely to result from the small increases in 
insulin? Many studies in animals both in vitro [29, 36, 37] 
and in vivo [38, 39] provide evidence of a stimulatory 
effect of insulin on muscle protein synthesis, most sensi­
tive in the range 0-15 m-units/1 [40], Studies in adult man 
conflict with these animal-based results, suggesting that 
insulin may not have an anabolic effect [8, 41]. An 
increase occurred in glucagon but this hormone certainly 
does not stimulate muscle protein synthesis at the con­
centrations found and may decrease it at pathophysiologi­
cal concentrations [42].
It remains possible that growth hormone itself induced 
the reported changes as this hormone is shown to have an 
acute, direct insulin-like effect on rat muscle protein 
synthesis in vitro [43]. Insulin-like growth factors, 
expressed by messenger ribonucleic acids in most human 
foetal tissues, including muscle [44], may have exerted a 
paracrine influence to modulate increases in protein 
synthesis in response to amino acid provision, but in 
identical studies we were unable to measure any change in 
plasma insulin-like growth factor 1 concentration in 
response to an identical infusion of amino acids [basal 
790 ( s d  240) versus amino acids 790 ( s d  220) units/1, 
n = 5]. Since the anabolic effect of the exogenous amino 
acids on muscle cannot be firmly identified with changes 
in availability of insulin, glucagon (or cortisol, glucose and 
ketone bodies, none of which changed in concentration), 
we are therefore forced to the conclusion that either the 
simple increase in intramuscular concentration of amino 
acids or an increase in some other unknown anabolic 
factor caused the observed increase in muscle protein 
synthesis. The present results strongly suggest that a 
major component in the twofold increase seen in muscle 
protein synthesis in going from the postabsorptive to the 
fed state [1, 2] is simply due to an increased availability of 
amino acids.
The values in the postabsorptive state for anterior 
tibialis muscle mixed protein synthesis are somewhat 
higher than those for quadriceps [0.046 ( s d  0.012) %/h]
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obtained with identical methods and methods of calcula­
tion, by ourselves and other workers [2, 5]. This dif­
ference may be due to the greater type 1 fibre content of 
anterior tibial muscle [73 ( s d  10) %] compared with 
quadriceps [47 ( s d  9) %] [45], At present the relative 
synthetic rates for human type 1 and type 2 muscle fibres 
are not known, but it is known that in animals muscles 
with predominantly type 1 fibre composition turn over 
faster than those with predominantly type 2 [36,42,46].
The absolute values, and the changes that occurred 
between the postabsorptive and amino acid supplemented 
states in the plasma fluxes of leucine and KIC, and the 
rates of oxidation of leucine, are in accord with these 
expected from previous work [10, 11]. The most impor­
tant feature of the results for the present discussion is the 
net anabolic effect of exogenous amino acids due to an 
increase in non-oxidative leucine disappearance (whole- 
body protein synthesis) and a reduction in the appearance 
of leucine from protein breakdown.
Given the fact that skeletal muscle contributes about 
50% of lean body mass [47], it is possible to calculate 
(assuming that muscle contains 180 mg of protein/g, 
protein contains 8% leucine and all skeletal muscle is 
similar to anterior tibialis) the contribution of muscle to 
whole-body protein synthesis (non-oxidized leucine dis­
appearance): it would be 24 /¿mol h"1 kg"1 in the post- 
absorptive state and 33 /rmol h '1 kg"1 during exogenous 
amino acid infusion. These estimates would be reduced 
by 16% if skeletal muscle turnover generally reflected that 
of quadriceps. Such calculations suggest that in the post- 
absorptive state skeletal muscle may account for between 
20 and 24% of whole-body protein synthesis. The relative 
change, on addition of exogenous amino acids, was twice 
as great for anterior tibialis than for the whole-body 
protein mass, suggesting that muscle increased its contri­
bution; indeed calculations show that the proportion of 
whole-body protein synthesis due to muscle rose to 
between 23 and 28%. This is less than the contribution 
previously calculated [1] because of the revised, lower 
values now routinely obtained for skeletal muscle protein 
synthesis [2, 5].
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